Anti-cancer nuclear hormone receptor targeting compounds

Compounds targeting nuclear receptors in tumor cells with a nuclear payload enhance tumor cell death and reduce side effects by selectively accumulating in these cells, addressing the limitations of current PARP inhibitors.

JP7590872B2Active Publication Date: 2024-11-27NUVATION BIO INC
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2020563915
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-05-14
Filing Date
2019-05-14
Publication Date
2024-11-27
Estimated Expiration
2039-05-14

AI Technical Summary

Technical Problem

Current PARP inhibitors used in cancer treatment face challenges such as rapid dose-dependent neutropenia, limiting their long-term efficacy, and there is a need for compounds that can selectively target tumor cells while minimizing side effects on normal cells.

Method used

Development of compounds comprising a nuclear payload and a nuclear receptor targeting epitope, such as an androgen or estrogen receptor epitope, which accumulate in the nucleus of tumor cells, enhancing tumor cell death and reducing side effects by sparing normal cells.

Benefits of technology

These compounds demonstrate improved efficacy and selectivity for tumor cells, reducing side effects and potentially overcoming the limitations of existing PARP inhibitors by preferentially accumulating in nuclear receptor-positive cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590872000001
    Figure 0007590872000001
  • Figure 0007590872000002
    Figure 0007590872000002
  • Figure 0007590872000003
    Figure 0007590872000003
Patent Text Reader

Abstract

The present disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binding agents, products containing same, and methods of their use and preparation.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No. 62 / 671,382, filed May 14, 2018, which is incorporated herein by reference in its entirety. [Background technology]

[0002] The present disclosure relates to anti-cancer compounds derived from nuclear receptor binding agents, such as nuclear steroid receptor binding agents, products containing same, and methods of their use and preparation. PARP inhibitors are drugs that prevent DNA repair from leading to cell death and thus tumor growth inhibition. This mechanism of cell growth prevention results in significant antitumor activity in tumors harboring BRCA1, BRCA2, and PALB2 mutations, as these proteins are critical for repairing double-stranded DNA breaks via the homologous recombination repair (HRR) pathway. Normal cells, which do not divide as rapidly as tumors and do not harbor mutated BRCA1 or BRCA2, do not yet have an impaired HRR pathway, allowing them to survive in the face of PARP inhibition. In addition to PARP catalytic inhibition, in 2012, researchers at the National Cancer Institute discovered additional mechanisms that contribute to the toxic effects of PARP inhibitors in tumor cells. Their finding that certain PARP inhibitors, in addition to blocking PARP enzymatic activity, can localize PARP proteins to sites of DNA damage correlated with the cytotoxicity of these inhibitors. This mechanism of action, termed "PARP trapping," is an additional mechanism by which this class of drugs acts to prevent tumor growth and survival (Murai, et al. Cancer Research (2012) 72(21):5588-99). PARP enzyme inhibitors (such as olaparib, rucaparib, niraparib, and tarzoparib) have been approved for the treatment of breast and ovarian cancer in patients with BRCA mutations. Several others (e.g., velaparib) are currently undergoing clinical trials for breast, prostate, and ovarian cancer. The use of PARP inhibitors is not without side effects, and one of the major obstacles to their long-term use is the rapid and dose-dependent development of neutropenia. This necessitates drug holidays and / or dose reductions in clinical practice, which impairs the ability to achieve maximal efficacy. [Prior art documents] [Non-patent literature]

[0003] [Non-Patent Document 1] Murai,et al.Cancer Research(2012)72(21):5588-99 Summary of the Invention [Means for solving the problem]

[0004] Provided herein is a compound that comprises at least one nuclear payload and at least one nuclear receptor targeting epitope.The compound described herein is designed to bind to intracellular nuclear receptor, and allow the compound with its nuclear payload to accumulate in the nucleus.

[0005] Also provided herein is a compound that comprises at least one nuclear payload and at least one nuclear steroid receptor targeting epitope.The compound described herein is designed to bind to intracellular nuclear steroid receptor (for example, the androgen receptor of cytosol), allowing the compound with its nuclear payload to accumulate in the nucleus.This approach allows the compound not only to improve efficacy, but also to have cell type selectivity and possibly a higher therapeutic index.

[0006] Furthermore, the compounds described herein provide targeted delivery of nuclear payloads.These compounds both target tumor tissue and localize therein.The transport of compounds comprising at least one nuclear receptor targeting epitope, such as a nuclear steroid receptor targeting epitope, covalently linked to at least one nuclear payload into the nucleus allows the nuclear payload to accumulate in the nucleus, enhancing tumor cell death.By doing so, the compounds described herein can exhibit excellent efficacy.In addition, the compounds described herein preferentially accumulate in nuclear receptor-positive cells, such as steroid receptor-positive cells, sparing cells that do not express specific nuclear steroid receptors, thus reducing side effects.

[0007] In certain embodiments, provided is a compound that comprises at least one nuclear payload and at least one nuclear receptor targeting epitope.In certain embodiments, when the compound comprises one nuclear payload and one nuclear receptor targeting epitope, the nuclear receptor targeting epitope is not a peptide, protein, nanoparticle, or antibody.In certain embodiments, when the compound comprises one nuclear payload and one nuclear receptor targeting epitope, and the nuclear receptor targeting epitope is an androgen receptor targeting epitope or an estrogen receptor targeting epitope, the nuclear payload is not doxorubicin or its analog.In certain embodiments, when the compound comprises one nuclear payload and one nuclear receptor targeting epitope, and the nuclear receptor targeting epitope is an androgen receptor targeting epitope or an estrogen receptor targeting epitope, the nuclear payload is not the hydroxamic acid that binds to histone deacetylase (HDAC).

[0008] In certain embodiments, a compound is provided that comprises at least one nuclear payload and at least one nuclear receptor targeting epitope, wherein when the compound comprises one nuclear payload and one nuclear receptor targeting epitope: the nuclear receptor targeting epitope is not a peptide, protein, nanoparticle, or antibody; and When the nuclear receptor targeting epitope is an androgen receptor targeting epitope or an estrogen receptor targeting epitope, the nuclear payload is not doxorubicin or an analog thereof, and is not a hydroxamic acid that binds to histone deacetylase (HDAC).

[0009] In certain embodiments, a compound is provided, comprising at least one nuclear payload that binds to the catalytic domain of poly(ADP-ribose) polymerase (PARP) and at least one nuclear receptor targeting epitope.In certain embodiments, at least one nuclear receptor targeting epitope is a nuclear steroid receptor targeting epitope.

[0010] In certain embodiments, compounds are provided that include at least one nuclear payload that binds to poly(ADP-ribose) polymerase (PARP) (e.g., PARP-1 and / or PARP-2) and at least one nuclear receptor targeting epitope. In certain embodiments, compounds are provided that include at least one nuclear payload that binds to poly(ADP-ribose) polymerase (PARP) (e.g., PARP-1 and / or PARP-2) and at least one estrogen receptor targeting epitope, glucocorticoid receptor targeting epitope, progesterone receptor targeting epitope, or androgen receptor targeting epitope.

[0011] In certain embodiments, compounds are provided that include at least one nuclear payload that binds to poly(ADP-ribose) polymerase (PARP) (e.g., PARP-1 and / or PARP-2) and at least one nuclear receptor-targeting epitope derived from an androgen receptor agonist, an androgen receptor antagonist, a selective androgen receptor modulator (SARM), an estrogen receptor agonist, an estrogen receptor antagonist, a selective estrogen receptor modulator (SERM), a selective estrogen receptor modulator (SERM), a glucocorticoid receptor agonist, a glucocorticoid receptor antagonist, a selective glucocorticoid receptor modulator (SGRM), a progesterone receptor antagonist, a progesterone receptor agonist, a selective progesterone receptor modulator (SPRM), or a combination thereof.

[0012] In certain embodiments, compounds are provided that include at least one nuclear payload that binds to poly(ADP-ribose) polymerase (PARP) (e.g., PARP-1 and / or PARP-2) and at least one nuclear steroid receptor targeting epitope derived from an androgen receptor agonist, an androgen receptor antagonist, a selective androgen receptor modulator (SARM), an estrogen receptor agonist, an estrogen receptor antagonist, a progesterone receptor antagonist, a progesterone receptor agonist, a selective progesterone receptor modulator (SPRM), or a combination thereof.

[0013] In certain embodiments, compounds are provided that include at least one nuclear payload that binds to poly(ADP-ribose) polymerase (PARP) (e.g., PARP-1 and / or PARP-2) and at least one nuclear receptor-targeting epitope derived from estrogen, estetrol, estriol, estrone, progesterone, enobosarm, bicalutamide, apalutamide, testosterone, dihydrotestosterone, estradiol, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, bazedoxifene, ospemifene, megestrol acetate, estramustine, abiraterone, LGD-2941, BMS-564929, ostarine, or an analog thereof.

[0014] A compound of Formula I or II, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analogue, or pharmaceutically acceptable salt thereof, is provided: A-(LB) m I AL-(B) m II During the ceremony, A is the nuclear payload, m is 1, 2, or 3; each B is independently a nuclear receptor targeting epitope; Each L is independently a covalent bond or a linking moiety.

[0015] In certain embodiments of Formula I or II, when m is 1, the nuclear receptor targeting epitope is not a peptide, protein, nanoparticle, or antibody. In certain embodiments of Formula I or II, when m is 1 and B is an androgen receptor targeting epitope or an estrogen receptor targeting epitope, A is not doxorubicin or an analog thereof. In certain embodiments of Formula I or II, when m is 1 and B is an androgen receptor targeting epitope or an estrogen receptor targeting epitope, A is not a hydroxamic acid that binds to histone deacetylase (HDAC).

[0016] Also provided is a compound of formula III, IV, V, or VI, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, [ka] During the ceremony, Each R 1 , R 2 , R 3 , and R 4 are independently -L-(B) m , hydrogen, C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 5 , -C(=O)OR 5 , -OC(=O)R 5 , -C(=O)NR 5 R 6 , -NR 5 C(=O)R 6 , -S(=O) 1-2 R 5 , -S(=O) 1-2 NR 5 R 6 , -NR 5 S(=O) 1-2 R 6, or -C=NOR 5 and R 1 , R 2 , R 3 , and R 4 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl independently, valence permitting, may have one or more (e.g., 1 to 5, or 1 to 3) R 10 optionally substituted with m is 1, 2, or 3; each L is independently a covalent bond or a linking moiety; each B is independently a nuclear receptor targeting epitope; Each R 10 are independently halo, cyano, nitro, -OR 7 , -SR 7 , -SF5, -NR 7 R 8 , C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 7 , -C(=O)OR 7 , -OC(=O)OR 7 , -OC(=O)R 7 , -C(=O)NR 7 R 8 , -OC(=O)NR 7 R 8 , -NR 7 C(=O)NR 7 R 8 , -S(=O) 1-2 R 7 , -S(=O) 1-2 NR 7 R 8 , -NR 7 S(=O) 1-2 R 8 , -NR 7 S(=O) 1-2 NR 7 R 8 , -NR 7 C(=O)R8 , -NR 7 C(=O)OR 8 , or -C=NOR 7 and R 10 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently C optionally substituted with one or more (e.g., 1 to 5 or 1 to 3) halo, or, where valence allows, oxo, halo, hydroxyl, or amino. 1-12 optionally substituted with alkyl; Each R 5 and R 6 are independently hydrogen, deuterium, and, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 Alkyl or C 3-12 cycloalkyl or R 5 and R 6 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, Each R 7 and R 8 are independently hydrogen, deuterium, or, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 alkyl or R 7 and R 8 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, R 9 is hydrogen or R 2 However, At least one R 1 , R 2 , R 3 , and R 4 -L-(B) m This is subject to the condition that:

[0017] Also provided is a compound of formula IIIA, IV, VA, or VI, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, [ka] During the ceremony, R 1 , R 2 , R 3 , and R 4 each independently represents -L-(B) m , hydrogen, C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 5 , -C(=O)OR 5 , -OC(=O)R 5 , -C(=O)NR 5 R 6 , -NR 5 C(=O)R 6 , -S(=O) 1-2 R 5 , -S(=O) 1-2 NR 5 R 6 , -NR 5 S(=O) 1-2 R 6 , or -C=NOR 5 and R 1 , R 2 , R 3 , and R 4 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl independently, valence permitting, may have one or more (e.g., 1 to 5, or 1 to 3) R 10 optionally substituted with m is 1, 2, or 3; each L is independently a covalent bond or a linking moiety; each B is independently a nuclear receptor targeting epitope; Each R10 are independently halo, cyano, nitro, -OR 7 , -SR 7 , -SF5, -NR 7 R 8 , C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 7 , -C(=O)OR 7 , -OC(=O)OR 7 , -OC(=O)R 7 , -C(=O)NR 7 R 8 , -OC(=O)NR 7 R 8 , -NR 7 C(=O)NR 7 R 8 , -S(=O) 1-2 R 7 , -S(=O) 1-2 NR 7 R 8 , -NR 7 S(=O) 1-2 R 8 , -NR 7 S(=O) 1-2 NR 7 R 8 , -NR 7 C(=O)R 8 , -NR 7 C(=O)OR 8 , or -C=NOR 7 and R 10 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently C optionally substituted with one or more (e.g., 1 to 5 or 1 to 3) halo, or, where valence allows, oxo, halo, hydroxyl, or amino. 1-12 optionally substituted with alkyl; Each R 5 and R 6are independently hydrogen, deuterium, and, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 Alkyl or C 3-12 cycloalkyl or R 5 and R 6 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, Each R 7 and R 8 are independently hydrogen, deuterium, or, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 alkyl or R 7 and R 8 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, R 1 , R 2 , R 3 , and R 4 At least one of the following is -L-(B) m This is subject to the condition that:

[0018] Also provided is a compound of formula IIIB, IVA, VB, or VIA, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, [ka] During the ceremony, R 2 -L-(B) m and m is 1, 2, or 3; L is a covalent bond or a linking moiety; Each B is independently a nuclear receptor targeting epitope.

[0019] Also provided are compounds of Table 1, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof.

[0020] Also provided are compositions comprising a compound described herein, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analogue, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0021] Also provided are methods of treating or preventing cancer, including administering an effective amount of a compound or composition described herein to an individual in need thereof. Cancers include, but are not limited to, liver cancer, melanoma, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, breast carcinoma, ovarian carcinoma, lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, soft tissue sarcoma, chronic lymphocytic leukemia, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, malignant melanoma, small cell lung carcinoma, gastric carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid ... The cancer may be blood cancer such as chromoma, choriocarcinoma, mycosis fungoides, head and neck carcinoma, osteosarcoma, pancreatic carcinoma, acute granulocytic leukemia, hairy cell leukemia, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial carcinoma, polycythemia vera, essential thrombocytosis, adrenocortical carcinoma, skin cancer, or prostate carcinoma, lung cancer, breast cancer, fallopian tube cancer, brain cancer, head and neck cancer, esophageal cancer, ovarian cancer, pancreatic cancer, peritoneal cancer, prostate cancer, or skin cancer.

[0022] Methods of treating or preventing bladder cancer, breast cancer, fallopian tube cancer, ovarian cancer, prostate cancer, peritoneal cancer, testicular cancer, endometrial cancer, or uterine cancer are also provided, comprising administering to an individual in need thereof an effective amount of a compound or composition described herein, or a pharmaceutically acceptable salt or solvate thereof.

[0023] Also provided are methods for treating or preventing cancer, including the use of testosterone, testosterone esters (e.g., testosterone enanthate, propionate, cypionate, etc., or analogs thereof), enobosarm, BMS-564929, PS178990, LGD-4033 (ligandrol), LGD-2941, AC-262, 356, JNJ-28330835, JNJ-37654032, JNJ-26146900 , LGD-2226, LGD-3303, LGD-121071, LG-120907, S-40503, S-23, RAD-140, acetothiolutamide, andarine (S-4), LG-121071, TFM-4AS-1, YK-11, MK-0773 (PF-05314882), GSK2849466, GSK2881078, GSK8698, GSK4336, ACP-105, TT701, LY2452473, a 1-(2-hydroxy-2-methyl-3-phenoxypropanoyl)-indoline-4-carbonitrile derivative (J Med Chem.2014,57(6),2462-71), Anordrin, bazedoxifene, broparestrol (Acnestrol), clomiphene (Clomid), cyclophen (Sexovid), lasofoxifene (Fablyn), ormeloxifene (Centron, Novex, Novex-DS, Sevista), ospemifene (Osphena, deaminohydroxyloremifene), raloxifene (Evista), tamoxifen (Nolvadex), toremifene (Faresto n;4-chlorotamoxifen), acolbifene, affimoxifen (4-hydroxytamoxifen; metabolite of tamoxifen), elastrant, enclomiphene ((E)-clomiphene), endoxifen (4-hydroxy-N-desmethyltamoxifen; metabolite of tamoxifen), zuclomiphene ((Z)-clomiphene), bazedofen, arzoxifene, brilanestrant, clomiphene oxide (clomiphene N-oxide; metabolite of clomiphene) ), droloxifene (3-hydroxytamoxifen), etacstil, fispemifene, GW-7604 (4-hydroxyetaxtil), idoxifene (pyrrolidino-4-iodotamoxifen), levormeloxifene ((L)-olmeloxifene), miproxifene, nafoxidine, nitromiphene (CI-628), panomiphene, pipendoxifene (ERA-923), trioxifene, keoxifene, LY117018, onapristone, fairston ( The present invention includes administering an effective amount of a compound, or a pharmaceutically acceptable salt or solvate thereof, comprising at least one nuclear payload and at least one nuclear receptor-targeting epitope, including toremifine citrate, zindoxifene (D-16726), fulvestrant, ARN-810, GW5638, GW7604, ulipristal acetate, asoprisnil (J867), mifepristone, telapristone (CDB-4124, Proellex, Progenta), or an analog thereof. In certain embodiments, the nuclear payload comprises a PARP inhibitor.

[0024] Also provided is a method for treating or preventing androgen receptor overexpression cancer, which comprises administering an effective amount of a compound, or its pharmaceutically acceptable salt or solvate, comprising at least one nuclear payload and at least one androgen receptor targeting epitope to an individual in need thereof.In certain embodiments, cancer is prostate cancer, breast cancer, triple-negative breast cancer, bladder cancer or liver cancer.In certain embodiments, the androgen receptor targeting epitope comprises an androgen receptor agonist, a selective androgen receptor modulator (SARM), an androgen receptor antagonist, a selective estrogen receptor modulator (SERM), an estrogen receptor antagonist, a progestin or an estrogen. In certain embodiments, the androgen receptor targeting epitope comprises enobosarm, bicalutamide, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, fulvestrant, megestrol acetate, estramustine, ketoconazole, abiraterone, darolutamide, or analogs thereof.In certain embodiments, the androgen receptor targeting epitope comprises enobosarm, bicalutamide, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, fulvestrant, megestrol acetate, estramustine, ketoconazole, abiraterone, or analogs thereof.In certain embodiments, the nuclear payload comprises a PARP inhibitor.

[0025] Also provided is a method for treating or preventing estrogen and / or progesterone receptor overexpression cancer, which comprises administering to an individual in need thereof an effective amount of a compound, or its pharmaceutically acceptable salt or solvate, comprising at least one nuclear payload and at least one estrogen and / or progesterone receptor targeting epitope.In certain embodiments, cancer is breast cancer, uterine cancer or ovarian cancer.In certain embodiments, the nuclear payload comprises a PARP inhibitor.

[0026] Also provided is a method for treating or preventing glucocorticoid receptor overexpression cancer, which comprises administering to an individual in need thereof an effective amount of a compound, or its pharmaceutically acceptable salt or solvate, comprising at least one nuclear payload and at least one glucocorticoid receptor targeting epitope.In certain embodiments, cancer is prostate cancer, breast cancer, uterine cancer or ovarian cancer.In certain embodiments, the nuclear payload comprises a PARP inhibitor.

[0027] Also provided are methods of treating or preventing cancer, comprising administering to an individual in need thereof an effective amount of a compound or composition described herein, or a pharmaceutically acceptable salt or solvate thereof, in combination with an additional chemotherapeutic agent.

[0028] There is also provided a method for treating or preventing a condition that can be ameliorated by inhibiting PARP in an individual in need thereof, the method comprising administering to the individual an effective amount of a compound or composition according to any of the preceding claims, or a pharmaceutically acceptable salt thereof. In an embodiment of the present invention, for example, the following items are provided: (Item 1) A compound comprising at least one nuclear payload and at least one nuclear receptor targeting epitope, wherein said compound comprises one nuclear payload and one nuclear receptor targeting epitope: The nuclear receptor targeting epitope is not a peptide, a protein, a nanoparticle, or an antibody; and The compound provided that when the nuclear receptor targeting epitope is an androgen receptor targeting epitope or an estrogen receptor targeting epitope, the nuclear payload is not doxorubicin or an analog thereof, and is not a hydroxamic acid that binds to histone deacetylase (HDAC). (Item 2) A compound comprising at least one nuclear payload that binds to the catalytic domain of poly(ADP-ribose) polymerase (PARP) and at least one nuclear receptor targeting epitope. (Item 3) 3. The compound according to item 1 or 2, wherein at least one nuclear receptor targeting epitope is a nuclear steroid receptor targeting epitope. (Item 4) 4. The compound according to any of items 1 to 3, wherein the nuclear payload is linked to one nuclear receptor targeting epitope via a non-biocleavable linking moiety and to one or more nuclear receptor targeting epitope(s) via a biocleavable linking moiety. (Item 5) 5. The compound according to any of items 1 to 4, wherein the compound comprises at least one nuclear payload that binds to a protein involved in the DNA damage repair process. (Item 6) 6. The compound according to any one of items 1 to 5, wherein the compound comprises at least one nuclear payload that binds to poly(ADP-ribose) polymerase (PARP), DNA-dependent protein kinase (DNA-PK), histone deacetylase (HDAC), enhancer of zeste homolog 2 (EZH2), histone acetyltransferase (HAT), methyltransferase, bromodomain, myelin transcription factor 1 (MYT1), p53, melanocyte-stimulating hormone (MSH), mutL homolog (MLH), ERCC1, apurinic / apyrimidinic site endonuclease 1 (APE1), topoisomerase I (Topo I), topoisomerase II (Topo II), Wee1, checkpoint kinase 1 (Chk1), checkpoint kinase 2 (Chk2), ataxia telangiectasia mutated (ATR), or ataxia telangiectasia mutated (ATM). (Item 7) The nuclear payload is selected from the group consisting of olaparib (AZD-2281), olaparib TOPARP-A, rucaparib (AG014699, PF-01367338), niraparib, talazoparib (BMN-673), veliparib (ABT-888), CEP 9722, E7016, BGB-290, 3-aminobenzamide, methoxyamine, CC-115, MSC2490484A, AZD6738, VX-970, AZD0156, GDC-0575, MK-8776, LY2606368, AZD1775, belotecan, CRLX101, irinotecan, LMP 400, LMP 776, NKTR-102, topotecan, doxorubicin, epirubicin, etoposide, idarubicin, mitoxantrone, teniposide, vorinostat, romidepsin (Istodax), chidamide, panobinostat (Farydak), belinostat (PXD101), panobinostat (LBH589), valproic acid (as magnesium valproate), mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat (MS-275), SB939 , resminostat (4SC-201), gibinostat (ITF2357), xinostat (JNJ-26481585), HBI-8000, quebetrine, CUDC-101, AR-42, CHR-2845, CHR-3996, 4SC-202, CG200745, ACY-1215, ME-344, sulforaphane, tazemetostat, MAK638, CPI-1205), DS-3201b, anacardic acid, MG149, C646, S-adenosylmethionine, JQ1, I-BET 151 (GSK1210151A), I-BET 762 (GSK525762), OTX-015, TEN-010, CPI-203, CPI-0610, Orinone, LY294002, or an analog thereof. (Item 8) 3. The compound according to item 2, wherein the compound comprises at least one nuclear payload that binds to the catalytic domain of poly(ADP-ribose) polymerase (PARP). (Item 9) 3. The compound according to item 2, wherein the catalytic domain contains a conserved HYE motif. (Item 10) The compound has an IC of less than about 500 nM 50 10. The compound according to any one of items 1 to 9, comprising at least one nuclear payload that binds to poly(ADP-ribose) polymerase (PARP) in a manner consistent with the present invention. (Item 11) 9. The compound according to item 8, wherein the PARP comprises PARP-1 and / or PARP-2, or a mutant form thereof. (Item 12) the compound is of formula I or II, A-(LB) m I AL-(B) m II During the ceremony, A is the nuclear payload, m is 1, 2, or 3; each B is independently a nuclear receptor targeting epitope; 12. The compound according to any of items 1 to 11, wherein each L is independently a covalent bond or a linking moiety. (Item 13) A compound of formula III, IV, V, or VI,

change

change

[0029] The following description describes exemplary embodiments of the present technology, but it should be recognized that such description is not intended as a limitation on the scope of the present disclosure, but is instead provided as a description of exemplary embodiments.

[0030] 1.Definition As used herein, the following words, phrases, and symbols are intended to have the meanings generally set forth below, except to the extent that the context in which they are used indicates otherwise.

[0031] The term "about" refers to a ±1%, ±3%, ±5%, or ±10% variation of the specified value. For example, "about 50" may, in some embodiments, include a range of 45 to 55. In the case of integer ranges, the term "about" may include one or two integers greater than and / or less than the recited integers at either end of the range. Unless otherwise indicated herein, the term "about" is intended to include values ​​adjacent to the recited range, e.g., weight percent, that are equivalent in terms of the function of the individual component, composition, or embodiment. Additionally, the singular forms "a" and "the" include plural referents unless the context clearly dictates otherwise. Thus, reference to "the compound" includes a plurality of such compounds, and reference to "the assay" includes reference to one or more compounds and equivalents thereof known to those of skill in the art.

[0032] "Alkyl" refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl refers to an alkyl group having 1 to 10 carbon atoms (i.e., C 1-10 alkyl), 1 to 8 carbon atoms (i.e., C 1-8 alkyl), 1 to 6 carbon atoms (i.e., C 1-6 alkyl), or 1 to 4 carbon atoms (i.e., C 1-4 Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue having a specific number of carbons is named by a chemical name or identified by a molecular formula, all positional isomers having that number of carbons can be encompassed. Thus, for example, "butyl" refers to n-butyl (i.e., -(CH2)3CH3), sec-butyl (i.e., -(CH2)3CH3), ... "propyl" includes n-propyl (i.e., -(CH2)2CH3) and isopropyl (i.e., -CH(CH3)2).

[0033] "Haloalkyl" refers to an unbranched or branched alkyl group, as defined above, in which one or more hydrogen atoms are replaced with halogen. For example, if a residue is substituted with two or more halogens, it can be referred to by using a prefix corresponding to the number of halogen moieties attached. Dihaloalkyl and trihaloalkyl refer to alkyl substituted with two ("di") or three ("tri") halo groups, which may, but are not necessarily, the same halogen. Examples of haloalkyl include difluoromethyl (-CHF2) and trifluoromethyl (-CF3).

[0034] "Heteroalkyl" refers to an alkyl group in which one or more of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatom groups. The term "heteroalkyl" includes unbranched or branched saturated chains having carbon and heteroatoms. By way of example, one, two, or three carbon atoms may be independently replaced with the same or different heteroatom groups. Heteroatom groups include, but are not limited to, -NH-, -O-, -S-, -S(O)-, -S(O)2-, and the like. As used herein, heteroalkyl includes 1 to 8 carbon atoms, or 1 to 4 carbon atoms and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom.

[0035] "Alkoxy" refers to the group "-O-alkyl."

[0036] "Alkenyl" refers to an alkyl group containing at least one carbon-carbon double bond and having 2 to 20 carbon atoms (i.e., C 2-20 alkenyl), 2 to 8 carbon atoms (i.e., C 2-8alkenyl), 2 to 6 carbon atoms (i.e., C 2-6 alkenyl), or 2 to 4 carbon atoms (i.e., C 2-4 Examples of alkenyl groups include ethenyl, propenyl, and butadienyl (including 1,2-butadienyl and 1,3-butadienyl).

[0037] "Alkynyl" refers to an alkyl group containing at least one carbon-carbon triple bond and having 2 to 20 carbon atoms (i.e., C 2-20 alkynyl), 2 to 8 carbon atoms (i.e., C 2-8 alkynyl), 2 to 6 carbon atoms (i.e., C 2-6 alkynyl), or 2 to 4 carbon atoms (i.e., C 2-4 The term "alkynyl" also includes those groups having one triple bond and one double bond.

[0038] "Alkoxy" refers to the group "alkyl-O-." Examples of alkoxy groups include, for example, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.

[0039] "Alkoxyalkyl" refers to the group "alkyl-O-alkyl."

[0040] "Amino" is R y and R z are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; y R z each of which may be optionally substituted as defined herein.

[0041] "Aryl" refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic), including fused systems. As used herein, aryl refers to an aromatic carbocyclic group having 6 to 20 ring carbon atoms (i.e., C 6-20 aryl), 6 to 12 carbon ring atoms (i.e., C 6-12 aryl), or 6 to 10 carbon ring atoms (i.e., C 6-10 aryl). Examples of aryl groups include, for example, phenyl, naphthyl, fluorenyl, and anthryl. However, aryl does not encompass or overlap in any way with heteroaryl, as defined below. When one or more aryl groups are fused with a heteroaryl, the resulting ring system is a heteroaryl. When one or more aryl groups are fused with a heterocyclyl, the resulting ring system is a heterocyclyl.

[0042] "Cycloalkyl" refers to saturated or partially unsaturated cyclic alkyl groups having a single ring or multiple rings, including fused, bridged, and spiro ring systems. The term "cycloalkyl" refers to cycloalkenyl groups (i.e., cyclic groups having at least one double bond) and cyclic groups having at least one sp 3 As used herein, cycloalkyl includes carbocyclic fused ring systems (i.e., at least one non-aromatic ring) having 3 to 20 ring carbon atoms (i.e., C 3-20 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C 3-12 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C 3-10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C 3-8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C 3-6Cycloalkyls have a cyclic group (cycloalkyl). Monocyclic groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Furthermore, the term cycloalkyl is intended to encompass any non-aromatic ring that can be fused to an aryl ring, regardless of attachment to the rest of the molecule. Furthermore, cycloalkyl also includes "spirocycloalkyls" when there are two positions for substitution on the same carbon atom.

[0043] "Heteroaryl" refers to an aromatic group having a single ring, multiple rings, or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. As used herein, heteroaryl refers to an aromatic group having 1 to 20 ring carbon atoms (i.e., C 1-20 heteroaryl), 3 to 12 ring carbon atoms (i.e., C 3-12 heteroaryl), or 3 to 8 carbon ring atoms (i.e., C 3-8 Heteroaryl) and 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. In certain cases, heteroaryl includes 5-10-membered, 5-7-membered, or 5-6-membered ring systems, each independently having 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. Any aromatic ring having single or multiple fused rings containing at least one heteroatom is considered heteroaryl regardless of attachment to the rest of the molecule (i.e., through any one of the fused rings). Heteroaryl does not encompass or overlap with aryl, as defined above.

[0044] "Heterocyclyl" refers to a saturated or partially unsaturated cyclic alkyl group having one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. The term "heterocyclyl" includes heterocycloalkenyl groups (i.e., heterocyclyl groups having at least one double bond), bridged heterocyclyl groups, fused heterocyclyl groups, and spiroheterocyclyl groups. A heterocyclyl may be a single ring or multiple rings, where the multiple rings may be fused, bridged, or spiro, and may contain one or more (e.g., 1-3) oxo (=O) or N-oxide (-O) groups. - ). Non-aromatic rings containing at least one heteroatom are considered heterocyclyl, regardless of attachment (i.e., they may be attached via a carbon atom or a heteroatom). Additionally, the term heterocyclyl is intended to encompass any non-aromatic ring containing at least one heteroatom, regardless of attachment to the rest of the molecule, and the ring may be fused to an aryl or heteroaryl ring. As used herein, heterocyclyl refers to a ring having 2 to 20 ring carbon atoms (i.e., C 2-20 heterocyclyl), 2 to 12 ring carbon atoms (i.e., C 2-12 heterocyclyl), 2 to 10 ring carbon atoms (i.e., C 2-10 heterocyclyl), 2 to 8 ring carbon atoms (i.e., C 2-8 heterocyclyl), 3 to 12 ring carbon atoms (i.e., C 3-12 heterocyclyl), 3 to 8 ring carbon atoms (i.e., C 3-8 heterocyclyl), or 3 to 6 ring carbon atoms (i.e., C 3-6 Heterocyclyl) having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur, or oxygen. The term "heterocyclyl" also includes "spiroheterocyclyl" when there are two positions for substitution on the same carbon atom.

[0045] "Alkylene" refers to a divalent alkyl group, as defined above. As used herein, alkylene refers to an alkyl group having 1 to 10 carbon atoms (i.e., C 1-10 alkylene), 1 to 8 carbon atoms (i.e., C 1-8 alkylene), 1 to 6 carbon atoms (i.e., C 1-6 alkylene), or 1 to 4 carbon atoms (i.e., C 1-4 alkylene).

[0046] "Heteroalkylene" refers to an alkylene group in which one or more of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatom groups. The term "heteroalkylene" includes unbranched or branched saturated chains having carbon and heteroatoms. By way of example, one, two, or three carbon atoms may be independently replaced with the same or different heteroatom groups. Heteroatom groups include, but are not limited to, -NH-, -O-, -S-, -S(O)-, -S(O)2-, and the like. As used herein, heteroalkylene includes 1 to 8 carbon atoms, or 1 to 4 carbon atoms and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom.

[0047] "Alkenylene" refers to an alkyl group containing at least one carbon-carbon double bond and having 2 to 8 carbon atoms (i.e., C 2-8 alkenylene), 2 to 6 carbon atoms (i.e., C 2-6 alkenylene), or 2 to 4 carbon atoms (i.e., C 2-4 It refers to an alkylene group having an alkylene group (alkenylene).

[0048] "Heteroalkenylene" refers to a heteroalkylene group containing at least one carbon-carbon double bond and having 2 to 8 carbon atoms, 2 to 6 carbon atoms, or 2 to 4 carbon atoms and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom. The term "heteroalkynyl" also includes those groups having one triple bond and one double bond.

[0049] "Alkynylene" refers to an alkyl group containing at least one carbon-carbon triple bond and having 2 to 8 carbon atoms (i.e., C 2-8 alkynylene), 2 to 6 carbon atoms (i.e., C 2-6 alkynylene), or 2 to 4 carbon atoms (i.e., C 2-4 The term "alkynyl" also includes those groups having one triple bond and one double bond.

[0050] "Heteroalkynylene" refers to a heteroalkylene group containing at least one carbon-carbon triple bond and having 2 to 8 carbon atoms, 2 to 6 carbon atoms, or 2 to 4 carbon atoms and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom. The term "heteroalkynyl" also includes those groups having one triple bond and one double bond.

[0051] "Cycloalkylene" refers to a divalent saturated or partially unsaturated cyclic alkyl group having a single ring or multiple rings, including fused, bridged, and spiro ring systems. The term "cycloalkylene" includes cycloalkenylene groups (i.e., cyclic groups having at least one double bond). As used herein, cycloalkenylene refers to a cyclic group having 3 to 10 ring carbon atoms (i.e., C 3-10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C 3-8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C 3-6 cycloalkyl).

[0052] "Heterocycloalkylene" refers to a cycloalkylene group in which one or more of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatom groups. By way of example, one, two, or three carbon atoms may be independently replaced with the same or different heteroatom groups. Heteroatom groups include, but are not limited to, -NH-, -O-, -S-, -S(O)-, -S(O)2-, and the like. As used herein, heterocycloalkylene contains 1 to 9 carbon atoms, or 1 to 4 carbon atoms, and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom.

[0053] "Oxo" refers to =O.

[0054] "Halogen" or "halo" includes fluoro, chloro, bromo, and iodo.

[0055] The term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur. The term "optionally substituted" refers to the fact that any one or more hydrogen atoms on a specified atom or group may or may not be replaced by a non-hydrogen moiety.

[0056] Also provided are stereoisomers, mixtures of stereoisomers, tautomers, hydrates, solvates, isotopically enriched analogs, and pharmaceutically acceptable salts of the compounds described herein.

[0057] The compounds disclosed herein, or their pharmaceutically acceptable salts, contain asymmetric centers and can therefore give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined with respect to absolute stereochemistry as (R)- or (S)-, or for amino acids, as (D)- or (L)-. The present disclosure is intended to encompass all such possible isomers, as well as their racemic and optically pure forms. Optically active (+)- and (-), (R)- and (S)-, or (D)- and (L)-isomers can be prepared using chiral synthons or chiral reagents or separated using conventional techniques, such as chromatography and fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from suitable optically pure precursors or separation of the racemate (or racemate of a salt or derivative) using, for example, chiral high-pressure liquid chromatography (HPLC). When compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, unless otherwise specified, the compounds are intended to include both E and Z geometric isomers.

[0058] "Stereoisomer" refers to a compound composed of the same atoms bonded by the same bonds but with different, incompatible three-dimensional structures. The present disclosure contemplates various stereoisomers and mixtures thereof, including "enantiomers," which refer to two stereoisomers whose molecules are non-superimposable mirror images of one another, and "diastereomers," which refer to stereoisomers that have at least two asymmetric atoms but are not mirror images of one another. Thus, all stereoisomers (e.g., geometric isomers, optical isomers, etc.) of the present compounds (including salts, solvates, and hydrates of the compounds), including those that may exist due to asymmetric carbons on various substituents (including enantiomeric forms (which may exist even when asymmetric carbons are absent), rotamer forms, atropisomers, and diastereomeric forms), are contemplated.

[0059] Diastereomeric mixtures can be separated into their individual diastereomers based on their physical chemical differences by methods well known to those skilled in the art, such as, for example, chromatography and / or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture to a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., a chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers, and converting the individual diastereomers to the corresponding pure enantiomers (e.g., by hydrolysis). Additionally, some of the compounds of Formula (1) may be atropisomers and are considered part of the present disclosure. Stereoisomers can also be separated using chiral HPLC.

[0060] Some compounds exist as tautomers. Tautomers are in equilibrium with each other. For example, an amide-containing compound may exist in equilibrium with an imidic acid tautomer. Regardless of which tautomer is shown and the nature of the equilibrium between the tautomers, the compound is understood by those skilled in the art to include both the amide and imidic acid tautomers. Thus, amide-containing compounds are understood to include their imidic acid tautomers. Similarly, imidic acid-containing compounds are understood to include their amide tautomers.

[0061] The term "hydrate" refers to a complex formed by combining a compound described herein with water.

[0062] "Solvate" refers to an association or complex of one or more solvent molecules with a compound of the present disclosure. Examples of solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, and ethanolamine.

[0063] Any formula or structure described herein is also intended to represent unlabeled and isotopically labeled forms of compounds.These forms of compounds are sometimes referred to as "isotopically enriched analogs."Isotopically labeled compounds have the structure shown herein, except that one or more atoms are replaced by atoms with selected atomic masses or mass numbers.Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine and iodine, for example, 2 H, 3 H, 11 C. 13 C. 14 C. 13 N, 15 N, 15 O. 17 O. 18 O. 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I, and 125 I. Various isotopically labeled compounds of the present disclosure, such as 3 H, 13 C, and 14 Those incorporating a radioactive isotope such as C. Such isotopically labeled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques such as positron emission tomography (PET) or single photon emission computed tomography (SPECT) (including drug or substrate tissue distribution assays), or in radiotherapy of patients. Such compounds may exhibit increased resistance to metabolism and are therefore useful for increasing the half-life of any compound when administered to mammals, particularly humans. Such compounds are synthesized by means well known in the art, for example, by using starting materials in which one or more hydrogens have been replaced by deuterium.

[0064] Certain compounds disclosed herein contain one or more ionizable groups (groups that can remove a proton (e.g., —COOH) or add a proton (e.g., an amine), or groups that can be quaternized (e.g., an amine)). All possible ionic forms of such molecules and salts thereof are intended to be individually included in the disclosure herein. With respect to salts of the compounds described herein, one of skill in the art can select an appropriate counterion from among a wide variety of available counterions. For certain applications, the selection of a given anion or cation for the preparation of a salt can increase or decrease the solubility of the salt.

[0065] As used herein, the term "non-biocleavable linking moiety" is intended to refer to a linking moiety that is not readily hydrolyzed under physiological conditions. As used herein, the term "biocleavable linking moiety" is intended to refer to a linking moiety that is readily hydrolyzed under physiological conditions. In certain embodiments, at least one linking moiety is hydrolyzed under intracellular conditions (e.g., low pH).

[0066] As used herein, the term "cancer" refers to a class of mammalian diseases characterized by uncontrolled cell growth. The term "cancer" is used interchangeably with the terms "tumor," "solid tumor," "malignant tumor," "hyperproliferative," and "neoplasm." Cancer includes all types of hyperproliferative, hyperplastic, neoplastic, cancerous growths or carcinogenic processes, metastatic tissues, or malignantly transformed cells, tissues, or organs, regardless of histopathological type or stage of invasion. Examples include lung, prostate, head and neck, breast, and colorectal cancers, melanoma, and gliomas (such as high-grade gliomas, including glioblastoma multiforme (GBM)—the most common and most lethal malignant primary brain tumor in adults).

[0067] The phrase "solid tumor" includes, for example, lung cancer, head and neck cancer, brain cancer, oral cancer, colorectal cancer, breast cancer, prostate cancer, pancreatic cancer, and liver cancer. Other types of solid tumors are named for the particular cells that form them, such as sarcomas formed from connective tissue cells (e.g., bone, cartilage, fat), carcinomas formed from epithelial tissue cells (e.g., breast, colon, pancreas), and lymphomas formed from lymphatic tissue cells (e.g., lymph node, spleen, thymus). Regardless of the naming convention, treatment of all types of solid tumors is within the scope of this disclosure.

[0068] "Chemotherapeutic agent" refers to any substance that can reduce or prevent the growth, proliferation, or spread of cancer cells, populations of cancer cells, tumors, or other malignant tissue. The term is also intended to encompass radiation therapy or any anti-tumor or anti-cancer agent.

[0069] As used herein, "treatment" or "treating" is an approach for obtaining beneficial or desired results, such as clinical results. For purposes of this disclosure, beneficial or desired clinical results include, but are not limited to, alleviating symptoms associated with a disease or condition, and / or reducing the severity of symptoms, and / or preventing worsening of symptoms. In one variation, beneficial or desired clinical results include, but are not limited to, alleviating symptoms associated with cognitive disorders, psychiatric disorders, neurotransmitter-mediated disorders, and / or neurological disorders, and / or reducing the severity of symptoms, and / or preventing worsening of symptoms. Preferably, treatment of a disease or condition with a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is achieved with no or fewer side effects than those associated with currently available treatments for the disease or condition, and / or by improving the quality of life of the individual.

[0070] The terms "inhibit," "inhibiting," and "inhibition" refer to slowing, stopping, or reversing the growth or progression of a disease, infection, condition, or group of cells. Inhibition can be, for example, about 20%, 40%, 60%, 80%, 90%, 95%, or 99% greater than the growth or progression that would occur in the absence of treatment or contact.

[0071] As used herein, "combination therapy" refers to a therapy comprising two or more different compounds. Thus, in one aspect, a combination therapy comprising a compound detailed herein and anther compound is provided. In some variations, the combination therapy optionally includes one or more pharmaceutically acceptable carriers or excipients, non-pharmacologically active compounds, and / or inactive substances. In various embodiments, treatment with a combination therapy may produce additive or even synergistic (e.g., greater than additive) results compared to administration of a single compound of the present disclosure alone. In some embodiments, a lower amount of each compound is used as part of the combination therapy compared to the amount typically used in the individual therapy. Preferably, the same or greater therapeutic effect is achieved by using the combination therapy than by using any of the individual compounds alone. In some embodiments, the same or greater therapeutic effect is achieved by using a lower amount of the compound in the combination therapy (e.g., a lower dose or a less frequent administration schedule) than the amount typically used for the individual compound or therapy. Preferably, the use of lower amounts of the compound results in a reduction in the number, severity, frequency, and / or duration of one or more side effects associated with the compound.

[0072] As used herein, the term "effective amount" refers to that amount of a compound of the present disclosure that should be effective in a given treatment regimen, based on efficacy and toxicity parameters and the knowledge of the practitioner.As understood in the art, an effective amount may be one or more doses, i.e., a single dose or multiple doses may be required to achieve a desired therapeutic endpoint.An effective amount may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if it can achieve or achieves a desired or beneficial result in conjunction with one or more other agents.The appropriate dose of any co-administered compound may optionally be lowered due to the combined effects (e.g., additive or synergistic effects) of the compounds.

[0073] As used herein, the term "agonist" refers to a compound, the presence of which results in a biological activity of a protein that is the same as the biological activity that results from the presence of a naturally occurring ligand of the protein, e.g., PARP.

[0074] As used herein, the term "partial agonist" refers to a compound whose presence results in a biological activity of a protein that is of the same kind, but of a lesser magnitude, as would result from the presence of the protein's naturally occurring ligand.

[0075] As used herein, the terms "antagonist" or "inhibitor" refer to a compound, the presence of which results in a decrease in the magnitude of the biological activity of a protein. In certain embodiments, the presence of an antagonist results in complete inhibition of the biological activity of a protein, such as, for example, the enzyme poly(ADP-ribose) polymerase (PARP).

[0076] As used herein, IC 50 refers to the amount, concentration, or dosage of a particular test compound that achieves 50% inhibition of a maximal response, such as modulation of PARP, in an assay that measures such response.

[0077] As used herein, EC 50 refers to the dose, concentration, or amount of a particular test compound that elicits a dose-dependent response at 50% of the maximal expression of the particular response induced, elicited, or potentiated by the particular test compound.

[0078] As used herein, the term "cancer" refers to an abnormal growth of cells that tend to proliferate in an uncontrolled manner and, in some cases, metastasize (spread). Types of cancer include, but are not limited to, solid tumors (such as those of the bladder, bowel, brain, breast, endometrium, heart, kidney, lung, lymphatic tissue (lymphoma), ovary, pancreas, or other endocrine organs (thyroid)), prostate, skin (melanoma), or blood tumors (such as leukemia).

[0079] As used herein, the term "carrier" refers to relatively nontoxic chemical compounds or agents that facilitate the incorporation of a compound into cells or tissues.

[0080] As used herein, "unit dosage form" refers to physically discrete units suitable as unitary dosage forms, each unit containing a predetermined quantity of active ingredient calculated to produce a desired therapeutic effect in association with the required pharmaceutical carrier. Unit dosage forms may include monotherapy or combination therapy.

[0081] As used herein, the term "controlled release" refers to a drug-containing formulation or fraction thereof in which the release of the drug is not immediate; i.e., in a "controlled release" formulation, administration does not result in the immediate release of the drug into an absorption pool. The term also encompasses depot formulations designed to gradually release a drug compound over an extended period of time. Controlled release formulations can include a wide variety of drug delivery systems, generally involving mixing a drug compound with a carrier, polymer, or other compound having the desired release characteristics (e.g., pH-dependent or pH-independent solubility, varying degrees of water solubility, etc.) and formulating the mixture according to the desired delivery route (e.g., coated capsules, implantable reservoirs, injectable solutions containing biodegradable capsules, etc.).

[0082] As used herein, "pharmaceutically acceptable" or "pharmacologically acceptable" is intended to mean a material that is not biologically or otherwise undesirable, e.g., a material that can be incorporated into a pharmaceutical composition administered to a patient without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained. A pharmaceutically acceptable carrier or excipient preferably meets the required standards of toxicological and manufacturing testing and / or is included in the Inactive Ingredients Guide prepared by the U.S. Food and Drug Administration.

[0083] A "pharmaceutically acceptable salt" is a salt that retains at least some of the biological activity of the free (non-salt) compound and can be administered to an individual as a drug or pharmaceutical. Examples of such salts include: (1) acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid, or with organic acids such as acetic acid, oxalic acid, propionic acid, succinic acid, maleic acid, and tartaric acid; and (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion, such as an alkali metal ion, an alkaline earth ion, or an aluminum ion, or with an organic base. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, and the like. Acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like. Further examples of pharmaceutically acceptable salts include those listed in Berge et al., Pharmaceutical Salts, J. Pharm. Sci. 1977 Jan;66(1):1-19. Pharmaceutically acceptable salts can be prepared in situ during the manufacturing process or by separately reacting the purified compounds of the present disclosure in their free or base form with a suitable organic or inorganic base or acid, respectively, and isolating the salt thus formed during subsequent purification. Reference to a pharmaceutically acceptable salt should be understood to include its solvent addition or crystalline forms, particularly solvates or polymorphs. Solvates contain either stoichiometric or non-stoichiometric amounts of solvent and are often formed during the crystallization process. They form hydrates when the solvent is water, or alcoholate salts when the solvent is alcohol. Polymorphs include different crystalline packing arrangements of the same elemental composition of a compound. Polymorphs typically have different X-ray diffraction patterns, infrared spectra, melting points, densities, hardness, crystal shapes, optical and electrical properties, stability, and solubility. Various factors, such as the recrystallization solvent, crystallization rate, and storage temperature, can cause a single crystalline form to predominate.

[0084] As used herein, the term "excipient" refers to an inactive or non-active substance that can be used in the manufacture of a drug or pharmaceutical preparation, such as a tablet, containing a compound of the present disclosure as an active ingredient. A variety of substances can be encompassed by the term excipient, including, but not limited to, binders, disintegrants, coatings, compression / encapsulation aids, creams or lotions, lubricants, solutions for parenteral administration, chewable tablet materials, sweeteners or flavorings, suspending / gelling agents, or any substance used as a wet granulator. Binders include, for example, carbomer, povidone, xanthan gum, and the like. Coatings include, for example, cellulose acetate phthalate, ethyl cellulose, gellan gum, maltodextrin, enteric coatings, and the like. Compression / encapsulation aids include, for example, calcium carbonate, dextrose, fructose dc (directly compressible), honey dc, lactose (anhydrous or monohydrate; optionally in combination with aspartame, cellulose, or microcrystalline cellulose), starch dc, sucrose, etc. Disintegrants include, for example, croscarmellose sodium, gellan gum, sodium starch glycolate, etc. Creams or lotions include, for example, maltodextrin, carrageenan, etc. Lubricants include, for example, magnesium stearate, stearic acid, sodium stearyl fumarate, etc. Chewable tablet materials include, for example, dextrose, fructose dc, lactose (monohydrate, optionally in combination with aspartame or cellulose), etc. Suspending / gelling agents include, for example, carrageenan, sodium starch glycolate, xanthan gum, etc. Sweeteners include, for example, aspartame, dextrose, fructose dc, sorbitol, sucrose dc, etc., and wet granulating agents include, for example, calcium carbonate, maltodextrin, microcrystalline cellulose, etc.

[0085] compound Provided herein is a compound comprising at least one nuclear payload and at least one nuclear receptor targeting epitope.The compounds described herein can target the nucleus of a cell by recognizing and binding the nuclear receptor targeting epitope to its respective binding site, and delivering the nuclear payload to the nucleus of a cell.The nuclear payload can then bind to one or more target sites in the nucleus and / or disrupt one or more cellular processes, causing cell death.In certain embodiments, the nuclear payload is linked to the nuclear receptor targeting epitope(s) via a linking moiety.In certain embodiments, the linking moiety provides a single or single link, which means that the linker is only conjugated to one atom of each of the payload and the epitope.

[0086] The compounds described herein can comprise two or more nuclear receptor targeting epitopes, which can be the same or different, such that the compounds are directed to one or more cellular targets in addition to the nucleus.

[0087] Thus, there is provided a compound of formula I, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analogue, or pharmaceutically acceptable salt thereof, A-(LB) m I During the ceremony, A is the nuclear payload, m is 1, 2, or 3; each B is independently a nuclear receptor targeting epitope; Each L is independently a covalent bond or a linking moiety.

[0088] In certain embodiments, one or more nuclear receptor targeting epitopes are linked to the nuclear payload via a single linking moiety.Therefore, there is also provided a compound of Formula II, or a stereoisomer, a mixture of stereoisomers, a hydrate, a solvate, an isotopically enriched analog, or a pharmaceutically acceptable salt thereof, AL-(B) m II During the ceremony, A is the nuclear payload, m is 1, 2, or 3; each B is independently a nuclear receptor targeting epitope; L is a linking moiety.

[0089] In certain embodiments, the nuclear receptor targeting epitope of Formula I or II is a nuclear hormone receptor targeting epitope. In certain embodiments, the nuclear receptor targeting epitope of Formula I or II is a nuclear steroid receptor targeting epitope.

[0090] Also provided is a compound of Formula I or Formula II, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, A-(LB) m I AL-(B) m II During the ceremony, A is the nuclear payload, m is 1, 2, or 3; each B is independently a nuclear receptor-targeting epitope derived from estrogen, estetrol, estriol, estrone, progesterone, enobosarm, bicalutamide, apalutamide, testosterone, dihydrotestosterone, testosterone, 19-nortestosterone, progesterone, andarine, cortisol, prednisone, estradiol, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, bazedoxifene, ospemifene, megestrol acetate, estramustine, abiraterone, LGD-2941, BMS-564929, ostarine, ulipristal acetate, asoprisnil (J867), mifepristone, telapristone (CDB-4124, Proellex, Progenta), or an analog thereof; Each L is independently a covalent bond or a linking moiety.

[0091] Also provided is a compound of formula I, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, A-(LB) m I During the ceremony, A is a nuclear payload that binds to poly(ADP-ribose) polymerase-1 (PARP-1) and / or poly(ADP-ribose) polymerase PARP-2); m is 1, 2, or 3; each B is independently a nuclear receptor-targeting epitope derived from estrogen, estetrol, estriol, estrone, progesterone, enobosarm, bicalutamide, apalutamide, testosterone, dihydrotestosterone, estradiol, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, bazedoxifene, ospemifene, megestrol acetate, estramustine, abiraterone, LGD-2941, BMS-564929, ostarine, or an analog thereof; Each L is independently a covalent bond or a linking moiety.

[0092] Also provided is a compound of formula II, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, AL-(B) m II During the ceremony, A is a nuclear payload that binds to poly(ADP-ribose) polymerase-1 (PARP-1) and / or poly(ADP-ribose) polymerase PARP-2); m is 1, 2, or 3; each B is independently a nuclear receptor-targeting epitope derived from estrogen, estetrol, estriol, estrone, progesterone, enobosarm, bicalutamide, apalutamide, testosterone, dihydrotestosterone, estradiol, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, bazedoxifene, ospemifene, megestrol acetate, estramustine, abiraterone, LGD-2941, BMS-564929, ostarine, or an analog thereof; Each L is independently a covalent bond or a linking moiety.

[0093] The "linking moiety" of any compound described herein can be biocleavable (e.g., acid labile) or non-biocleavable. A linking moiety can be linear, branched, saturated, unsaturated, all carbon, or heteroatoms. A linking moiety can also be fused, saturated, unsaturated, and contain one or more rings that are all carbon or heteroatoms. In certain embodiments, a linking moiety is a non-biocleavable linking moiety. In certain embodiments, a linking moiety is a biocleavable linking moiety. In certain embodiments, a nuclear payload is linked to one nuclear steroid receptor targeting epitope via a non-biocleavable linking moiety and to one or more nuclear steroid receptor targeting epitope(s) via a biocleavable linking moiety. In certain embodiments, a biocleavable linking moiety is an acid labile linking moiety. In some embodiments, a linking moiety comprises a hydrazone linkage.

[0094] It is contemplated that any linking moiety may be used in the compounds described herein, provided that it does not significantly interfere with or disrupt the desired binding of the nuclear payload or nuclear receptor targeting epitope. In some embodiments, the linking moiety is an alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, arylene, heteroarylene, cycloalkylene, or heterocycloalkylene, wherein each alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, arylene, heteroarylene, cycloalkylene, or heterocycloalkylene may optionally include an arylene, heteroarylene, cycloalkylene, or heterocycloalkylene, and further, each alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, arylene, heteroarylene, cycloalkylene, or heterocycloalkylene may independently be selected from the group consisting of oxo, halo, C 1-4 Alkyl, C 1-4 Alkoxy, and C 1-4 Optionally substituted with 1 to 5 substituents independently selected from haloalkyl.

[0095] In certain embodiments, the linking moiety is of the formula: -Y 1 -(CH2) n’ -Y 2 -(CH2) m’ -Y 3 - During the ceremony, Y 1 , Y 2 , and Y 3 each independently represents a bond, -NR 11 -, -O-, -S(O) 0-2 -, -NR 11 C(O)-, -C(O)NR 11 -, -NR 11 S(O)2-, -S(O)2NR 11 -, -CR 12 =N-NR 11 -, -NR 11 -N=CR 12-, -C(O)-, arylene, heteroarylene, cycloalkylene, or heterocycloalkylene, and each alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, arylene, heteroarylene, cycloalkylene, or heterocycloalkylene independently is selected from oxo, halo, C 1-4 Alkyl, C 1-4 Alkoxy, and C 1-4 optionally substituted with 1 to 5 substituents independently selected from haloalkyl; Each R 11 independently, C 1-4 Alkyl, C 1-4 haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; Each R 12 independently, C 1-4 Alkyl, C 1-4 haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; n' and m' are each independently 0, 1, 2, 3, 4, 5, 6, 7, or 8.

[0096] Also provided is a compound of formula IA, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, A-(Y 1 -(CH2) p -Y 2 -(CH2) q -Y 3 -B) r IA During the ceremony, A is a nuclear payload that binds to poly(ADP-ribose) polymerase-1 (PARP-1) and / or poly(ADP-ribose) polymerase PARP-2); r is 1, 2, or 3; each B is independently a nuclear receptor-targeting epitope derived from estrogen, estetrol, estriol, estrone, progesterone, enobosarm, bicalutamide, apalutamide, testosterone, dihydrotestosterone, estradiol, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, bazedoxifene, ospemifene, megestrol acetate, estramustine, abiraterone, LGD-2941, BMS-564929, ostarine, or an analog thereof; Y 1 , Y 2 , and Y 3 each independently represents a bond, -NR 11 -, -O-, -S(O) 0-2 -, -NR 11 C(O)-, -C(O)NR 11 -, -NR 11 S(O)2-, -S(O)2NR 11 -, -CR 12 =N-NR 11 -, -NR 11 -N=CR 12 -, -C(O)-, arylene, heteroarylene, cycloalkylene, or heterocycloalkylene, and each alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, arylene, heteroarylene, cycloalkylene, or heterocycloalkylene independently is selected from oxo, halo, C 1-4 Alkyl, C 1-4 Alkoxy, and C 1-4 optionally substituted with 1 to 5 substituents independently selected from haloalkyl; Each R 11 independently, C 1-4 Alkyl, C 1-4 haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; Each R 12 independently, C 1-4 Alkyl, C 1-4 haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; p and q are each independently 0, 1, 2, 3, 4, 5, 6, 7, or 8.

[0097] Also provided is a compound of formula IIA, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, AY 1 -(CH2) p -Y 2 -(CH2) q -Y 3 -(B) r IIA During the ceremony, A is a nuclear payload that binds to poly(ADP-ribose) polymerase-1 (PARP-1) and / or poly(ADP-ribose) polymerase PARP-2); r is 1, 2, or 3; each B is independently a nuclear receptor-targeting epitope derived from estrogen, estetrol, estriol, estrone, progesterone, enobosarm, bicalutamide, apalutamide, testosterone, dihydrotestosterone, estradiol, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, bazedoxifene, ospemifene, megestrol acetate, estramustine, abiraterone, LGD-2941, BMS-564929, ostarine, or an analog thereof; Y 1 , Y 2 , and Y 3 each independently represents a bond, -NR 11 -, -O-, -S(O) 0-2 -, -NR 11 C(O)-, -C(O)NR 11 -, -NR 11 S(O)2-, -S(O)2NR 11 -, -CR 12 =N-NR 11 -, -NR 11 -N=CR 12-, -C(O)-, arylene, heteroarylene, cycloalkylene, or heterocycloalkylene, and each alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, arylene, heteroarylene, cycloalkylene, or heterocycloalkylene independently is selected from oxo, halo, C 1-4 Alkyl, C 1-4 Alkoxy, and C 1-4 optionally substituted with 1 to 5 substituents independently selected from haloalkyl; Each R 11 independently, C 1-4 Alkyl, C 1-4 haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; Each R 12 independently, C 1-4 Alkyl, C 1-4 haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; p and q are each independently 0, 1, 2, 3, 4, 5, 6, 7, or 8.

[0098] In certain embodiments, the linking moiety is not a bond. In certain embodiments, each R 11 are independently hydrogen, C 1-4 Alkyl, C 1-4 haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl, and each R 12 are independently hydrogen, C 1-4 Alkyl, C 1-4 It is haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl.

[0099] In certain embodiments, the linking moiety is of the formula: -Y 1 -(CH2) n’ -Y 2 -(CH2) m’ -Y 3 - During the ceremony, Y 1 , Y2 , and Y 3 each independently represents a bond, -NR 11 -, -O-, -S(O) 0-2 -, -NR 11 C(O)-, -C(O)NR 11 -, -NR 11 S(O)2-, -S(O)2NR 11 -, -CR 12 =N-NR 11 -, -NR 11 -N=CR 12 -, -C(O)-, arylene, heteroarylene, cycloalkylene, or heterocycloalkylene, and each alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, arylene, heteroarylene, cycloalkylene, or heterocycloalkylene independently is selected from oxo, halo, C 1-4 Alkyl, C 1-4 Alkoxy, and C 1-4 optionally substituted with 1 to 5 substituents independently selected from haloalkyl; Each R 11 are independently hydrogen, C 1-4 Alkyl, C 1-4 haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; Each R 12 are independently hydrogen, C 1-4 Alkyl, C 1-4 haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; n' and m' are each independently 0, 1, 2, 3, 4, 5, 6, 7, or 8.

[0100] A compound of Formula I or II, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analogue, or pharmaceutically acceptable salt thereof, is provided: A-(LB) m I AL-(B) m II During the ceremony, A is the nuclear payload, m is 1, 2, or 3; each B is independently a nuclear receptor targeting epitope; Each L is independently a covalent bond or a linking moiety.

[0101] A compound of Formula I or II, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analogue, or pharmaceutically acceptable salt thereof, is provided: A-(LB) m I AL-(B) m II During the ceremony, A is the nuclear payload, m is 1, 2, or 3; each B is independently a nuclear steroid receptor target epitope; Each L is independently a covalent bond or a linking moiety.

[0102] In certain embodiments of any formula or subformula disclosed herein (e.g., Formula I or II), when m is 1, the nuclear receptor targeting epitope is not a peptide, protein, nanoparticle, or antibody. In certain embodiments of any formula or subformula disclosed herein (e.g., Formula I or II), when m is 1 and B is an androgen receptor targeting epitope, A is not doxorubicin or an analog thereof. In certain embodiments of any formula or subformula disclosed herein (e.g., Formula I or II), when m is 1 and B is an androgen receptor targeting epitope, A is not a hydroxamic acid that binds to histone deacetylase (HDAC). In certain embodiments of any formula or subformula disclosed herein (e.g., Formula I or II), when m is 1 and B is an estrogen receptor targeting epitope, A is not doxorubicin or an analog thereof. In certain embodiments of any formula or subformula disclosed herein (e.g., Formula I or II), when m is 1 and B is an estrogen receptor targeting epitope, A is not a hydroxamic acid that binds to histone deacetylase (HDAC).

[0103] Also provided is a compound of formula III, IV, V, or VI, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, [ka] During the ceremony, Each R 1 , R 2 , R 3 , and R 4 are independently -L-(B) m , hydrogen, C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 5 , -C(=O)OR 5 , -OC(=O)R 5, -C(=O)NR 5 R 6 , -NR 5 C(=O)R 6 , -S(=O) 1-2 R 5 , -S(=O) 1-2 NR 5 R 6 , -NR 5 S(=O) 1-2 R 6 or -C=NOR 5 and R 1 , R 2 , R 3 , and R 4 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl independently, valence permitting, may have one or more (e.g., 1 to 5, or 1 to 3) R 10 optionally substituted with m is 1, 2, or 3; each L is independently a covalent bond or a linking moiety; each B is independently a nuclear receptor targeting epitope; Each R 10 are independently halo, cyano, nitro, -OR 7 , -SR 7 , -SF5, -NR 7 R 8 , C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 7 , -C(=O)OR 7 , -OC(=O)OR 7 , -OC(=O)R 7 , -C(=O)NR 7 R 8 , -OC(=O)NR 7 R 8 , -NR 7 C(=O)NR 7 R 8 , -S(=O) 1-2 R7 , -S(=O) 1-2 NR 7 R 8 , -NR 7 S(=O) 1-2 R 8 , -NR 7 S(=O) 1-2 NR 7 R 8 , -NR 7 C(=O)R 8 , -NR 7 C(=O)OR 8 , or -C=NOR 7 and R 10 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently C optionally substituted with one or more (e.g., 1 to 5 or 1 to 3) halo, or, where valence allows, oxo, halo, hydroxyl, or amino. 1-12 optionally substituted with alkyl; Each R 5 and R 6 are independently hydrogen, deuterium, and, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 Alkyl or C 3-12 cycloalkyl or R 5 and R 6 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, Each R 7 and R 8 are independently hydrogen, deuterium, or, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 alkyl or R 7 and R 8 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12forming a heterocyclyl optionally substituted by alkyl, R 9 is hydrogen or R 2 However, At least one R 1 , R 2 , R 3 , and R 4 -L-(B) m This is subject to the condition that:

[0104] Also provided is a compound of formula IIIA, IV, VA, or VI, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, [ka] During the ceremony, R 1 , R 2 , R 3 , and R 4 each independently represents -L-(B) m , hydrogen, C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 5 , -C(=O)OR 5 , -OC(=O)R 5 , -C(=O)NR 5 R 6 , -NR 5 C(=O)R 6 , -S(=O) 1-2 R 5 , -S(=O) 1-2 NR 5 R 6 , -NR 5 S(=O) 1-2 R 6 , or -C=NOR 5 and R 1 , R 2 , R 3 , and R 4Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl independently, valence permitting, may have one or more (e.g., 1 to 5, or 1 to 3) R 10 optionally substituted with m is 1, 2, or 3; each L is independently a covalent bond or a linking moiety; each B is independently a nuclear receptor targeting epitope; Each R 10 are independently halo, cyano, nitro, -OR 7 , -SR 7 , -SF5, -NR 7 R 8 , C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 7 , -C(=O)OR 7 , -OC(=O)OR 7 , -OC(=O)R 7 , -C(=O)NR 7 R 8 , -OC(=O)NR 7 R 8 , -NR 7 C(=O)NR 7 R 8 , -S(=O) 1-2 R 7 , -S(=O) 1-2 NR 7 R 8 , -NR 7 S(=O) 1-2 R 8 , -NR 7 S(=O) 1-2 NR 7 R 8 , -NR 7 C(=O)R 8 , -NR 7 C(=O)OR 8 , or -C=NOR 7 and R 10Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently C optionally substituted with one or more (e.g., 1 to 5 or 1 to 3) halo, or, where valence allows, oxo, halo, hydroxyl, or amino. 1-12 optionally substituted with alkyl; Each R 5 and R 6 are independently hydrogen, deuterium, and, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 Alkyl or C 3-12 cycloalkyl or R 5 and R 6 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, Each R 7 and R 8 are independently hydrogen, deuterium, or, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 alkyl or R 7 and R 8 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, R 1 , R 2 , R 3 , and R 4 At least one of the following is -L-(B) m This is subject to the condition that:

[0105] Also provided is a compound of formula IIIB, IVA, VB, or VIA, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, [ka] During the ceremony, R 2 -L-(B) m and m is 1, 2, or 3; L is a covalent bond or a linking moiety; Each B is independently a nuclear receptor targeting epitope.

[0106] Also provided is a compound of formula III', IV', V', or VI', or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, [ka] During the ceremony, R 1 , R 2 , R 3 , and R 4 each independently represents -L-(B) m , hydrogen, C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 5 , -C(=O)OR 5 , -OC(=O)R 5 , -C(=O)NR 5 R 6 , -NR 5 C(=O)R 6 , -S(=O) 1-2 R 5 , -S(=O) 1-2 NR 5 R 6 , -NR 5 S(=O) 1-2 R 6 or -C=NOR 5 and R 1 , R 2 , R 3 , and R 4Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl independently, valence permitting, may have one or more (e.g., 1 to 5, or 1 to 3) R 10 optionally substituted with m is 1, 2, or 3; each L is independently a covalent bond or a linking moiety; each B is independently a nuclear steroid receptor target epitope; Each R 10 are independently halo, cyano, nitro, -OR 7 , -SR 7 , -SF5, -NR 7 R 8 , C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 7 , -C(=O)OR 7 , -OC(=O)OR 7 , -OC(=O)R 7 , -C(=O)NR 7 R 8 , -OC(=O)NR 7 R 8 , -NR 7 C(=O)NR 7 R 8 , -S(=O) 1-2 R 7 , -S(=O) 1-2 NR 7 R 8 , -NR 7 S(=O) 1-2 R 8 , -NR 7 S(=O) 1-2 NR 7 R 8 , -NR 7 C(=O)R 8 , -NR 7 C(=O)OR 8 , or -C=NOR 7 and R 10Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently C optionally substituted with one or more (e.g., 1 to 5 or 1 to 3) halo, or, where valence allows, oxo, halo, hydroxyl, or amino. 1-12 optionally substituted with alkyl; Each R 5 and R 6 are independently hydrogen, deuterium, or, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 alkyl or R 5 and R 6 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, Each R 7 and R 8 are independently hydrogen, deuterium, or, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 alkyl or R 7 and R 8 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, R 1 , R 2 , R 3 , and R 4 At least one of the following is -L-(B) m This is subject to the condition that:

[0107] Also provided is a compound of formula IIIA', IVA', VA', or VIA', or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, [ka] During the ceremony, R 2 -L-(B) m and m is 1, 2, or 3; L is a covalent bond or a linking moiety; Each B is independently a nuclear steroid receptor target epitope.

[0108] Nuclear payload As used herein, the intranuclear payload can generally bind to any site involved in cellular processes that are important for cancer development or cell replication.In certain embodiments, the intranuclear payload can bind to a target site in the nucleus, disrupt one or more cellular processes, and kill the cell.The target site in the nucleus includes, but is not limited to, intranuclear compartments (e.g., promyelocytic leukemia nuclear body (PML NB), nucleolus), intranuclear protein-protein interactions (e.g., hypoxia-inducible factor 1α (HIF-1α), FKBP25), or chromatin structure modification. In certain embodiments, the nuclear payload targets a protein involved in the DNA damage repair process, such as, but not limited to, poly(ADP-ribose) polymerase (PARP), DNA-dependent protein kinase (DNA-PK), myelin transcription factor 1 (MYT1), p53, melanocyte-stimulating hormone (MSH), mutL homolog (MLH), ERCC1, apurinic / apyrimidinic site endonuclease 1 (APE1), topoisomerase I (Topo I), topoisomerase II (Topo II), Wee1, checkpoint kinase 1 (Chk1), checkpoint kinase 2 (Chk2), ataxia telangiectasia mutated (ATR), or ataxia telangiectasia mutated (ATM).

[0109] In certain embodiments, the nuclear payload is selected from the group consisting of olaparib (AZD-2281), olaparib TOPARP-A, rucaparib (AG014699, PF-01367338), niraparib, talazoparib (BMN-673), veliparib (ABT-888), CEP 9722, E7016, BGB-290, 3-aminobenzamide, methoxyamine, CC-115, MSC2490484A, AZD6738, VX-970, AZD0156, GDC-0575, MK-8776, LY2606368, AZD1775, belotecan, CRLX101, irinotecan, LMP 400, LMP 776, NKTR-102, topotecan, doxorubicin, epirubicin, etoposide, idarubicin, mitoxantrone, teniposide, or analogs thereof. In certain embodiments, the intracellular payload comprises AZD-1775 (MK-1775, adavosertib), SCH900776 (MK-8776), AZD0156, M6620 (VX-970, VE-822, berzosertib), AZD6738, or CC-115, or analogs thereof. In certain embodiments, the intracellular payload comprises a combination of CC-115 and an additional intracellular payload. In certain embodiments, the intracellular payload comprises CC-115, and the compound comprises enzalutamide or an analog thereof.

[0110] The analogues are derived from the known nuclear payloads named herein and are modified to be conjugated to at least one nuclear receptor targeting epitope, optionally via a linking moiety. After modification to arrive at the compounds described herein, the analogues maintain comparable biological activity to that observed with the original unmodified nuclear payloads. In certain embodiments, the analogues exhibit binding activity or inhibition of at least about 98%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, or about 50% of that observed with the original unmodified nuclear payloads.

[0111] In certain embodiments, when used in reference to a nuclear payload, the terms "modified" and "derived" mean that at most one non-hydrogen atom of the original, unmodified nuclear payload (i.e., a known nuclear payload) has been replaced by a covalent bond, optionally via a linking moiety, linking at least one nuclear receptor-targeting epitope(s). In certain embodiments, when used in reference to a nuclear payload, the terms "modified" and "derived" mean that only one hydrogen atom of the original, unmodified nuclear payload (i.e., a known nuclear payload) has been replaced by a covalent bond, optionally via a linking moiety, linking at least one nuclear receptor-targeting epitope(s). In certain embodiments, one hydrogen atom bonded to a heteroatom (e.g., N, O, or S) of the original, unmodified nuclear payload (i.e., a known nuclear payload) has been replaced by a covalent bond, optionally via a linking moiety, linking at least one nuclear receptor-targeting epitope(s).

[0112] In certain embodiments, the nuclear payload is a histone deacetylase (HDAC) inhibitor (e.g., vorinostat, romidepsin (Istodax), chidamide, panobinostat (Farydak), belinstat (PXD101), panobinostat (LBH589), valproic acid (as Mg valproate), mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat (MS-275), SB939, resminostat (4SC-201), gibinostat (ITF2357), xinostat (JNJ-26481585), HBI-8000, quebetrine, CUDC- 101, AR-42, CHR-2845, CHR-3996, 4SC-202, CG200745, ACY-1215, ME-344, sulforaphane, etc., or analogs thereof), enhancer of zeste homolog 2 (EZH2) (e.g., tazemetostat, MAK638, CPI-1205), DS-3201b, etc., or analogs thereof), histone acetyltransferase (HAT) (e.g., anacardic acid, MG149, C646, etc., or analogs thereof), methyltransferase (e.g., S-adenosylmethionine, etc., or analogs thereof), bromodomain (e.g., JQ1, I-BET 151 (GSK1210151A), I-BET 762 (GSK525762), OTX-015, TEN-010, CPI-203, CPI-0610, Orinone, LY294002, or their analogs).

[0113] Any known nuclear payload that targets one or more cellular processes of proteins can be used as the nuclear payload of the compounds described herein.It is contemplated that small molecule nuclear payloads (i.e., molecular weight less than about 1,000 g / mol) are particularly useful in the compounds described herein (for example, tripazamine, chetomin, rapamycin, PARP inhibitors, etc.).

[0114] In certain embodiments, the compound comprises at least one nuclear payload that binds to poly(ADP-ribose) polymerase (PARP) and is herein referred to as a "PARP inhibitor." A PARP inhibitor is a cytotoxic agent that prevents such DNA repair from resulting in cell death and tumor growth inhibition. In certain embodiments, the PARP is human PARP, including PARP-1 and / or PARP-2, or mutant forms thereof. In certain embodiments, the nuclear payload can block the enzymatic activity of PARP and / or localize the PARP protein to the site of DNA damage (i.e., "PARP trapping"). Thus, in certain embodiments, the nuclear payload binds to PARP and induces an allosteric conformational change in the enzyme.

[0115] In certain embodiments, the nuclear payload binds to the PARP-1 catalytic domain. In certain embodiments, the nuclear payload binds to the PARP-2 catalytic domain. In certain embodiments, the nuclear payload binds to the conserved HYE motif. In certain embodiments, the nuclear payload binds to the nicotinamide binding pocket of PARP protein.

[0116] In one embodiment, nuclear payload is the analogue of known PARP inhibitor.The exemplary PARP inhibitor that can be used as nuclear payload in the compounds described herein includes but is not limited to olaparib (AZD-2281), olaparib TOPARP-A, rucaparib (AG014699, PF-01367338), niraparib, talazoparib (BMN-673), veliparib (ABT-888), CEP 9722, E7016, BGB-290 and 3-aminobenzamide or their analogues.

[0117] PARP inhibitor analogs are derived from PARP inhibitors and modified, optionally via a linking moiety, to be conjugated to at least one nuclear steroid receptor targeting epitope. After modification to arrive at the compounds described herein, PARP inhibitor analogs maintain biological activity comparable to that observed with the original, unmodified PARP inhibitor. In certain embodiments, PARP inhibitor analogs maintain the ability to inhibit PARP. In certain embodiments, PARP inhibitor analogs exhibit binding activity of at least about 98%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, or about 50% of that observed with the original, unmodified PARP inhibitor. In certain embodiments, the compounds described herein have an IC of less than about 500 nM, or less than about 400 nM, or less than about 350 nM, or less than about 300 nM, or less than about 200 nM, or less than about 100 nM, or less than about 50 nM. 50 and binds to poly(ADP-ribose) polymerase (PARP) (e.g., PARP-1 and / or PARP-2).

[0118] In certain embodiments, the nuclear payload (e.g., a PARP inhibitor analog) comprises one or more moieties capable of binding with G863, Y907, S904, A898, K903, E988, Y896, and / or Y889 of PARP-1. In certain embodiments, the nuclear payload (e.g., a PARP inhibitor analog) comprises one or more moieties capable of binding with Y889, Y896, H862, G863, S904, Y907, K903, E988, and / or M890 of PARP-1. In certain embodiments, the nuclear payload (e.g., a PARP inhibitor analog) comprises one or more moieties capable of binding with Y896, Q763, G863, S904, Y907, K903, and / or E988 of PARP-1. In certain embodiments, the nuclear payload (e.g., a PARP inhibitor analog) comprises one or more positively charged moieties (e.g., amino groups) that interact with the side chains of Q763, D766, and / or Y896 of PARP-1. In certain embodiments, the nuclear payload (e.g., a PARP inhibitor analog) comprises one or more moieties that can have binding interactions with E322, D326, I425, S417, H415, E545, and / or Y449 of PARP-2.

[0119] In certain embodiments, the nuclear payload comprises rucaparib (AG014699, PF-01367338), or an analog thereof (i.e., a rucaparib-containing analog). Thus, there is provided a compound of Formula III, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof: [ka] During the ceremony, R 1 , R 2 , R 3 , and R 4 each independently represents -L-(B) m , hydrogen, C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 5 , -C(=O)OR 5 , -OC(=O)R 5 , -C(=O)NR 5 R 6 , -NR 5 C(=O)R 6 , -S(=O) 1-2 R 5 , -S(=O) 1-2 NR 5 R 6 , -NR 5 S(=O) 1-2 R 6 or -C=NOR 5 and R 1 , R 2 , R 3 , and R 4 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl may independently be, as valence allows, one or more R 10 optionally substituted with m is 1, 2, or 3; each L is independently a covalent bond or a linking moiety; each B is independently a nuclear receptor targeting epitope; Each R 10 are independently halo, cyano, nitro, -OR 7 , -SR 7 , -SF5, -NR 7 R 8 , C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 7 , -C(=O)OR 7 , -OC(=O)OR 7 , -OC(=O)R 7 , -C(=O)NR 7 R 8 , -OC(=O)NR7 R 8 , -NR 7 C(=O)NR 7 R 8 , -S(=O) 1-2 R 7 , -S(=O) 1-2 NR 7 R 8 , -NR 7 S(=O) 1-2 R 8 , -NR 7 S(=O) 1-2 NR 7 R 8 , -NR 7 C(=O)R 8 , -NR 7 C(=O)OR 8 , or -C=NOR 7 and R 10 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently one or more halo, or, where valence allows, C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 optionally substituted with alkyl; Each R 5 and R 6 are independently hydrogen, deuterium, and, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 Alkyl or C 3-12 cycloalkyl or R 5 and R 6 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, Each R 7 and R 8 are independently hydrogen, deuterium, or, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 alkyl or R 7 and R 8together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, R 1 , R 2 , R 3 , and R 4 At least one of the following is -L-(B) m This is subject to the condition that:

[0120] In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, R 1 , R 2 , R 3 , and R 4 Only one of the -L-(B) m is.

[0121] In certain embodiments, there is provided a compound of formula IIIA, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, [ka] During the ceremony, R 1 , R 2 , R 3 , and R 4 each independently represents -L-(B) m , hydrogen, C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 5 , -C(=O)OR 5 , -OC(=O)R 5 , -C(=O)NR 5 R 6 , -NR 5 C(=O)R 6 , -S(=O) 1-2 R 5, -S(=O) 1-2 NR 5 R 6 , -NR 5 S(=O) 1-2 R 6 , or -C=NOR 5 and R 1 , R 2 , R 3 , and R 4 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl may independently be, as valence allows, one or more R 10 optionally substituted with m is 1, 2, or 3; each L is independently a covalent bond or a linking moiety; each B is independently a nuclear receptor targeting epitope; Each R 10 are independently halo, cyano, nitro, -OR 7 , -SR 7 , -SF5, -NR 7 R 8 , C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 7 , -C(=O)OR 7 , -OC(=O)OR 7 , -OC(=O)R 7 , -C(=O)NR 7 R 8 , -OC(=O)NR 7 R 8 , -NR 7 C(=O)NR 7 R 8 , -S(=O) 1-2 R 7 , -S(=O) 1-2 NR 7 R 8 , -NR 7 S(=O) 1-2 R 8 , -NR7 S(=O) 1-2 NR 7 R 8 , -NR 7 C(=O)R 8 , -NR 7 C(=O)OR 8 , or -C=NOR 7 and R 10 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently one or more halo, or, where valence allows, C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 optionally substituted with alkyl; Each R 5 and R 6 are independently hydrogen, deuterium, and, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 Alkyl or C 3-12 cycloalkyl or R 5 and R 6 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, Each R 7 and R 8 are independently hydrogen, deuterium, or, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 alkyl or R 7 and R 8 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, R 1 , R 2 , R 3 , and R 4 At least one of the following is -L-(B) m This is subject to the condition that:

[0122] In certain embodiments, there is provided a compound of formula IIIB, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof: [ka] During the ceremony, R 2 -L-(B) m and m is 1, 2, or 3; L is a covalent bond or a linking moiety; Each B is independently a nuclear receptor targeting epitope.

[0123] In certain embodiments of Formula III, IIIA, and IIIB, the nuclear receptor targeting epitope is a nuclear steroid receptor targeting epitope. In certain embodiments of Formula III, IIIA, and IIIB, m is 1. In certain embodiments of Formula III, IIIA, and IIIB, m is 2. In certain embodiments of Formula III and IIIA, R 1 , R 2 , R 3 , and R 4 Only one of the -L-(B) m is.

[0124] In certain embodiments, the nuclear payload is derived from talazoparib (BMN-673) or an analog thereof (i.e., a talazoparib-containing analog). Thus, there is provided a compound of Formula IV, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, [ka] During the ceremony, R 1 , R 2 , R 3 , and R 4 each independently represents -L-(B) m , hydrogen, C1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 5 , -C(=O)OR 5 , -OC(=O)R 5 , -C(=O)NR 5 R 6 , -NR 5 C(=O)R 6 , -S(=O) 1-2 R 5 , -S(=O) 1-2 NR 5 R 6 , -NR 5 S(=O) 1-2 R 6、 or -C=NOR 5 and R 1 , R 2 , R 3 , and R 4 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl may independently be, as valence allows, one or more R 10 optionally substituted with m is 1, 2, or 3; each L is independently a covalent bond or a linking moiety; each B is independently a nuclear receptor targeting epitope; Each R 10 are independently halo, cyano, nitro, -OR 7 , -SR 7 , -SF5, -NR 7 R 8 , C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 7 , -C(=O)OR 7 , -OC(=O)OR 7 , -OC(=O)R 7, -C(=O)NR 7 R 8 , -OC(=O)NR 7 R 8 , -NR 7 C(=O)NR 7 R 8 , -S(=O) 1-2 R 7 , -S(=O) 1-2 NR 7 R 8 , -NR 7 S(=O) 1-2 R 8 , -NR 7 S(=O) 1-2 NR 7 R 8 , -NR 7 C(=O)R 8 , -NR 7 C(=O)OR 8 , or -C=NOR 7 and R 10 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently one or more halo, or, where valence allows, C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 optionally substituted with alkyl; Each R 5 and R 6 are independently hydrogen, deuterium, and, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 Alkyl or C 3-12 cycloalkyl or R 5 and R 6 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, Each R 7 and R 8 are independently hydrogen, deuterium, or, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12alkyl or R 7 and R 8 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, R 1 , R 2 , R 3 , and R 4 At least one of the following is -L-(B) m This is subject to the condition that:

[0125] In certain embodiments, there is provided a compound of formula IVA, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, [ka] During the ceremony, R 2 -L-(B) m and m is 1, 2, or 3; L is a covalent bond or a linking moiety; Each B is independently a nuclear receptor targeting epitope.

[0126] In certain embodiments, there is provided a compound of formula IVB, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, [ka] During the ceremony, R 21 and R 23 are each independently hydrogen, halo, hydroxyl, C 1-12 Alkyl, C 3-10 Cycloalkyl, C 1-12 Alkoxy, C 1-12alkoxyalkyl, wherein each alkyl, cycloalkyl, alkoxy, and alkoxyalkyl is independently selected from cyano, halo, hydroxyl, nitro, C 1-12 Alkyl, and C 3-10 cycloalkyl; and R 23 is not a hydroxyl, R 22 and R 24 are each independently hydrogen, C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 1-12 Alkoxy, -C(=O)R 50 , -C(=O)OR 50 , -C(=O)N(R 50 )2, -S(=O) 0-2 R 50 , -S(=O) 1-2 N(R 50 )2, -NR 50 S(=O) 1-2 R 50 , C 3-10 cycloalkyl, aryl, heterocyclyl, or heteroaryl, and each C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 1-12 Alkoxy, C 3-10 A cycloalkyl, aryl, heterocyclyl, or heteroaryl may independently be one, two, or three R 29 may be substituted with R 20 and R 25 are each independently hydrogen, C 1-12 Alkyl, C 3-10 Cycloalkyl, C 1-12 Alkoxyalkyl, C 1-12 Haloalkyl, C 1-12 Alkyl-OH, and C 1-12 Alkyl-NR 51 R 52 is selected from the group consisting of R 26 , R 27 , and R28 are each independently hydrogen, halo, cyano, nitro, amino, hydroxyl, C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 1-12 Alkoxy, C 3-10 cycloalkyl, -C(=O)-alkyl, -C(=O)-alkoxy, haloalkoxy, haloalkyl, heteroalkyl; R 10 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl in 1-12 optionally substituted with alkyl; Each R 29 is hydroxyl, halo, cyano, nitro, -OR 51 , -SR 51 , -SF5, -NR 51 R 52 , C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 51 , -C(=O)OR 51 , -OC(=O)OR 51 , -OC(=O)R 51 , -C(=O)NR 51 R 52 , -OC(=O)NR 51 R 52 , -NR 51 C(=O)NR 51 R 52 , -S(=O) 1-2 R 51 , -S(=O) 1-2 NR 51 R 52 , -NR 51 S(=O) 1-2 R 52 , -NR 51 S(=O)1-2 NR 51 R 52 , -NR 51 C(=O)R 52 , -NR 51 C(=O)OR 52 ,or -C=NOR 51 Selected from R 29 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently one or more halo, or, where valence allows, C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 optionally substituted with alkyl; Each R 50 are independently hydrogen, C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 3-10 cycloalkyl, aryl, heterocyclyl, or heteroaryl, and R 50 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently one or more halo, or, where valence allows, C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 optionally substituted with alkyl; Each R 51 and R 52 are independently hydrogen, C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl, and R 51 and R 52 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl in is optionally substituted with oxo, halo, hydroxyl, or amino, where valence allows, or R 51 and R 52together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, At least one R 22 or R 24 is bound to -L-(B) m wherein each L is independently a covalent bond or a linking moiety; each B is independently a nuclear receptor targeting epitope; and m is 1, 2, or 3.

[0127] In the compound of formula VIB, at least one R 22 or R 24 is bound to -L-(B) m Therefore, -L-(B) m It should be understood that the groups are not directly attached to the tricyclic core.

[0128] In certain embodiments of Formulas IV, IVA, and IVB, the nuclear receptor targeting epitope is a nuclear steroid receptor targeting epitope. In certain embodiments of Formulas IV, IVA, and IVB, m is 1. In certain embodiments of Formulas IV, IVA, and IVB, m is 2. In certain embodiments of Formula IV, R 1 , R 2 , R 3 , and R 4 Only one of the -L-(B) m is.

[0129] In certain embodiments, the nuclear payload is derived from olaparib (AZD-2281), or an analog thereof (i.e., an olaparib-containing analog). In certain embodiments, the compound is of Formula V, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof: [ka] During the ceremony, Each R 1 , R 2 , R 3 , and R 4 are independently -L-(B) m , hydrogen, C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 5 , -C(=O)OR 5 , -OC(=O)R 5 , -C(=O)NR 5 R 6 , -NR 5 C(=O)R 6 , -S(=O) 1-2 R 5 , -S(=O) 1-2 NR 5 R 6 , -NR 5 S(=O) 1-2 R 6 or -C=NOR 5 and R 1 , R 2 , R 3 , and R 4 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl may independently be, as valence allows, one or more R 10 optionally substituted with m is 1, 2, or 3; each L is independently a covalent bond or a linking moiety; each B is independently a nuclear receptor targeting epitope; Each R 10 are independently halo, cyano, nitro, -OR 7 , -SR 7 , -SF5, -NR 7 R 8 , C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 7 , -C(=O)OR 7 , -OC(=O)OR 7 , -OC(=O)R 7 , -C(=O)NR 7 R 8 , -OC(=O)NR 7 R 8 , -NR 7 C(=O)NR 7 R 8 , -S(=O) 1-2 R 7 , -S(=O) 1-2 NR 7 R 8 , -NR 7 S(=O) 1-2 R 8 , -NR 7 S(=O) 1-2 NR 7 R 8 , -NR 7 C(=O)R 8 , -NR 7 C(=O)OR 8 , or -C=NOR 7 and R 10 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently one or more halo, or, where valence allows, C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 optionally substituted with alkyl; Each R 5 and R 6 are independently hydrogen, deuterium, and, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 Alkyl or C 3-12 cycloalkyl or R 5 and R 6 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12forming a heterocyclyl optionally substituted by alkyl, Each R 7 and R 8 are independently hydrogen, deuterium, or, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 alkyl or R 7 and R 8 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, R9 is hydrogen or R 2 However, At least one R 1 , R 2 , R 3 , and R 4 -L-(B) m This is subject to the condition that:

[0130] In certain embodiments, there is provided a compound of formula VA, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, [ka] During the ceremony, R 1 , R 2 , R 3 , and R 4 each independently represents -L-(B) m , hydrogen, C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 5 , -C(=O)OR 5 , -OC(=O)R 5 , -C(=O)NR 5 R 6 , -NR 5C(=O)R 6 , -S(=O) 1-2 R 5 , -S(=O) 1-2 NR 5 R 6 , -NR 5 S(=O) 1-2 R 6 or -C=NOR 5 and R 1 , R 2 , R 3 , and R 4 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl may independently be, as valence allows, one or more R 10 optionally substituted with m is 1, 2, or 3; each L is independently a covalent bond or a linking moiety; each B is independently a nuclear receptor targeting epitope; Each R 10 are independently halo, cyano, nitro, -OR 7 , -SR 7 , -SF5, -NR 7 R 8 , C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 7 , -C(=O)OR 7 , -OC(=O)OR 7 , -OC(=O)R 7 , -C(=O)NR 7 R 8 , -OC(=O)NR 7 R 8 , -NR 7 C(=O)NR 7 R 8 , -S(=O) 1-2 R 7 , -S(=O) 1-2 NR 7 R 8 , -NR7 S(=O) 1-2 R 8 , -NR 7 S(=O) 1-2 NR 7 R 8 , -NR 7 C(=O)R 8 , -NR 7 C(=O)OR 8 , or -C=NOR 7 and R 10 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently one or more halo, or, where valence allows, C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 optionally substituted with alkyl; Each R 5 and R 6 are independently hydrogen, deuterium, and, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 Alkyl or C 3-12 cycloalkyl or R 5 and R 6 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, Each R 7 and R 8 are independently hydrogen, deuterium, or, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 alkyl or R 7 and R 8 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, R 1 , R 2 , R 3 , and R 4At least one of the following is -L-(B) m This is subject to the condition that:

[0131] In certain embodiments, there is provided a compound of formula VB, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, [ka] During the ceremony, R 2 -L-(B) m and m is 1, 2, or 3; L is a covalent bond or a linking moiety; Each B is independently a nuclear receptor targeting epitope.

[0132] In certain embodiments, there is provided a compound of formula VC, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, [ka] During the ceremony, A and B together represent an optionally substituted fused aromatic ring; R 30 and R 31 are independently hydrogen or C 1-12 alkyl or X is -CR 33 R 34 If R 30 , R 31 , R 33 , and R 34 may, together with the carbon atoms to which they are attached, form an optionally substituted fused aromatic ring; R 32 is hydrogen or halo, X is -NR 33 or -CR 33 R 34 and X is -NR 33 When t is 1 or 2, and X is -CR33 R 34 t is 1 when R 33 is hydrogen, optionally substituted C 1-12 Alkyl, aryl, heterocyclyl, -C(=O)R 50 , -C(=O)OR 50 , -C(=O)N(R 50 )2, -S(=O) 0-2 R 50 , -S(=O) 1-2 N(R 50 )2, -NR 50 S(=O) 1-2 R 50 and R 34 is hydrogen, hydroxyl, or amino; Or R 33 and R 34 Together, C 3-10 may form a cycloalkyl or heterocyclyl group, Each R 50 are independently hydrogen, C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 3-10 cycloalkyl, aryl, heterocyclyl, or heteroaryl, and R 50 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently one or more halo, or, where valence allows, C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 optionally substituted with alkyl, At least one R 30 , R 31 , R 33 , or R 34 The group has attached thereto -L-(B) m wherein each L is independently a covalent bond or a linking moiety; each B is independently a nuclear receptor targeting epitope; and m is 1, 2, or 3.

[0133] In certain embodiments of Formulas V, VA, VB, and VC, the nuclear receptor targeting epitope is a nuclear steroid receptor targeting epitope. In certain embodiments of Formulas V, VA, VB, and VC, m is 1. In certain embodiments of Formulas V, VA, VB, and VC, m is 2. In certain embodiments of Formulas V and VA, R 1 , R 2 , R 3 , and R 4 Only one of the -L-(B) m is.

[0134] In certain embodiments, the nuclear payload is derived from veliparib (ABT-888), or an analog thereof (i.e., a veliparib-containing analog). Also provided is a compound of Formula VI, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof: [ka] During the ceremony, R 1 , R 2 , R 3 , and R 4 each independently represents -L-(B) m , hydrogen, C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 5 , -C(=O)OR 5 , -OC(=O)R 5 , -C(=O)NR 5 R 6 , -NR 5 C(=O)R 6 , -S(=O) 1-2 R 5 , -S(=O) 1-2 NR 5 R 6 , -NR 5 S(=O) 1-2 R 6or -C=NOR 5 and R 1 , R 2 , R 3 , and R 4 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl may independently be, as valence allows, one or more R 10 optionally substituted with m is 1, 2, or 3; each L is independently a covalent bond or a linking moiety; each B is independently a nuclear receptor targeting epitope; Each R 10 are independently halo, cyano, nitro, -OR 7 , -SR 7 , -SF5, -NR 7 R 8 , C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 7 , -C(=O)OR 7 , -OC(=O)OR 7 , -OC(=O)R 7 , -C(=O)NR 7 R 8 , -OC(=O)NR 7 R 8 , -NR 7 C(=O)NR 7 R 8 , -S(=O) 1-2 R 7 , -S(=O) 1-2 NR 7 R 8 , -NR 7 S(=O) 1-2 R 8 , -NR 7 S(=O) 1-2 NR 7 R 8 , -NR 7 C(=O)R 8 , -NR7 C(=O)OR 8 , or -C=NOR 7 and R 10 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently one or more halo, or, where valence allows, C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 optionally substituted with alkyl; Each R 5 and R 6 are independently hydrogen, deuterium, and, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 Alkyl or C 3-12 cycloalkyl or R 5 and R 6 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, Each R 7 and R 8 are independently hydrogen, deuterium, or, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 alkyl or R 7 and R 8 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, R 1 , R 2 , R 3 , and R 4 At least one of the following is -L-(B) m This is subject to the condition that:

[0135] In certain embodiments, there is provided a compound of formula VIA, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof: [ka] During the ceremony, R 2 -L-(B) m and m is 1, 2, or 3; L is a covalent bond or a linking moiety; Each B is independently a nuclear receptor targeting epitope.

[0136] In certain embodiments of Formula VI and VIA, the nuclear receptor targeting epitope is a nuclear steroid receptor targeting epitope. In certain embodiments of Formula VI and VIA, m is 1. In certain embodiments of Formula VI and VIA, m is 2. In certain embodiments of Formula V, R 1 , R 2 , R 3 , and R 4 Only one of the -L-(B) m is.

[0137] In certain embodiments, the nuclear payload comprises CC-115 or an analog thereof (a CC-115-containing analog). Also provided is a compound of Formula VII, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof: [ka] R 1 , R 2 , and R 3 each independently represents -L-(B) m , hydrogen, C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R5 , -C(=O)OR 5 , -OC(=O)R 5 , -C(=O)NR 5 R 6 , -NR 5 C(=O)R 6 , -S(=O) 1-2 R 5 , -S(=O) 1-2 NR 5 R 6 , -NR 5 S(=O) 1-2 R 6 or -C=NOR 5 and R 1 , R 2 , and R 3 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl may independently be, as valence allows, one or more R 10 optionally substituted with each L is independently a covalent bond or a linking moiety; each B is independently a nuclear receptor targeting epitope; Each R 10 are independently halo, cyano, nitro, -OR 7 , -SR 7 , -SF5, -NR 7 R 8 , C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 7 , -C(=O)OR 7 , -OC(=O)OR 7 , -OC(=O)R 7 , -C(=O)NR 7 R 8 , -OC(=O)NR 7 R 8 , -NR 7 C(=O)NR 7 R 8 , -S(=O) 1-2 R7 , -S(=O) 1-2 NR 7 R 8 , -NR 7 S(=O) 1-2 R 8 , -NR 7 S(=O) 1-2 NR 7 R 8 , -NR 7 C(=O)R 8 , -NR 7 C(=O)OR 8 , or -C=NOR 7 and R 10 Each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently one or more halo, or, where valence allows, C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 optionally substituted with alkyl; Each R 5 and R 6 are independently hydrogen, deuterium, and, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 Alkyl or C 3-12 cycloalkyl or R 5 and R 6 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 forming a heterocyclyl optionally substituted by alkyl, Each R 7 and R 8 are independently hydrogen, deuterium, or, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 alkyl or R 7 and R 8 together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12forming a heterocyclyl optionally substituted by alkyl, R 1 , R 2 , and R 3 At least one of the following is -L-(B) m This is subject to the condition that:

[0138] In certain embodiments, there is provided a compound of formula VIIA, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof: [ka] During the ceremony, R 2 -L-(B) m and m is 1, 2, or 3; L is a covalent bond or a linking moiety; Each B is independently a nuclear receptor targeting epitope.

[0139] In certain embodiments of Formula VII and VIIA, the nuclear receptor targeting epitope is a nuclear steroid receptor targeting epitope. In certain embodiments of Formula VII and VIIA, m is 1. In certain embodiments of Formula VII and VIIA, m is 2. In certain embodiments of Formula VII, R 1 , R 2 , R 3 , and R 4 Only one of the -L-(B) m is.

[0140] In certain embodiments of the formulas disclosed herein, each R 5 and R 6 are independently hydrogen, deuterium, or, where valence allows, C optionally substituted with oxo, halo, hydroxyl, or amino. 1-12 alkyl or R 5 and R 6together with the atoms to which they are attached, are halo, or C optionally substituted by oxo, halo, hydroxyl, or amino. 1-12 Alkyl forms an optionally substituted heterocyclyl.

[0141] In certain embodiments, the nuclear payload binds to DNA-dependent protein kinase (DNA-PK). In certain embodiments, the nuclear payload is an inhibitor of DNA-dependent protein kinase (DNA-PK). In certain embodiments, the nuclear payload is derived from AZD-1775 (MK-1775, adavosertib), SCH900776 (MK-8776), AZD0156, M6620 (VX-970, VE-822, berzosertib), AZD6738, or CC-115, or an analog thereof. In certain embodiments, compounds of the following formula are provided: [ka] In the formula, one hydrogen atom is -L-(B) m is replaced by m is 1, 2, or 3; L is a covalent bond or a linking moiety; Each B is independently a nuclear receptor targeting epitope.

[0142] In certain embodiments, -L-(B) m The hydrogen atom replaced by -L-(B) is on a heteroatom. m The hydrogen atom replaced by -L-(B) is on the nitrogen. m The hydrogen atom replaced by -L-(B) is on the oxygen. m The hydrogen atom replaced by is on the carbon. In certain embodiments, the nuclear receptor targeting epitope is a nuclear steroid receptor targeting epitope. In certain embodiments, m is 1. In certain embodiments, m is 2.

[0143] In certain embodiments, compounds of the following formula are provided: [ka] During the ceremony, R 2 -L-(B) m and m is 1, 2, or 3; L is a covalent bond or a linking moiety; Each B is independently a nuclear receptor targeting epitope.

[0144] In certain embodiments of any compound, formula or embodiment disclosed herein, the nuclear receptor targeting epitope is a nuclear steroid receptor targeting epitope.In certain embodiments, m is 1.In certain embodiments, m is 2.

[0145] Nuclear receptor targeting epitopes As used herein, the term "nuclear receptor targeting epitope" refers to the portion of a compound described herein (e.g., the "B" portion of Formula I or Formula II) derived from a nuclear targeting agent disclosed herein that interacts with the ligand-binding domain of a target nuclear receptor, i.e., the portion of the compound that drives the ligand-binding interaction. The nuclear receptor targeting epitope associates the compound with the target nuclear receptor, such as a nuclear steroid receptor, facilitates localization of the compound in nuclear steroid receptor-expressing cells, translocates the nuclear payload from the cytosol to the nucleus, and serves to accumulate the compound in the nucleus. The level of accumulation can be controlled by selecting an appropriate nuclear receptor targeting epitope. For example, the compounds described herein may accumulate in the nucleus to varying degrees via nuclear translocation of the nuclear steroid receptor following epitope binding to the receptor, with the accumulation being high for full agonists (e.g., dihydrotestosterone (DHT)), moderate for partial agonists (e.g., bicalutamide), and low for antagonists (e.g., enzalutamide).

[0146] The target of steroid receptor can be any steroid receptor, including but not limited to those that are overexpressed in cancer cells.In certain embodiments, at least one nuclear steroid receptor targeting epitope can bind to the ligand binding domain of nuclear steroid receptor, for example, the ligand binding domain on estrogen receptor, glucocorticoid receptor, progesterone receptor or androgen receptor.

[0147] Exemplary nuclear steroid receptor targeting epitopes include those derived from androgen receptor agonists, androgen receptor antagonists, selective androgen receptor modulators (SARMs), estrogen receptor agonists, estrogen receptor antagonists, selective estrogen receptor modulators (SERMs), glucocorticoid receptor antagonists, glucocorticoid receptor agonists, selective glucocorticoid receptor modulators (SGRMs), progesterone receptor antagonists, progesterone receptor agonists, selective progesterone receptor modulators (SPRMs), or combinations thereof. Nuclear steroid receptor targeting epitopes typically have an IC of less than about 500 nM, or less than about 400 nM, or less than about 300 nM, or less than about 200 nM, or less than about 100 nM. 50 or an EC of less than about 1 μM, or less than about 900 nM, or less than about 800 nM, or less than about 700 nM, or less than about 600 nM, or 500 nM, or less than about 400 nM, or less than about 3400 nM, or less than about 200 nM, or less than about 100 nM. 50 It can bind to nuclear steroid receptors having the formula:

[0148] In certain embodiments, the nuclear steroid receptor targeting epitope is an agonist at the androgen receptor. In certain embodiments, the nuclear steroid receptor targeting epitope is an antagonist at the androgen receptor.

[0149] In certain embodiments, the nuclear steroid receptor targeting epitope is steroidal (e.g., dihydrotestosterone). In certain embodiments, the nuclear steroid receptor targeting epitope is non-steroidal (e.g., enzalutamide, apalutamide, and bicalutamide).

[0150] The analogs are derived from known nuclear steroid receptor targeting epitopes described herein and are modified to be conjugated to at least one nuclear steroid payload, optionally via a linking moiety. After modification to arrive at the compounds described herein, the analogs maintain comparable biological activity to that observed with the original unmodified nuclear steroid receptor targeting epitopes. In certain embodiments, the analogs exhibit binding activity or inhibition of at least about 98%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, or about 50% of that observed with the original unmodified nuclear steroid receptor targeting epitopes.

[0151] In certain embodiments, the analogue is derived from a known nuclear receptor targeting epitope, such as a known nuclear steroid receptor targeting epitope.In certain embodiments, when used in reference to a nuclear receptor targeting epitope, the term "derived from" means that at most one non-hydrogen atom of the original unmodified nuclear receptor targeting compound (i.e., a known nuclear steroid receptor targeting compound) is replaced by a covalent bond to a nuclear payload, optionally via a linking moiety.Exemplary non-hydrogen atoms include -CH3, -OH, =O, and In certain embodiments, when used in reference to a nuclear receptor targeting epitope, the term "derived from" means that at most one non-hydrogen atom of the original unmodified nuclear receptor targeting compound (i.e., a known nuclear steroid receptor targeting compound) is replaced by a covalent bond to a nuclear payload, optionally via a linking moiety. In certain embodiments, one hydrogen atom bonded to a heteroatom (e.g., N, O, or S) of the original unmodified nuclear receptor targeting compound (i.e., a known nuclear steroid receptor targeting compound) is replaced by a covalent bond to a nuclear payload, optionally via a linking moiety.

[0152] In certain embodiments, the nuclear steroid receptor targeting epitope is an androgen receptor targeting epitope.As used herein, the term " androgen receptor targeting epitope " refers to the part of a compound that can bind to androgen receptor agonist or androgen receptor antagonist (including partial androgen receptor agonist or partial androgen receptor antagonist), and can make the compound go from cytoplasm to the nucleus of cell.Also known as " androgen receptor" (AR) (nuclear receptor subfamily 3, group C, member 4), NR3C4 is a kind of nuclear receptor that can be activated by binding to androgen receptor binding agent (for example, androgen hormones such as testosterone or dihydrotestosterone) in cytoplasm, and can make androgen hormones go into the nucleus.

[0153] Exemplary androgen receptor targeting epitopes that may be used in the compounds described herein include, but are not limited to, androgen receptor agonists, selective androgen receptor modulators (SARMs) (e.g., enobosarm), androgen receptor antagonists (e.g., bicalutamide, flutamide, nilutamide, or enzalutamide), selective estrogen receptor modulators (SERMs) (e.g., tamoxifen, toremifene, or raloxifene), estrogen receptor antagonists (e.g., fulvestrant), progestins (e.g., megestrol acetate), estrogen (e.g., estramustine), ketoconazole, abiraterone, darolutamide, or analogs thereof.

[0154] In certain embodiments, the nuclear steroid receptor targeting epitope is a selective androgen receptor modulator (SARM).In certain embodiments, the compound comprises at least one nuclear steroid receptor targeting epitope, and is independently selected from testosterone, testosterone ester (e.g., testosterone enanthate, testosterone propionate, testosterone cypionate, etc., or analogs thereof), enobosarm, BMS-564929, PS178990, LGD-4033 (ligandrol), LGD-2941, AC-262, 356, JNJ-28330835, JNJ-37654032, JNJ-26146900, LGD-2226, L The epitopes include those derived from GD-3303, LGD-121071, LG-120907, S-40503, S-23, RAD-140, acetothiolutamide, andarine (S-4), LG-121071, TFM-4AS-1, YK-11, MK-0773 (PF-05314882), GSK2849466, GSK2881078, GSK8698, GSK4336, ACP-105, TT701, LY2452473, 1-(2-hydroxy-2-methyl-3-phenoxypropanoyl)-indoline-4-carbonitrile derivatives (J Med Chem. 2014, 57(6), 2462-71), or analogs thereof.

[0155] In certain embodiments, a single atom on a nuclear receptor targeting epitope disclosed herein is replaced for binding to the remainder of the compound (e.g., the AL- moiety of Formula I and Formula II). In certain embodiments, a halogen atom on a nuclear receptor targeting epitope disclosed herein is replaced for binding to the remainder of the compound. In certain embodiments, a hydrogen atom on a nuclear receptor targeting epitope disclosed herein is replaced for binding to the remainder of the compound. In certain embodiments, the hydrogen atom is on a heteroatom. In certain embodiments, the hydrogen atom is on a nitrogen. In certain embodiments, the hydrogen atom is on an oxygen. In certain embodiments, the hydrogen atom is on a carbon.

[0156] In certain embodiments, moiety -B of Formula I or Formula II is [ka] [ka] [ka] or a stereoisomer or mixture of stereoisomers thereof, or an analog thereof.

[0157] These and other selective androgen receptor modulators (SARMs) that can be used as nuclear steroid receptor targeting epitopes in the compounds described herein are disclosed in US 6,462,038, US 6,777,427, WO 2001 / 027086, WO 2004 / 013104, WO 2004 / 000816, WO 2004 / 0113309, US 2006 / 0211756, US 2006 / 0063819, US 2005 / 245485, US 2005 / 250741 ... 005 / 277681, WO2006 / 060108, WO2004 / 041277, WO2003 / 034987, US2006 / 0148893, US2006 / 0142387, WO2005 / 000795, WO2005 / 085185, WO2006 / 133216, WO2006 / 044707, WO2006 / 124447, WO2007 / 002181, WO2005 / 108351, WO2005 / 115361, and US2006 / 0160845.

[0158] In certain embodiments, the nuclear steroid receptor targeting epitope is a selective estrogen receptor modulator (SERM). In certain embodiments, the compounds comprise at least one nuclear steroid receptor targeting epitope and are independently selected from the group consisting of anordrin, bazedoxifene, broparestrol (Acnestrol), clomiphene (Clomid), cyclophen (Sexovid), lasofoxifene (Fablyn), ormeloxifene (Centron, Novex, Novex-DS, Sevista), ospemifene (Osphena, deaminohydroxytoremifene), raloxifene (Evista), tamoxifen (Nolvadex), toremifene (Fareston; 4-chlorotamoxifen), acolbifene, afimoxifen (4-hydroxytamoxifen; metabolite of tamoxifen), elastrant, enclomiphene ((E)-clomiphene), endoxifen (4-hydroxy-N-desmethicone), tamoxifen (a metabolite of tamoxifen), zuclomiphene ((Z)-clomiphene), bazedofen, arzoxifene, brillanestran, clomiphene oxide (clomiphene N-oxide; a metabolite of clomiphene), droloxifene (3-hydroxytamoxifen), etacstil, fispemifene, GW-7604 (4-hydroxyethaxtil), idoxifene (pyrrolidino-4- iodotamoxifen), levormeloxifene ((L)-olmeloxifene), miproxifene, nafoxidine, nitromifene (CI-628), panomifene, pipendoxifene (ERA-923), trioxifene, keoxifene, LY117018, onapristone, fareston (toremifine citrate), or zindoxifene (D-16726), or an analog thereof.

[0159] In certain embodiments, the SERM is structurally classified as a triphenylethylene (such as tamoxifen, clomiphene, toremifene, droloxifene, idoxifene, ospemifene, fispemifene, afimoxifene, or an analog thereof), a benzothiophene (such as raloxifene, arzoxifene, or an analog thereof), an indole (such as bazedoxifene, zindoxifene, pipendoxifene, or an analog thereof), a tetrahydronaphthalene (such as lasofoxifene, nafoxidine, or an analog thereof), or a benzopyran (such as acolbifene, ormeloxifene, levormeloxifene, or an analog thereof).

[0160] In certain embodiments, the nuclear steroid receptor targeting epitope is a selective estrogen receptor downregulator (SERD). In certain embodiments, the compound comprises at least one nuclear steroid receptor targeting epitope, and independently comprises an epitope derived from fulvestrant, ARN-810, GW5638 or GW7604.

[0161] In certain embodiments, the nuclear steroid receptor targeting epitope is a selective progesterone receptor modulator (SPRM). In certain embodiments, the compound comprises at least one nuclear steroid receptor targeting epitope, and independently comprises an epitope derived from ulipristal acetate, asoprisnil (J867), mifepristone, telapristone (CDB-4124, Proellex, Progenta), or an analog thereof.

[0162] In certain embodiments, the compound comprises at least one nuclear steroid receptor targeting epitope, independently comprising an epitope derived from estrogen, estetrol, estriol, estrone, progesterone, enobosarm, bicalutamide, apalutamide, testosterone, dihydrotestosterone, estradiol, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, bazedoxifene, ospemifene, megestrol acetate, estramustine, abiraterone, LGD-2941, BMS-564929, ostarine, or an analog thereof.

[0163] In certain embodiments, the at least one nuclear steroid receptor targeting epitope is an androgen receptor targeting epitope; [ka] or a stereoisomer or mixture of stereoisomers thereof, or analogs thereof, wherein the wavy line indicates the point of attachment to the linking moiety or core payload.

[0164] In certain embodiments, at least one nuclear steroid receptor targeting epitope is an estrogen receptor targeting epitope; [ka] or a stereoisomer or mixture of stereoisomers thereof, or analogs thereof, wherein the wavy line indicates the point of attachment to the linking moiety or core payload.

[0165] In certain embodiments, the nuclear steroid receptor targeting epitope is not or does not include a peptide, protein, nanoparticle, or antibody.

[0166] Exemplary compounds provided by the present disclosure include, but are not limited to, the compounds shown in Table 1, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof.

Table 1-1

Table 1-2

Table 1-3

Table 1-4

Table 1-5

Table 1-6

Table 1-7

Table 1-8

Table 1-9

Table 1-10

Table 1-11

Table 1-12

Table 1-13

Table 1-14

Table 1-15

Table 1-16

Table 1-17

Table 1-18

Table 1-19

Table 1-20

Table 1-21

Table 1-22

Table 1-23

Table 1-24

Table 1-25

Table 1-26

Table 1-27

Table 1-28

Table 1-29

Table 1-30

Table 1-31

Table 1-32

Table 1-33

Table 1-34

Table 1-35

Table 1-36

Table 1-37

Table 1-38

Table 1-39

Table 1-40

Table 1-41

Table 1-42

Table 1-43

Table 1-44

Table 1-45

Table 1-46

Table 1-47

Table 1-48

Table 1-49

Table 1-50

Table 1-51

Table 1-52

Table 1-53

Table 1-54

Table 1-55

Table 1-56

Table 1-57

Table 1-58

Table 1-59

Table 1-60

Table 1-61

Table 1-62

Table 1-63

Table 1-64

Table 1-65

Table 1-66

Table 1-67

Table 1-68

Table 1-69

Table 1-70

Table 1-71

Table 1-72

Table 1-73

Table 1-74

Table 1-75

Table 1-76

Table 1-77

Table 1-79

Table 1-80

Table 1-81

Table 1-82

Table 1-83

Table 1-84

Table 1-85

Table 1-86

Table 1-87

Table 1-88

Table 1-89

Table 1-90

Table 1-91

Table 1-92

Table 1-93

Table 1-94

Table 1-95

Table 1-96

Table 1-97

Table 1-98

Table 1-99

Table 1-100

[0167] Treatment Provided herein are compounds that can be used to treat, prevent, and / or delay the onset and / or development of cancer.Therefore, in certain embodiments, a method for treating cancer is provided, which comprises administering a therapeutically effective amount of a compound or composition as described herein to a subject in need of treatment.Certain embodiments provide a method for enhancing cytotoxic cancer therapy in a subject who has a recognized need for such treatment, which comprises administering a therapeutically acceptable amount of a compound or composition as described herein to the subject.

[0168] It is contemplated that any cancer patient may benefit from treatment with the compound and composition described herein.Therefore, in certain embodiments, cancer includes liver cancer, melanoma, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, breast carcinoma, ovarian carcinoma, lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, soft tissue sarcoma, chronic lymphocytic leukemia, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, malignant melanoma, small cell lung carcinoma, gastric carcinoma, ovarian carcinoma, ovarian carcinoma, lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, soft tissue sarcoma, chronic lymphocytic leukemia, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, malignant melanoma, small cell lung carcinoma, gastric carcinoma, carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, malignant melanoma, choriocarcinoma, mycosis fungoides, head and neck carcinoma, osteosarcoma, pancreatic carcinoma, acute granulocytic leukemia, hairy cell leukemia, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial carcinoma, polycythemia vera, essential thrombocytosis, adrenocortical carcinoma, skin cancer, or prostate carcinoma. In certain embodiments, the cancer is bladder cancer, a blood cancer such as leukemia (e.g., chronic leukemia, chronic lymphocytic leukemia (CLL), or lymphoma (e.g., Hodgkin's lymphoma, non-Hodgkin's lymphoma, low-grade lymphoma, high-grade lymphoma), lung cancer (e.g., small cell lung cancer), breast cancer, fallopian tube cancer, glioblastoma multiforme, head and neck cancer, esophageal cancer, ovarian cancer, pancreatic cancer, peritoneal cancer, prostate cancer, testicular cancer, skin cancer (e.g., melanoma), or uterine cancer. In certain embodiments, the cancer is bladder cancer, breast cancer, fallopian tube cancer, ovarian cancer, prostate cancer, peritoneal cancer, testicular cancer, endometrial cancer, or uterine cancer.

[0169] In certain embodiments, the compounds and compositions described herein are tailored to target cancers that overexpress a specific receptor, such as, but not limited to, the androgen receptor, the estrogen receptor, the progesterone receptor, and / or the glucocorticoid receptor, by including an epitope that targets that specific nuclear receptor. The epitope may be derived from a steroid hormone or any non-steroidal drug that targets that specific receptor.

[0170] In certain embodiments, a method for treating or preventing androgen receptor overexpression cancer is provided, which comprises administering an effective amount of a compound, or its pharmaceutically acceptable salt or solvate, comprising at least one nuclear payload and at least one androgen receptor targeting epitope to an individual in need thereof.The specific cancers that are intended to be treated by such a method include, but are not limited to, prostate cancer, breast cancer, triple-negative breast cancer, bladder cancer, or liver cancer.Also provided is a method for treating or preventing metastatic castration-resistant prostate cancer (mCRPC), which comprises administering an effective amount of the compound or composition described herein, or its pharmaceutically acceptable salt or solvate to an individual in need thereof.

[0171] In certain embodiments, provided is a method for treating or preventing androgen receptor overexpression cancer, comprising administering an effective amount of a compound, or its pharmaceutically acceptable salt or solvate, to an individual in need thereof, comprising at least one nuclear payload and at least one androgen receptor targeting epitope.In certain embodiments, the cancer is prostate cancer, breast cancer, triple-negative breast cancer, bladder cancer, or liver cancer.In certain embodiments, the androgen receptor targeting epitope comprises an androgen receptor agonist, a selective androgen receptor modulator (SARM), an androgen receptor antagonist, a selective estrogen receptor modulator (SERM), an estrogen receptor antagonist, a progestin, or an estrogen. In certain embodiments, the androgen receptor targeting epitope comprises enobosarm, bicalutamide, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, fulvestrant, megestrol acetate, estramustine, ketoconazole, abiraterone, darolutamide, or analogs thereof.In certain embodiments, the androgen receptor targeting epitope comprises enobosarm, bicalutamide, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, fulvestrant, megestrol acetate, estramustine, ketoconazole, abiraterone, or analogs thereof.In certain embodiments, the nuclear payload comprises a PARP inhibitor.

[0172] In certain embodiments, provided is a method for treating or preventing estrogen and / or progesterone receptor overexpression cancer, comprising administering to the individual in need thereof an effective amount of a compound, or its pharmaceutically acceptable salt or solvate, comprising at least one nuclear payload and at least one estrogen and / or progesterone receptor targeting epitope.The specific cancers that are intended to be treated by such method include but are not limited to breast cancer, uterine cancer or ovarian cancer.

[0173] In certain embodiments, provided is a method for treating or preventing glucocorticoid receptor overexpression cancer, which comprises administering an effective amount of a compound, or its pharmaceutically acceptable salt or solvate, comprising at least one nuclear payload and at least one androgen receptor targeting epitope to an individual in need thereof.The specific cancers that are intended to be treated by such method include but are not limited to breast cancer, uterine cancer or ovarian cancer.The specific cancers that are intended to be treated by such method include but are not limited to prostate cancer, possibly breast cancer, uterine cancer, ovarian cancer.

[0174] Breast cancer includes ductal carcinoma in situ (DCIS) and invasive breast cancer. Breast cancer can arise in the milk ducts, lactating lobules, and connective tissue. Breast cancer includes estrogen receptor (ER)-negative and hormone receptor (HR)-negative cancers and can also be classified as Group 3 (HER-2 positive) or Group 4 (basal-like).

[0175] Prostate cancer is cancer that develops in the prostate, a gland in the male reproductive system. It occurs when prostate cells mutate and begin to grow uncontrolled. These cells can spread from the prostate to virtually any other part of the body, including the bones and lymph nodes, as well as the kidneys, bladder, and even the brain (metastatic prostate cancer), among other tissues. Prostate cancer can cause pain, difficulty urinating, problems during intercourse, and erectile dysfunction. Other symptoms may develop in later stages of the disease. Prostate cancer detection rates vary greatly around the world, with South and East Asia experiencing lower detection rates than Europe and, particularly, the United States. Prostate cancer most frequently occurs in men over the age of 50 and is one of the most common types of cancer in men. However, many men who develop prostate cancer have no symptoms, do not receive treatment, and ultimately die of other causes. This is due in most cases to the slow growth of prostate cancer and the fact that most affected men are over 60 years old. Therefore, they often die of causes unrelated to prostate cancer. Many factors, including genetics and diet, contribute to the development of prostate cancer. The presence of prostate cancer may be indicated by symptoms, physical examination, prostate-specific antigen (PSA), or biopsy. Concerns exist about the accuracy of the PSA test and its usefulness for screening. Suspected prostate cancer is typically confirmed by a prostate biopsy and microscopic examination. Further tests, such as CT scans and bone scans, can be performed to determine whether the prostate cancer has spread. Surgery and radiation therapy, primarily in combination with other treatments such as hormone therapy, chemotherapy, proton therapy, cryosurgery, and high-intensity focused ultrasound (HIFU), are also contemplated.

[0176] Certain embodiments provide a method of inhibiting PARP in a subject having a recognized need for such treatment, comprising administering to the subject a therapeutically acceptable amount of a compound or composition described herein. In one embodiment, provided herein is a method of treating a disease ameliorated by inhibiting PARP, comprising administering to a subject in need of treatment a therapeutically effective amount of a compound or composition described herein.

[0177] Certain embodiments provide a method of treating leukemia, colon cancer, glioblastoma, lymphoma, melanoma, breast carcinoma, or cervical carcinoma in a subject having a recognized need for such treatment, comprising administering to the subject a therapeutically acceptable amount of a compound or composition described herein.

[0178] In some embodiments, provided herein are methods for treating cancers with defects in the homologous recombination (HR)-dependent DNA double-strand break (DSB) repair pathway, comprising administering a therapeutically effective amount of a compound or composition described herein to a subject in need of treatment. In certain embodiments, the cancer comprises one or more cancer cells that have reduced or suppressed ability to repair DNA DSBs by HR compared to normal cells. In some embodiments, the cancer cells have a BRCA1 or BRCA2-deficient phenotype. In some embodiments, the cancer cells are BRCA1 or BRCA2-deficient. In some embodiments, the methods provided herein involve treating an individual who is heterozygous for a mutation in a gene encoding a component of the HR-dependent DNA DSB repair pathway. In certain embodiments, the individual is heterozygous for a mutation in BRCA1 and / or BRCA2. In some embodiments, the methods for treating cancer include treating breast cancer, ovarian cancer, pancreatic cancer, and / or prostate cancer. In some embodiments, the methods for treating cancer further comprise administering ionizing radiation or a chemotherapeutic agent.

[0179] The primary function of the DNA mismatch repair (MMR) system is to eliminate single-base mismatches and insertion-deletion loops that can arise during DNA replication. Insertion-deletion loops result from the loss or gain of short repeat units within microsatellite sequences, also known as microsatellite instability (MSI). At least six distinct MMR proteins are required. For mismatch recognition, the MSH2 protein heterodimerizes with either MSH6 or MSH3, depending on the type of lesion being repaired (MSH6 is required for the correction of single-base mismatches, while both MSH3 and MSH6 can contribute to the correction of insertion-deletion loops). The MLH1 and PMS2 heterodimer coordinates interactions between the mismatch recognition complex and other proteins required for MMR. These additional proteins may include at least exonuclease 1 (EXO1), possibly a helicase, proliferating cell nuclear antigen (PCNA), single-stranded DNA-binding protein (RPA), and DNA polymerases δ and ε. In addition to PMS2, MLH1 can heterodimerize with two additional proteins, MLH3 and PMS1. Recent findings indicate that PMS2 is required for the correction of single-base mismatches, and that both PMS2 and MLH3 contribute to the correction of insertion-deletion loops. Additional homologs of human MMR proteins are known that are required for functions other than MMR. These proteins include MSH4 and MSH5, which are required for meiotic (and possibly mitotic) recombination but do not appear to be involved in MMR.

[0180] Germline mutations in human MMR genes cause susceptibility to hereditary nonpolyposis colon cancer (HNPCC), one of the most common cancer syndromes in humans. Diagnosed at an early age and transmitted as an autosomal dominant trait, excess colon cancer and a defined range of extracolonic cancers constitute the clinical definition of the syndrome. MSI, a hallmark of HNPCC, occurs in approximately 15%–25% of sporadic colorectal tumors and in other organs. According to international standards, high-grade MSI (MSI-H) is defined as instability at two or more of five loci or ≥30%–40% of all microsatellite loci studied, while instability at fewer loci is referred to as MSI-low (MSI-L). MSI occurs in a significant proportion (2%–50% of tumors) of non-HNPCC cancers (e.g., breast, prostate, and lung cancers). Based on the proportion of unstable markers, categories MSS, MSI-L and MSI-H can be distinguished in these cancers as well as HNPCC cancer.In one embodiment, the method is for treating cancer with defective mismatch DNA repair pathway.In another embodiment, the method is for treating cancer that shows microsatellite instability due to reduced or impaired DNA repair pathway.In another embodiment, the method is for treating cancer that shows genomic instability due to reduced or impaired DNA repair pathway.

[0181] In certain embodiments, the compounds or compositions described herein may be used in the preparation of a medicament for the treatment of a cancer that is deficient in homologous recombination (HR)-dependent DNA double-strand break (DSB) repair activity, or in the treatment of a patient with a cancer that is deficient in HR-dependent DNA DSB repair activity, comprising administering a therapeutically effective amount of the compound or composition to the patient.

[0182] The HR-dependent DNA DSB repair pathway repairs DNA double-strand breaks (DSBs) via a homologous mechanism, reforming the continuous DNA helix. Components of the HR-dependent DNA DSB repair pathway include ATM (NM_000051), RAD51 (NM_002875), RAD51L1 (NM_002877), RAD51C (NM_002876), RAD51L3 (NM_002878), DMC1 (NM_007068), XRCC2 (NM_005431), XRCC3 (NM_005432), and RA. These proteins include, but are not limited to, D52 (NM_002879), RAD54L (NM_003579), RAD54B (NM_012415), BRCA1 (NM_007295), BRCA2 (NM_000059), RAD50 (NM_005732), MRE11A (NM_005590), and NBS11M_00248_5. Other proteins involved in the HR-dependent DNA DSB repair pathway include regulatory factors such as EMSY (Wood, et al., Science, 291, 1284-1289 (2001); Khanna et al., Nat. Genet. 27(3):247-254 (2001) and Hughes-Davies, et al., Cell, 115, pp 523-535).

[0183] In some embodiments, a cancer that is deficient in HR-dependent DNA DSB repair comprises one or more cancer cells that have a reduced or inhibited ability to repair DNA DSBs through that pathway compared to normal cells, i.e., activity of the HR-dependent DNA DSB repair pathway is reduced or inhibited in the one or more cancer cells.

[0184] In certain embodiments, the activity of one or more components of the HR-dependent DNA DSB repair pathway is inhibited in one or more cancer cells of an individual with a cancer that is deficient in HR-dependent DNA DSB repair. Components of the HR-dependent DNA DSB repair pathway include those described above.

[0185] In some embodiments, cancer cells have a BRCA1 and / or BRCA2-deficient phenotype, i.e., BRCA1 and / or BRCA2 activity is reduced or suppressed in cancer cells. In certain embodiments, cancer cells with this phenotype are BRCA1 and / or BRCA2-deficient, i.e., BRCA1 and / or BRCA2 expression and / or activity is reduced or suppressed in cancer cells, for example, by mutation or polymorphism in the encoding nucleic acid, or by amplification, mutation, or polymorphism of a gene encoding a regulator, for example, the EMSY gene encoding the BRCA2 regulator, or by epigenetic mechanisms such as methylation of the gene promoter.

[0186] BRCA1 and BRCA2 are tumor suppressors, and their wild-type alleles are frequently lost in tumors of heterozygous carriers. Mutations in BRCA1 and / or BRCA2 are associated with breast cancer. Amplification of the EMSY gene, which encodes a BRCA2 binding factor, is associated with breast and ovarian cancer (Jasin M., Oncogene, 21(58), 8981-93(2002); Tutt, et al., Trends Mol. Med., 8(12), 571-6,(2002); and Radice, PJ, Exp Clin Cancer Res., 21(3 Suppl), 9-12(2002)).

[0187] Carriers of BRCA1 and / or BRCA2 mutations are also at increased risk for ovarian, prostate, and pancreatic cancer.

[0188] In some embodiments, individual is heterozygous for one or more mutations, such as mutation and polymorphism in BRCA1 and / or BRCA2 or its regulator.Detection of BRCA1 and BRCA2 mutations is described in, for example, EP699 754, EP705 903, Neuhausen, SL and Ostrander, EA, Genet.Test, 1, 75-83 (1992), Janatova M., et al., Neoplasma, 50 (4), 246-50 (2003).Determining the amplification of BRCA2 binding factor EMSY is described in Hughes-Davies, et al., Cell, 115, 523-535.

[0189] In certain cases, cancer-associated mutations and polymorphisms are detected at the nucleic acid level by detecting the presence of a mutant nucleic acid sequence, or at the protein level by detecting the presence of a mutant (i.e., mutant or allelic variant) polypeptide.

[0190] In certain embodiments, the compounds described herein are intended to be useful for patients who have relapsed or become refractory. The term "relapse" refers to a disease (or cancer) that reappears or grows again after a period of remission. The term "refractory" is used to describe when a cancer does not respond to treatment or when the response to treatment does not last long. For example, the compounds described herein may be useful for treating cancer in patients who have previously been treated with a cancer therapy described herein, such as edenzalutamide.

[0191] composition Any composition (including pharmaceutical compositions) of the compounds detailed herein is encompassed by the present disclosure.Therefore, provided herein is a pharmaceutical composition comprising a compound of the present disclosure, or its pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier or excipient.The pharmaceutical compositions provided herein can be in a form suitable for oral, buccal, parenteral (for example, intravenous, intramuscular, infusion, or subcutaneous injection), nasal, topical, or rectal administration, or in a form suitable for administration by inhalation.

[0192] In one aspect, the compounds described herein may be in a purified form. Compositions comprising the compounds described herein or salts thereof, e.g., compositions of substantially pure compounds, are provided. In some embodiments, compositions comprising the compounds described herein or salts thereof are in substantially pure form. Unless otherwise specified, "substantially pure" refers to a composition containing 35% or less impurities, where impurities refer to compounds other than the desired compound or salt thereof that make up the majority of the composition. In one variation, a substantially pure composition of a compound or salt thereof is provided when the composition contains 25% or less impurities. In another variation, a substantially pure composition of a compound or salt thereof is provided when the composition contains 20% or less impurities. In yet another variation, a substantially pure composition of a compound or salt thereof is provided when the composition contains 10% or less impurities. In a further variation, a substantially pure composition of a compound or salt thereof is provided when the composition contains 5% or less impurities. In another variation, a substantially pure composition of a compound or salt thereof is provided when the composition contains 3% or less impurities. In yet another variation, a substantially pure composition of a compound or salt thereof is provided when the composition contains 1% or less impurities. In a further variation, a composition of a substantially pure compound or salt thereof is provided, where the composition contains 0.5% or less of an impurity.

[0193] In certain embodiments, pharmaceutical compositions can be formulated in any manner, including by using one or more physiologically acceptable carriers, including excipients and / or auxiliaries that facilitate the processing of active compound into pharmaceutical compositions.In some embodiments, suitable formulations depend on the selected route of administration.In various embodiments, any suitable technique, carrier and excipient can be used.

[0194] Provided herein are pharmaceutical compositions comprising the compounds described herein and pharmaceutically acceptable diluents(s), excipients(s), and / or carrier(s). Additionally, in some embodiments, the compounds described herein are administered as pharmaceutical compositions in which the compounds described herein are mixed with other active ingredients, similar to combination therapy.

[0195] As used herein, a pharmaceutical composition refers to a mixture of a compound described herein with other chemical components, such as carriers, stabilizers, diluents, dispersants, suspending agents, thickeners, and / or excipients. In certain embodiments, the pharmaceutical composition facilitates administration of the compound to an organism. In some embodiments, practicing the methods of treatment or use provided herein involves administering or using a pharmaceutical composition comprising a therapeutically effective amount of a compound provided herein. In certain embodiments, the methods of treatment provided herein involve administering such a pharmaceutical composition to a mammal having the disease or condition being treated. In one embodiment, the mammal is a human. In some embodiments, the therapeutically effective amount will vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used, and other factors. In various embodiments, the compounds described herein are used alone or in combination with one or more therapeutic agents as components of a mixture.

[0196] In certain embodiments, the pharmaceutical compositions provided herein are formulated for intravenous injection. In certain aspects, the intravenous injection formulations provided herein are formulated as aqueous solutions, in some embodiments, in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. In certain embodiments, the pharmaceutical compositions provided herein are formulated for transmucosal administration. In some aspects, transmucosal formulations contain penetrants appropriate for the barrier to be permeated. In certain embodiments, the pharmaceutical compositions provided herein are formulated for other parenteral injections, and suitable formulations include aqueous or non-aqueous solutions, in one embodiment, containing physiologically compatible buffers or excipients.

[0197] In certain embodiments, the pharmaceutical compositions provided herein are formulated for oral administration.In certain aspects, the oral formulations provided herein comprise the compounds described herein formulated with pharmaceutically acceptable carriers or excipients.Such carriers allow the compounds described herein to be formulated as tablets, powders, pills, dragees, capsules, liquids, gels, syrups, elixirs, slurries, suspensions, etc., for oral ingestion by the patient to be treated.

[0198] In some embodiments, pharmaceutical compositions for oral use are prepared by mixing one or more solid excipients with one or more of the compounds described herein, optionally grinding the resulting mixture, and, if desired, adding suitable excipients, processing the resulting granular mixture to obtain tablets or dragee cores. Suitable excipients include, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations, such as corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth gum, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others, such as polyvinylpyrrolidone (PVP or povidone) or calcium phosphate. If desired, disintegrants, such as cross-linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or its salts (such as sodium alginate), are optionally added.

[0199] In certain embodiments, pharmaceutical compositions are provided herein formulated as dragee cores with suitable coatings, etc. In certain embodiments, concentrated sugar solutions are used to form suitable coatings, optionally containing gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and / or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. In some embodiments, dyes and / or pigments are added to tablets, dragees, and / or their coatings, for example, to identify or characterize different combinations of active compound doses.

[0200] In certain embodiments, pharmaceutical compositions that can be used include push-fit capsules made of gelatin and soft, sealed capsules made of gelatin, and oral administration containing a plasticizer such as glycerol or sorbitol. In some embodiments, the push-fit capsules contain the active ingredient mixed with a filler such as lactose, a binder such as starch, and / or a lubricant such as talc or magnesium stearate, and optionally a stabilizer. In certain embodiments, in soft capsules, the active compound is dissolved or suspended in a suitable liquid such as fatty oils, liquid paraffin, or liquid polyethylene glycol. In addition, stabilizers are optionally added. In certain embodiments, the formulation for oral administration is in a dosage suitable for such administration.

[0201] In certain embodiments, the pharmaceutical compositions provided herein are formulated for buccal or sublingual administration. In certain embodiments, the buccal or sublingual compositions take the form of tablets, lozenges, or gels formulated in conventional manner. In certain embodiments, parenteral injection involves bolus injection or continuous infusion. In some embodiments, the injectable formulation is presented in unit dosage form, e.g., in ampoules or multi-dose containers, with an added preservative. In some embodiments, the pharmaceutical compositions described herein are in a form suitable for parenteral injection as a sterile suspension, solution, or emulsion in an oily or aqueous vehicle, optionally containing formulating agents such as suspending agents, stabilizers, and / or dispersing agents. Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compound in water-soluble form. In some embodiments, a suspension of the active compound is prepared as an appropriate oily injection suspension. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters such as ethyl oleate or triglycerides, or liposomes. In certain embodiments, aqueous injection suspensions contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension also contains suitable stabilizers or agents that increase the solubility of the compounds, allowing for the preparation of highly concentrated solutions. In an alternative embodiment, the active ingredient is in powder form for constitution with a suitable vehicle, for example, sterile, pyrogen-free water, before use.

[0202] In some embodiments, the compounds described herein are administered topically. In certain embodiments, the compounds described herein are formulated into various topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams, or ointments. Such pharmaceutical compounds optionally include solubilizers, stabilizers, tonicity enhancing agents, buffers, and / or preservatives.

[0203] In certain embodiments, pharmaceutical compositions provided herein are formulated for transdermal administration of the compounds described herein. In some embodiments, administration of such compositions uses transdermal delivery devices and transdermal delivery patches. In certain embodiments, the compositions are lipophilic emulsions or buffered aqueous solutions dissolved and / or dispersed in a polymer or adhesive. Such patches include those designed for continuous, pulsatile, or on-demand delivery of pharmaceuticals. In some embodiments, transdermal delivery of the compounds described herein is achieved using iontophoretic patches, etc. In certain embodiments, the absorption rate is slowed by using rate-controlling membranes or by entrapment of the compound within a polymer matrix or gel. Conversely, absorption enhancers are optionally used to increase absorption. Absorption enhancers and carriers include absorbable pharmaceutically acceptable solvents that aid in the passage of the compound through the skin. For example, a transdermal device is in the form of a bandage, including a backing member, a reservoir containing the compound, optionally with a carrier, a rate-controlling barrier for delivering the compound to the host's skin at a controlled, predetermined rate over an extended period of time, and a means for securing the device to the skin.

[0204] In certain embodiments, the pharmaceutical compositions provided herein are formulated for administration by inhalation. In certain embodiments, in such pharmaceutical compositions formulated for inhalation, the compounds described herein are in the form of aerosol, mist, or powder. In some embodiments, the pharmaceutical compositions described herein are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or nebulizer using a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. In certain aspects of pressurized aerosols, the dosage unit can be determined by providing a valve to deliver a metered amount. In certain embodiments, by way of example only, capsules and cartridges such as gelatin for use in an inhaler or insufflator are formulated, which contain a powder mix of the compounds described herein and a suitable powder base, such as lactose or starch.

[0205] In some embodiments, the compounds described herein are formulated into rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas.In certain embodiments, the rectal compositions optionally contain a conventional suppository base, such as cocoa butter or other glycerides, and synthetic polymers, such as polyvinylpyrrolidone, PEG, etc.In certain suppository forms of the composition, a low-melting wax, such as, but not limited to, a mixture of fatty acid glycerides, optionally combined with cocoa butter, is first melted.

[0206] In various embodiments provided herein, pharmaceutical compositions are formulated in a conventional manner using one or more physiologically acceptable carriers, including excipients and auxiliaries that facilitate the processing of active compounds into pharmaceutically acceptable preparations.In certain embodiments, the appropriate formulation depends on the selected route of administration.In various embodiments, any suitable technique, carrier, and excipient is used.In some embodiments, pharmaceutical compositions comprising compounds described herein are prepared in a conventional manner, such as by conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or compressing processes, for example.

[0207] In certain embodiments, pharmaceutical compositions comprise at least one pharmaceutically acceptable carrier, diluent, or excipient and a compound described herein as an active ingredient in free acid or free base form, or in pharmaceutically acceptable salt form. Additionally, the methods and pharmaceutical compositions described herein include the use of N-oxides, crystalline forms (also known as polymorphs), and active metabolites of these compounds with the same type of activity. In some cases, the compounds described herein exist as tautomers. All tautomers are included within the scope of the compounds presented herein. Additionally, solvated and unsolvated forms of the compounds described herein are included herein. Solvates include those solvated with pharmaceutically acceptable solvents such as water, ethanol, and the like. Solvated forms of the compounds presented herein are also considered to be disclosed herein. In some embodiments, the pharmaceutical compositions described herein contain other medicinal or pharmaceutical agents, carriers, adjuvants, such as preservatives, stabilizers, wetting or emulsifying agents, solution enhancers, salts for adjusting osmotic pressure, and / or buffers. In additional embodiments, the pharmaceutical compositions described herein also contain other therapeutically useful substances.

[0208] Methods for preparing compositions containing the compounds described herein include formulating the compounds with one or more inert, pharmaceutically acceptable excipients or carriers to form solid, semi-solid, or liquid forms. Solid compositions include, but are not limited to, powders, tablets, dispersible granules, capsules, cachets, and suppositories. Liquid compositions include solutions in which the compounds disclosed herein are dissolved, emulsions containing the compounds, or solutions containing liposomes, micelles, or nanoparticles containing the compounds. Semi-solid compositions include, but are not limited to, gels, suspensions, and creams. In various embodiments, the compositions are in liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid before use, or as emulsions. These compositions optionally contain minor amounts of nontoxic auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and the like.

[0209] In some embodiments, the compositions comprising the compounds described herein are in the form of a liquid in which the drug is present in solution, suspension, or both. In some embodiments, when the composition is administered as a solution or suspension, a first portion of the drug is present in solution, and a second portion of the drug is present in particulate form in suspension in a liquid matrix. In some embodiments, the liquid composition comprises a gel formulation. In other embodiments, the liquid composition is aqueous.

[0210] Useful aqueous suspensions optionally contain one or more polymers as suspending agents. Useful polymers include water-soluble polymers such as cellulose-based polymers, for example, hydroxypropylmethylcellulose, and water-insoluble polymers such as cross-linked carboxyl-containing polymers. Useful compositions optionally contain mucoadhesive polymers selected from, for example, carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methyl methacrylate), polyacrylamide, polycarbophil, acrylic acid / butyl acrylate copolymer, sodium alginate, and dextran.

[0211] Useful compositions optionally contain a solubilizing agent to aid in the solubility of the compounds described herein. The term "solubilizing agent" generally includes agents that result in the formation of a micellar solution or a true solution of the drug. Solubilizing agents include certain acceptable nonionic surfactants, such as polysorbate 80, and ophthalmically acceptable glycols, polyglycols, such as polyethylene glycol 400, and glycol ethers.

[0212] Useful compositions optionally contain one or more pH adjusters or buffers, including acids such as acetic acid, boric acid, citric acid, lactic acid, phosphoric acid, and hydrochloric acid; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate, and tris-hydroxymethylaminomethane; and buffers such as citrate / dextrose, sodium bicarbonate, and ammonium chloride. Such acids, bases, and buffers are included in amounts necessary to maintain the pH of the composition within an acceptable range.

[0213] Useful compositions optionally contain one or more salts in an amount necessary to make the osmolality of the composition acceptable.Such salts include those with sodium, potassium, or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate, or bisulfite anions.Suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite, and ammonium sulfate.

[0214] Certain useful compositions optionally contain one or more preservatives to inhibit microbial activity. Suitable preservatives include mercury-containing substances such as merphen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide, and cetylpyridinium chloride.

[0215] Some useful compositions optionally contain one or more surfactants to enhance physical stability or for other purposes. Suitable nonionic surfactants include polyoxyethylene fatty acid glycerides and vegetable oils, such as polyoxyethylene (60) hydrogenated castor oil, and polyoxyethylene alkyl ethers and alkylphenyl ethers, such as Octoxynol 10 and Octoxynol 40.

[0216] Certain useful compositions optionally include one or more antioxidants to enhance chemical stability, if desired. Suitable antioxidants include, by way of example only, ascorbic acid and sodium metabisulfite.

[0217] In some embodiments, aqueous suspension compositions are packaged in single-dose or non-reclosable containers. In alternative embodiments, multi-dose reclosable containers are used, in which case it is typical to include a preservative in the composition.

[0218] In various embodiments, any delivery system for hydrophobic pharmaceutical compounds is used. Liposomes and emulsions are examples of delivery vehicles or carriers for hydrophobic drugs. In certain embodiments, certain organic solvents, such as N-methylpyrrolidone, are used. In some embodiments, the compound is delivered using a sustained-release system, such as a semipermeable matrix of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials are utilized in embodiments herein. In certain embodiments, sustained-release capsules release the compound for several weeks to over 100 days. In some embodiments, depending on the chemical nature and biological stability of the therapeutic reagent, additional strategies for protein stabilization are used.

[0219] In certain embodiments, the formulations or compositions described herein benefit from and / or optionally include antioxidants, metal chelators, thiol-containing compounds, and other general stabilizers. Examples of such stabilizers include, but are not limited to, (a) about 0.5% to about 2% w / v glycerol, (b) about 0.1% to about 1% w / v methionine, (c) about 0.1% to about 2% w / v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e) about 0.01% to about 2% w / v ascorbic acid, (f) 0.003 to about 0.02% w / v polysorbate 80, (g) 0.001% to about 0.05% w / v polysorbate 20, (h) arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrin, (l) pentosan polysulfate and other heparinoids, (m) divalent cations such as magnesium and zinc, or (n) combinations thereof.

[0220] Medication and Treatment Regimen In certain embodiments, compositions containing the compound(s) described herein are administered for preventive and / or therapeutic treatment. In certain therapeutic applications, the compositions are administered to patients already suffering from a disease or condition in an amount sufficient to cure or at least partially prevent the symptoms of the disease or condition. In some embodiments, the effective amount for this use will depend on the severity and course of the disease or condition, previous therapy, the patient's health status, weight, and response to drugs, and the judgment of the treating physician. In certain cases, it may be appropriate for caregivers to determine such therapeutically effective amounts through routine experimentation (including, but not limited to, dose escalation clinical trials).

[0221] In certain prophylactic applications, compositions containing the compounds described herein are administered to a patient susceptible to or otherwise at risk of a particular disease, disorder, or condition. In some embodiments, the amount administered is defined as a "prophylactically effective amount or dose." In certain embodiments of this use, the precise amount of compound administered will depend on the patient's health, weight, and the like. In some embodiments, it may be appropriate for a caregiver to determine such prophylactically effective amounts by routine experimentation (e.g., a dose escalation clinical trial). In certain embodiments, when used in a patient, the effective amount for this use will depend on the severity and course of the disease, disorder, or condition, previous therapy, the patient's health, and response to the drugs, as well as the judgment of the treating physician.

[0222] In certain cases, the patient's condition does not improve or does not significantly improve after administration of a compound or composition described herein, and at the physician's discretion, administration of the compound is optionally administered chronically, i.e., long-term, including for the patient's lifetime, to ameliorate or otherwise control or limit the symptoms of the patient's disease or condition.

[0223] In certain cases where the patient's condition improves or does not substantially improve, at the discretion of the physician, administration of the compound is optionally continued. Alternatively, the administered drug dose is optionally temporarily reduced or temporarily suspended for a certain period of time (i.e., a "drug holiday"). In certain embodiments, the length of the drug holiday varies from 2 days to 1 year, and includes, by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days. Dose reductions during drug holidays include reductions of about 10% to about 100%, including, by way of example only, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%.

[0224] In certain embodiments, after the patient's condition has improved, a maintenance dose is administered as needed.In some embodiments, for example, the dosage or frequency of administration of the maintenance dose, or both, is reduced as a function of symptoms to a level at which the improved disease, disorder, or condition is maintained.However, in certain embodiments, the patient is optionally given long-term intermittent treatment upon any recurrence of symptoms.

[0225] In certain embodiments, the amount of a given agent that corresponds to an effective amount will vary depending on factors such as the particular compound, disease, or condition, and its severity, the identity (e.g., weight) of the subject or host requiring treatment, and other factors. In some embodiments, the effective amount will nevertheless be determined according to the particular circumstances surrounding the case, including, for example, the particular agent being administered, the route of administration, the condition being treated, and the subject or host being treated. However, in certain embodiments, doses used for adult treatment range from about 0.02 to about 5000 mg per day, and in certain embodiments, from about 1 to about 1500 mg per day. In various embodiments, the desired dose is conveniently presented as a single dose or as divided doses administered simultaneously (or over a short period of time) or at appropriate intervals, e.g., as two, three, four, or more subdoses per day.

[0226] In some embodiments, the pharmaceutical compositions described herein are in unit dosage form suitable for single administration of precise dosage amounts. In some unit dosage forms, the formulation is divided into unit doses containing appropriate amounts of one or more compounds. In certain embodiments, the unit dosage is in the form of a package containing individual amounts of the formulation. Non-limiting examples are packaged tablets or capsules, and powders in vials or ampoules. In some embodiments, aqueous suspension compositions are packaged in single-dose or non-reclosable containers. In alternative embodiments, multi-dose reclosable containers are used, in which case it is typical to include a preservative in the composition. By way of example only, formulations for parenteral injection are in some embodiments presented in unit dosage form, including, but not limited to, ampoules, or in multi-dose containers with added preservatives.

[0227] In certain embodiments, a suitable daily dosage for the compounds described herein is about 0.01 to about 2.5 mg / kg of body weight. In some embodiments, indicated daily dosages in larger subjects, including but not limited to humans, range from about 0.5 mg to about 100 mg, conveniently administered in divided doses, including but not limited to, up to four times daily or in sustained-release form. In certain embodiments, a unit dosage form suitable for oral administration contains about 1 to about 50 mg of active ingredient. The foregoing ranges are merely suggestive, as there are many variables regarding individual treatment regimens, and significant deviations from these recommendations are not uncommon. In certain embodiments, dosages will vary depending on several variables, including but not limited to, the activity of the compound used, the disease or condition being treated, the mode of administration, the requirements of the individual subject, the severity of the disease or condition being treated, and the judgment of the practitioner.

[0228] In certain embodiments, the toxicity and therapeutic efficacy of such a treatment regimen is greater than or equal to the LD 50 (a dose lethal to 50% of the population) and ED 50 The LD (therapeutic effective dose in 50% of the population) is determined by standard pharmaceutical procedures in cell cultures or experimental animals. The dose ratio between toxic and therapeutic effects is the therapeutic index, and is known as the LD 50 / ED 50 The therapeutic index can be expressed as a ratio. In certain embodiments, compounds exhibiting a high therapeutic index are preferred. In some embodiments, data obtained from cell culture assays and animal studies are used to formulate various dosages for human use. In certain embodiments, the dosage of such compounds is determined to be the ED with minimal toxicity. 50 In certain embodiments, the dosage varies within this range depending upon the dosage form employed and the route of administration utilized.

[0229] In certain embodiments, the disclosed compounds exhibit increased affinity for nuclear targets, increased potency, or increased therapeutic index compared to the unmodified nuclear payload from which the compounds are derived. In certain embodiments, this higher affinity, potency, or therapeutic index may provide benefits such as allowing for the administration of lower doses, thus reducing the potential for toxicity, improving the therapeutic index, and reducing the overall cost of treatment. In certain embodiments, a suitable daily dosage for administration of a compound described herein is less than 100% of the recommended daily dose of the unmodified nuclear payload, or less than about 90%, or less than about 80%, or less than about 70%, or less than about 60%, or less than about 50%, or less than about 40%, or between about 20% and about 90%, or between about 30% and about 90%, or between about 40% and about 90%, or About 50% to about 90%, or about 60% to about 90%, or about 70% to about 90%, or about 20% to about 80%, or about 30% to about 80%, or about 40% to about 80%, or about 50% to about 80%, or about 60% to about 80%, or about 70% to about 80%, or about 20% to about 70%, or about 30% to about 70%, or about 40% to about 70%, or about 50% to about 70%, or about 60% to about 70%.

[0230] In certain embodiments, the compounds described herein are used in the preparation or manufacture of a medicament for the treatment of a disease or condition mediated by the enzyme poly(ADP-ribose) polymerase (PARP), or in which inhibition of the enzyme poly(ADP-ribose) polymerase (PARP) ameliorates the disease or condition. In some embodiments, a method for treating any of the diseases or conditions described herein in a subject in need of such treatment involves administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one compound described herein, or a pharmaceutically acceptable salt, pharmaceutically acceptable N-oxide, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof.

[0231] Combination therapy The compounds described herein (e.g., compounds of Table 1, compounds of Formula I or II, or any other formula disclosed herein) can also be used in combination with other active ingredients. Such combinations are selected based on the condition being treated, cross-reactivity of the ingredients, and the pharmacological properties of the combination. In one embodiment, the present disclosure provides the use of the compounds described herein in combination with another agent or treatment method, such as another cancer treatment. For example, when treating cancer, the composition can be combined with other anti-cancer compounds (such as paclitaxel or rapamycin).

[0232] The compound of the present disclosure can also be combined with one or more other active ingredients in a single dosage form for simultaneous or sequential administration to patients.Combined therapy can be administered as a simultaneous or sequential regimen.When administered sequentially, the combination can be administered in two or more doses.

[0233] Combination therapy can result in "synergistic" and "synergistic" effects, i.e., effects achieved when the active ingredients used together are greater than the sum of the effects resulting from using the compounds separately. Synergistic effects can be achieved when the active ingredients are (1) co-formulated and administered or delivered simultaneously in a combination formulation, (2) delivered in parallel as alternating or separate formulations, or (3) delivered by other regimens. When delivered in alternation therapy, synergistic effects can be achieved when the compounds are administered or delivered sequentially, for example, in separate tablets, pills, or capsules, or by different injections in separate syringes. Generally, during alternation therapy, effective dosages of each active ingredient are administered sequentially, i.e., consecutively, whereas in combination therapy, effective dosages of two or more active ingredients are administered together. Synergistic anticancer effect refers to an anticancer effect that is greater than the predicted purely additive effect of the individual compounds of the combination.

[0234] The administration of the compounds and compositions of the present disclosure to patients follows the general protocol for the administration of chemotherapy, taking into account toxicity, if any.It is expected that the treatment cycle will be repeated as necessary.It is also contemplated that various standard or adjuvant cancer therapies and surgical interventions can be applied in combination with the described active agent(s).These therapies include, but are not limited to, chemotherapy, radiation therapy, immunotherapy, gene therapy, and surgery.

[0235] In some embodiments, provided herein are methods for treating cancer, comprising administering to a subject in need of treatment a therapeutically effective amount of a compound or composition described herein in combination with ionizing radiation or one or more chemotherapeutic agents. In some embodiments, the compound described herein is administered simultaneously with ionizing radiation or one or more chemotherapeutic agents. In other embodiments, the compound described herein is administered sequentially with ionizing radiation or one or more chemotherapeutic agents.

[0236] In certain embodiments, provided herein is a method for treating cancer, which includes administering to a subject in need of treatment a therapeutically effective amount of a compound or composition described herein in combination with ionizing radiation and one or more chemotherapeutic agents.In some embodiments, the compound described herein is administered simultaneously with ionizing radiation and one or more chemotherapeutic agents.In other embodiments, the compound described herein is administered sequentially with ionizing radiation and one or more chemotherapeutic agents.

[0237] In certain embodiments, a method for treating cancer is provided herein, comprising administering a therapeutically effective amount of a compound or composition described herein in combination with ionizing radiation to a subject in need of treatment.In certain embodiments, radiation is administered at a dose of about 2.5 Gy / day, or about 2.0 Gy / day, or about 1.8 Gy / day, or about 1.6 Gy / day, or about 1.4 Gy / day, or less than about 1.2 Gy / day.In certain embodiments, radiation is administered at a dose of about 2.5 Gy / day, or about 2.0 Gy / day, or about 1.8 Gy / day, or about 1.6 Gy / day, or about 1.4 Gy / day, or less than about 1.2 Gy / day, about 5 times per week.In certain embodiments, radiation is administered at a dose of about 2.5 Gy / day, or about 2.0 Gy / day, or about 1.8 Gy / day, or about 1.6 Gy / day, or about 1.4 Gy / day, or less than about 1.2 Gy / day. In certain embodiments, the dose is about 2.5 Gy, or about 2.0 Gy, or about 1.8 Gy, or about 1.6 Gy, or about 1.4 Gy, or less than about 1.2 Gy, administered about 6 times a week.It is contemplated that by administering radiation in combination with the compound or composition described herein, prostate-specific chemical prostatectomy can be achieved while avoiding the harmful side effects of surgical prostatectomy, such as impotence and incontinence, due to the destruction of blood vessels and nerves.

[0238] Cancer therapy also includes a variety of combination therapies using both chemo- and radiation-based treatments. Combination chemotherapy includes cisplatin, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilone, taxotere, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, SCH 66336, R115777, L778123, BMS 214662, IRESSA® (gefitinib), TARCEVAR® (erlotinib hydrochloride), antibodies against EGFR, GLEEVEC® (matinib), Intron, ara-C, adriamycin, cytoxan, gemcitabine, uracil mustard, chlormethine, ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine, triethylenethiophosphoramine, busulfan, and carm statin, lomustine, streptozocin, dacarbazine, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatin, vinblastine, vincristine, vindesine, bleomycin, doxorubicin, dactinomycin, daunorubicin, epirubicin, idarubicin, mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, teniposide, 17α-ethynyl Estradiol, diethylstilbestrol, testosterone, prednisone, fluoxymesterone, dromostanolone propionate, testolactone, megestrol acetate, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianisene, hydroxyprogesterone, aminoglutethimide, estramustine, medroxyprogesterone acetate, leuprolide, flutamide, toremifene, goserelin , carboplatin, hydroxyurea, amsacrine, procarbazine, mitotane, mitoxantrone, levamisole, navelbene, anastrazole, letrazole, capecitabine, reloxafine, droloxafine, hexamethylmelamine, Avastin, Herceptin, Bexar, Velcade, Zevalin, Trisenox, Xeroda, vinorelbine, porfimer,Erbitux® (cetuximab), liposomal, thiotepa, altretamine, melphalan, trastuzumab, lerozole, fulvestrant, exemestane, ifosfomide, rituximab, C225, Camppath, carboplatin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, busulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP 16), including the use of chemotherapeutic agents such as tamoxifen, raloxifene, estrogen receptor binding agents, paclitaxel, gemcitabine, navelbine, farnesyl-protein transferase inhibitors, transplatin, 5-fluorouracil, vincristine, vinblastine, and methotrexate, or analog or derivative variants of any of the foregoing.

[0239] Other factors that cause DNA damage, such as radiation therapy, commonly known as gamma rays, X-rays, and / or the direct delivery of radioisotopes to tumor cells, are widely used. Other forms of DNA damage, such as microwave and ultraviolet radiation, are also contemplated. All of these factors most likely affect widespread damage to DNA, DNA precursors, DNA replication and repair, and chromosome assembly and maintenance. X-ray dose ranges from daily doses of 50–200 roentgens over extended periods (e.g., 3–4 weeks) to single doses of 2,000–6,000 roentgens. Dose ranges for radioisotopes vary widely and depend on the half-life of the isotope, the strength and type of radiation emitted, and uptake by the neoplastic cells. When applied to cells, the terms "contact" and "exposure" are used herein to describe the process by which therapeutic constructs and chemotherapeutic or radiotherapeutic agents are delivered to or directly juxtaposed with target cells. To achieve cell death or stasis, both agents are delivered to a cell in a combined amount effective to kill the cell or prevent it from dividing.

[0240] Immunotherapy generally relies on the use of immune effector cells and molecules to target and destroy cancer cells. The immune effector can be, for example, an antibody specific to some marker on the surface of tumor cells. The antibody alone may function as the therapeutic effector, or it may recruit other cells to actually affect cell killing. Antibodies can also be conjugated to drugs or toxins (such as chemotherapeutic agents, radionucleotides, ricin A chain, cholera toxin, pertussis toxin, etc.) and simply function as targeting agents. Alternatively, the effector can be a lymphocyte carrying a surface molecule that interacts either directly or indirectly with the tumor cell target. Various effector cells include cytotoxic T cells and NK cells.

[0241] Therefore, immunotherapy can be used in conjunction with gene therapy as part of a combination therapy. General approaches to combination therapy are discussed below. Generally, tumor cells must have some marker that is suitable for targeting, i.e., not present on the majority of other cells. Many tumor markers exist, any of which may be suitable for targeting in the context of the present disclosure. Common tumor markers include carcinoembryonic antigen, prostate-specific antigen, urinary tract tumor-associated antigen, fetal antigen, tyrosinase (p97), gp68, TAG-72, HMFG, sialyl Lewis antigen, MucA, MucB, PLAP, estrogen receptor, laminin receptor, erb B, and p155.

[0242] In yet another embodiment, the secondary treatment is a secondary gene therapy in which a therapeutic polynucleotide is administered before, after, or simultaneously with a first chemotherapeutic agent. Delivery of the chemotherapeutic agent in conjunction with a vector encoding a gene product has a combined anti-hyperproliferative effect on the target tissue.

[0243] Approximately 60% of individuals with cancer undergo some type of surgery, including preventative, diagnostic, or staging, curative, and palliative surgery. Curative surgery is a cancer treatment that can be used in conjunction with other therapies, such as the treatment of the present disclosure, chemotherapy, radiation therapy, hormone therapy, gene therapy, immunotherapy, and / or alternative therapies. Curative surgery includes resection, which physically removes, excises, and / or destroys all or part of the cancerous tissue. Tumor resection refers to the physical removal of at least part of the tumor. In addition to tumor resection, surgical treatments include laser surgery, cryosurgery, electrosurgery, and microsurgical (Mohs) surgery. Furthermore, it is contemplated that the present disclosure may be used in conjunction with the removal of superficial cancers, pre-cancers, or incidental amounts of normal tissue.

[0244] The administration of the compounds or compositions described herein can be performed before or after other anti-cancer agents or treatments, with intervals ranging from minutes to weeks. In embodiments in which other anti-cancer agents and expression constructs are applied separately, it is generally ensured that no significant period of time passes between each delivery, so that the agent and expression construct can still exert their beneficial combined effect on the cells. For example, in such cases, it is contemplated that cells, tissues, or organisms can be contacted with active agent(s) in two, three, four, or more modalities substantially simultaneously (i.e., within about one minute). In other aspects, the one or more agents may be administered within about 1 minute, about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 45 minutes, about 60 minutes, about 2 hours, about 3 hours, about 4 hours, about 6 hours, about 8 hours, about 9 hours, about 12 hours, about 15 hours, about 18 hours, about 21 hours, about 24 hours, about 28 hours, about 31 hours, about 35 hours, about 38 hours, about 42 hours, about 45 hours, up to about 48 hours or more before and / or after administration of the active agent(s). In certain other embodiments, the agents may be administered within about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 8 days, about 9 days, about 12 days, about 15 days, about 16 days, about 18 days, about 20 days, up to about 21 days before and / or after administration of the active agent(s). In some cases, however, it may be desirable to extend the treatment period significantly, with several weeks passing between administrations (e.g., about 1, about 2, about 3, about 4, about 6, or about 8 weeks or more).

[0245] kit A kit for use in achieving anti-cancer effects is provided, which includes a compound or composition described herein. In certain embodiments, the kit includes a unit dose of the compound or composition described herein and instructions for administering it. In certain aspects, the kit further includes instructions for co-administering a second drug suitable for anti-cancer therapy, or an additional anti-cancer therapy (such as radiation or gene therapy). In another aspect, the kit for use in achieving anti-cancer effects includes a low dose (e.g., less than about 500 mg / day, or less than about 400 mg / day, or less than about 300 mg / day, or less than about 200 mg) of the compound or composition described herein and a second drug suitable for anti-cancer therapy. In yet another variation, the kit for use in achieving anti-cancer effects includes a high dose (e.g., more than about 500 mg / day) of the compound or composition described herein and a second drug suitable for anti-cancer therapy.

[0246] Drug manufacturing methods In another aspect of the present disclosure, the use of compounds and compositions described herein in the manufacture of medicines is provided.In particular, the manufacture of medicines is provided for the treatment of cancer or diseases or conditions that can be mediated at least in part by blocking DNA repair and / or transcription activation, such as by inhibiting PARP.In addition, the pharmaceutical compositions of compounds described herein are also intended to be used for the manufacture of medicines for the treatment of diseases or conditions that can be mediated at least in part by inhibiting PARP. [Example]

[0247] The present disclosure is further illustrated by the following examples, which are non-limiting and merely representative of various aspects of the present disclosure. Solid and dotted wedges in the structures disclosed herein indicate relative stereochemistry; absolute stereochemistry is indicated only where specifically stated or depicted.

[0248] The compounds disclosed herein, or any formula or subformula described herein, can be synthesized using standard synthetic techniques known to those skilled in the art. The compounds of the present disclosure can be synthesized using the general synthetic procedures described in the synthetic examples of General Methods 1-5.

[0249] If it is desired to obtain a specific enantiomer of a compound, this can be achieved from the corresponding mixture of enantiomers by using any suitable conventional procedure for separating or resolving enantiomers.Thus, for example, diastereomeric derivatives can be produced by the reaction of a mixture of enantiomers, such as a racemate, and a suitable chiral compound.The diastereomers can then be separated by any convenient means, for example, by crystallization, and the desired enantiomer can be recovered.In another resolution process, a racemate can be separated using chiral high-performance liquid chromatography.Alternatively, if desired, a specific enantiomer can be obtained by using a suitable chiral intermediate in one of the processes described.

[0250] Chromatography, recrystallization, and other conventional separation procedures may be used with intermediates or final products where it is desired to obtain a particular isomer of a compound or to otherwise purify the product of a reaction.

[0251] General information 1 H NMR spectrum and 13 C NMR spectra were recorded on a Varian 400 MHz or a Bruker Avance III 500 MHz spectrometer. Unless otherwise noted, spectra were analyzed using residual chloroform (δ 7.26, 1 H), DMSO (δ 2.54, 1 H), or methanol (δ 3.34, 1H). Chemical shifts are reported in ppm (δ). Multiplicities are indicated as s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), sext (septet), m (multiplet), and br (broad). Coupling constants, J, are reported in Hertz. Silica gel chromatography was performed using Hi-Purit Silica Flash Cartridges (National Chromatography Inc.) or RediSep Rf Gold C18 Cartridges (Teledyne Isco) on a Teledyne Isco CombiFlash® Rf+ instrument. Analytical HPLC was performed on a Waters ACQUITY UPLC equipped with a photodiode array detector and a Waters ACQUITY BEH Shield RPC18 (2.1 × 50 mm, 1.7 μm) column. Analytical LCMS was performed on a Waters ACQUITY UPLC equipped with a Waters 3100 mass detector. Chiral HPLC was performed on a Waters Alliance e2695 equipped with a photodiode array detector using a Daicel Chiralpak AD-H, Chiralpak IA, Chiralpak IB, Chiralpak IC, Chiralcel OD-H, or Chiralcel OJ-H column. Optical rotations were obtained on a Jasco P-2000 digital polarimeter and [α] D T Temperature (T), concentration (c = g / 100 mL), and solvent are reported. Commercially available reagents and solvents were used as received unless otherwise stated.

[0252] General method General Method 1 Olaparib-containing analogs can be prepared according to the method described by Menear et al. (Menear, KA et al. J. Med. Chem. 2008, 51, 6581-6591). [ka]

[0253] Scheme 1. Proposed Route to Olaparib-Containing Analogs: (i) EtN, THF, room temperature; (ii) a. aqueous NaOH, THF, 100 °C; b. 2 M HCl; (iii) HNNH, HO; (iv) Boc-piperazine, HATU, DIPEA, DMA; (v) HCl, dioxane; (vi) using intermediate A or intermediate C, HATU, HOBt, DMF, or intermediate B or intermediate D, EtN, DMF.

[0254] General Method 2 Rucaparib-containing analogs can be prepared according to the method described by Gillmore et al. (Gillmore, AT et al. Org. Process Res. Dev. 2012, 16, 1897-1904). [ka]

[0255] Scheme 2. Proposed Route to Rucaparib-Containing Analogs: (i) a. HNO3, H2SO4; b. MeOH, H2SO4; (ii) DMF, DMA, Et3N, 120 °C; (iii) H2, Pd / C, AcONa, MeOH; (iv) phthalimidoacetaldehyde, TFA, TES, CHCl2; (v) aqueous MeNH2; (vi) pyr·HBr3, THF, CHCl2; (vii) Ar-B(OR)2, Pd(dppf)Cl2·CHCl2, aqueous Na2CO3, DMA; (viii) using intermediate A or intermediate C, HATU, HOBt, DMF, or using intermediate B or intermediate D, Et3N, DMF.

[0256] Common Method 3 Talazoparib-containing analogs can be prepared according to the method described by Wang et al. (Wang, B. et al. J. Med. Chem. 2016, 59, 335-357). [ka]

[0257] Scheme 3. Proposed Route to Talazoparib-Containing Analogs: (i) 1-Methyl-1H-1,2,4-triazole-5-carbaldehyde, EtN, AcO, 2-Me-THF, room temperature–80 °C, 2 h; (ii) MeOH, room temperature, overnight; (iii) aminobenzaldehyde, TiCl, THF, MeOH, 0 °C–room temperature; (iv) a. HNNH, MeOH, room temperature, overnight; b. Chiral Separation; (v) Using Intermediate A or Intermediate C, HATU, HOBt, DMF, or using Intermediate B or Intermediate D, EtN, DMF.

[0258] Common Method 4 DHT-containing intermediates can be prepared by treating commercially available DHT(XX) with the desired tethering group to give intermediates such as XXI. When R=COMe, slight saponification of the ester group gives carboxylate intermediate A. When R=OAc, slight saponification releases the primary alcohol, which is then treated with methanesulfonyl chloride to give intermediate B. [ka]

[0259] Scheme 4. Proposed Route to DHT-Containing Intermediates: (i) EtN, DMF; (ii) aqueous LiOH, MeOH; (iii) MsCl, EtN, DMF.

[0260] Common Method 5 Enzalutamide-containing intermediates can be prepared by starting with carboxylic acid XXII (Jadhavar, et al. Bioorg. Med. Chem. Lett. 2016, 26, 5222-5228) and coupling with the desired linking group to give intermediates such as XXIII. When R = COMe, minor saponification of the ester group gives carboxylate intermediate C. When R = OAc, minor saponification releases the primary alcohol, which is then treated with methanesulfonyl chloride to give intermediate D. [ka]

[0261] Scheme 5. Proposed Route to Enzalutamide-Containing Intermediates: (i) HATU, HOBt, DMF; (ii) aqueous LiOH, MeOH; (iii) MsCl, EtN, DMF.

[0262] Common Method 6 CC-115-containing analogs can be prepared according to the method described by Mortensen et al. (Mortensen, D.S. et al. J. Med. Chem. 2015, 58, 5599-5608). [ka] [ka] [ka]

[0263] Scheme 6. Proposed Route to CC-115-Containing Intermediates: (i) Ethyl Bromoacetate, Cs2CO3, DMF; ii) DIPEA, NMP; iii) AcOH, MeOH; iv) Pd(dppf)Cl2, K2CO3, DMF; v) NH2NH2.H2O, EtOH or H2, Pd / C; vi) Using Intermediate XXII, HATU, DIPEA, DMF, or MsCl, Intermediate XX, Et3N, DMF, and 2M HCl / MeOH; vii) K2CO3, DMF; viii) tri(o-tolyl)phosphine, Pd2(dba)3, Et3N, DMF; ix) EtNH2.HCl, DIPEA, NMP.

[0264] Synthesis Examples Example S-1. Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-(6-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)-6-oxohexyl)benzamide (Compound 1.1) [ka]

[0265] Step-1: Preparation of (Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile To a stirred solution of dimethyl 3-oxo-1,3-dihydroisobenzofuran-1-ylphosphonate (10 g, 41.3 mmol) and 2-fluoro-5-formylbenzonitrile (6.15 g, 41.3 mmol) in THF (50 mL) was slowly added triethylamine (5.76 mL, 41.3 mmol) at 0 °C. The resulting mixture was stirred at room temperature for 16 h. The reaction was monitored by TLC. Upon completion, water (200 mL) was added, and the resulting precipitate was filtered through a Buchner funnel. The resulting product was washed with water (50 mL), hexane (50 mL), diethyl ether (30 mL), and dried under vacuum to give (Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile (50:50 mixture of E and Z isomers), which was used in the next step without further purification. LC-MS: 266 [M+H] + . 1 H NMR(400 MHz, CDCl3)δ 8.13(1H,m),8.05(1H,m),7.98(1H,m),7.79(2H,m),7.61(1H,m),7.30(1H,m),6.35(1H,s).

[0266] Step-2: Preparation of 2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid To a stirred suspension of (Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile (3.7 g, 13.9 mmol) in water (20 mL) was added 13 N aqueous NaOH (5 mL), and the mixture was heated at 90 °C under nitrogen for 16 h. The reaction mixture was then cooled to 70 °C, and hydrazine hydrate (10 mL) was added and stirred at 70 °C for 16 h. The reaction was monitored by TLC. Upon completion, the reaction was cooled to room temperature and acidified using 2 N aqueous HCl (pH 1-2) at 0-5 °C to give a precipitate. The slurry was filtered through a Buchner funnel, washed with water (50 mL), hexane (50 mL), diethyl ether (30 mL), and dried under vacuum to give 2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid. LC-MS 299[M+H] + . 1 H NMR(400 MHz,DMSO-d6)δ 13.22(1H,br.s),12.61(1H,s),8.27(1H,m),7.99-7.81(4H,m),7.59(1H,m),7.25(1H,m),4.36(2H,s).

[0267] Step-3: Preparation of tert-butyl 4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazine-1-carboxylate To a stirred suspension of 2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid (0.1 g, 0.335 mmol) in DMA (4 mL) was added HBTU (0.15 g, 0.402 mmol, 1.2 equiv.) at 0 °C, and the mixture was stirred for 10 min. DIPEA (0.17 mL, 1 mmol, 3 equiv.) and tert-butyl piperazine-1-carboxylate (0.075 g, 0.402 mmol, 1.2 equiv.) were then added sequentially to the reaction mixture at 0 °C, and the resulting reaction mixture was stirred at room temperature for 75 min. The reaction was monitored by TLC. Upon completion, water (10 mL) was added, and the resulting precipitate was filtered through a Buchner funnel. The resulting product was washed with water (10 mL x 2) and n-pentane (10 mL x 2) and dried under reduced pressure to give tert-butyl 4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazine-1-carboxylate, which was carried on to the next step without further purification. LC-MS 467 [M+H] + .

[0268] Step-4: Preparation of 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one To a stirred solution of tert-butyl 4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazine-1-carboxylate (0.150 g, 0.321 mmol) was added 2N aqueous HCl in MeOH (5 mL) at room temperature, and the mixture was stirred at room temperature for 16 hours. The reaction was monitored by LC-MS. Upon completion, the reaction mixture was concentrated under reduced pressure to give 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one as the HCl salt. LC-MS 367 [M+H] + .

[0269] Step-1a: Preparation of methyl 6-aminohexanoate To 6-aminohexanoic acid (10.0 g, 76.23 mmol) was added 2N aqueous HCl in MeOH (30 mL) at room temperature, and the mixture was stirred at room temperature for 16 hours. 1Monitored by H NMR. Upon completion, the reaction mixture was concentrated under reduced pressure to give methyl 6-aminohexanoate, which was triturated with diethyl ether and pentane (1:3) to give the title compound as the hydrochloride salt. 1 H NMR(400 MHz,MeOD-d4)δ 3.66(s,3H),2.92(t,J=7.67 Hz,2H),2.37(t,J=7.45 Hz,2H),1.62-1.71(m,6H),1.37-1.45(m,2H).

[0270] Step-1b: Preparation of methyl 6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluorobenzamido)hexanoate To a stirred solution of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluorobenzoic acid (3 g, 6.64 mmol) in DMF (25 mL) was added HATU (5.05 g, 13.29 mmol, 2 equiv.) at 0 °C, and the mixture was stirred for 30 min. Then, DIPEA (5.78 mL, 33.2 mmol, 5 equiv.) and 6-aminohexanoate (1.81 g, 9.96 mmol, 1.5 equiv.) were added successively to the reaction mixture, and the mixture was stirred at room temperature for 4 h. The reaction was monitored by TLC and LC-MS. After completion, the reaction was diluted with EtOAc (250 mL). The organic layer was washed with saturated aqueous NaHCO3 (100 mL), saturated aqueous NH4Cl (100 mL), water (100 mL), brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by CombiFlash® to give methyl 6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluorobenzamido)hexanoate. LC-MS 579 [M+H] + .

[0271] Step-1c: Preparation of 6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluorobenzamido)hexanoic acid To a stirred solution of methyl 6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluorobenzamido)hexanoate (3.5 g, 6.05 mmol) in THF (30 mL) and MeOH (15 mL) was added LiOH·10H2O (2.53 g, 60.5 mmol, 10 equiv). The solid was dissolved in water (5 mL) at room temperature, and the mixture was stirred at room temperature for 16 h. The reaction was monitored by TLC. Upon completion, the reaction mixture was concentrated under reduced pressure. The resulting residue was diluted with water (30 mL) and acidified using 2 N aqueous HCl (pH ∼2). The aqueous layer was then extracted with EtOAc (300 mL × 3). The combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give 6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluorobenzamido)hexanoic acid, which was carried on to the next step without further purification. LC-MS 565 [M+H] + . 1 H NMR(400 MHz,DMSO-d6)δ 8.51(br.s.,1H),8.41(d,J=7.83 Hz,1H),8.30(s,1H),8.08(d,J=8.31 ​​Hz,1H),7.75(t,J=7.83 Hz,1H),7.42(d,J=10.27 Hz,1H),7.33(d,J=7.83 Hz,1H),3.25(d,J=6.36 Hz,2H),2.72-66(m,4H),2.51-2.4(m,2H),2.21(t,J=7.58 Hz,2H),1.54(s,6H),1.34(d,J=6.85 Hz,2H).

[0272] Step-5: Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-(6-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)-6-oxohexyl)benzamide (Compound 1.1) To a stirred solution of 6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluorobenzamido)hexanoic acid (0.150 g, 0.265 mmol) in DMA (4 mL) was added HBTU (0.12 g, 0.319 mmol, 1.2 equiv.) at 0 °C, and the mixture was stirred for 10 min. Then, DIPEA (0.16 mL, 0.93 mmol, 3.5 equiv.) and 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one hydrochloride (0.128 g, 0.319 mmol, 1.2 equiv.) were added successively to the reaction mixture, and the mixture was stirred at room temperature for 1.5 h. The reaction was monitored by TLC and LC-MS. After completion, water (10 mL) was added and the resulting precipitate was filtered through a Buchner funnel. The resulting product was washed with water (10 mL x 2) and n-pentane (10 mL x 2) and dried under reduced pressure to give the crude product, which was purified by reverse phase HPLC to give compound 1.1. LC-MS 913 [M+H] + . 1H NMR(400 MHz,CD3OD-d4)δ 8.36(d,J=7.8 Hz,1H),8.16(d,J=7.8 Hz,2H),7.99(dd,J=7.9,2.1 Hz,1H),7.94(dd,J=8.3,3.4 Hz,1H),7.91-7.78(m,3H),7.47(p,J=4.5,4.0 Hz,1H),7.36(td,J=9.2,8.8,5.1 Hz,3H),7.15(td,J=9.0,2.4 Hz,1H),4.37(s,2H),3.83-3.69(m,2H),3.69-3.62(m,2H),3.50(dt,J=9.2,4.9 Hz,2H),3.42(q,J=6.4,6.0 Hz,2H),3.35(m,2H),3.28(m,2H),2.48(t,J=7.3 Hz,1H),2.41(t,J=7.5 Hz,1H),1.67(q,J=7.5 Hz, 4H), 1.59 (s, 6H), 1.53-1.40 (m, 2H).

[0273] Example S-2. Preparation of 4-(3-(4-(6-(((5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)oxy)hexanoyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one (Compound 1.2) [ka]

[0274] Step-1: Preparation of (5S,8R,9S,10S,13S,14S,17S)-10,13-dimethylhexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolan]-17-ol To a stirred solution of (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one (3 g, 10.3 mmol) in benzene (100 mL) was added PTSA (0.982 g, 5.1 mmol, 0.5 equiv.), followed by ethylene glycol (2.88 g, 51.61 mmol, 5 equiv.) at room temperature. The resulting mixture was heated to 120 °C for 16 h using a Dean-Stark apparatus. The reaction was monitored by TLC. Upon completion, the reaction mixture was diluted with water (200 mL) and extracted with EtOAc (350 mL). The organic layer was washed with saturated NaHCO3 solution (100 mL), water (200 mL), brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give (5S,8R,9S,10S,13S,14S,17S)-10,13-dimethylhexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolan]-17-ol. LC-MS 335 [M+H] + . 1 H NMR(400 MHz,DMSO-d6)δ 4.40(d,J=5.26 Hz,1H),3.81(s,3H),3.37-3.45(m,2H),1.82(br.s.,2H),1.70(d,J=12.72 Hz,2H),1.59(d,J=13.15 Hz,2H),1.52(d,J=10.52 Hz,3H),1.35(br.s.,1H),1.23-1.33(m,3H),1.03-1.21(m,5H),0.87(dt,J=7.89,19.95 Hz,4H),0.76(s,3H),0.61(s,3H).

[0275] Step-2a: Preparation of 2-(6-chlorohexyloxy)tetrahydro-2H-pyran To a stirred solution of 6-chlorohexan-1-ol (10 g, 73.158 mmol) in diethyl ether (100 mL), pTSA (0.05 g, 0.365 mmol, 0.005 equiv.) was added, followed by 3,4-dihydro-2H-pyran (8.4 g, 102.48 mmol, 1.4 equiv.). The resulting reaction mixture was stirred at room temperature for 16 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was diluted with diethyl ether (350 mL). The organic layer was washed with 20% KOH solution (100 mL), water (300 mL), brine (200 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give 2-(6-chlorohexyloxy)tetrahydro-2H-pyran. 1 H NMR(400 MHz,DMSO-d6)δ 4.50(br.s.,1H),4.25(t,J=6.80 Hz,2H),4.20(s,1H),4.00-4.08(m,2H),3.66-3.74(m,2H),3.59(dd,J=6.36,16.01 Hz,2H),2.66(s,2H),1.81-1.90(m,2H),1.67(br.s.,1H),1.38-1.45(m,2H),1.20-1.27(m,2H),1.17(t,J=7.02 Hz,2H).

[0276] Step-2: Preparation of (5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-17-(6-(tetrahydro-2H-pyran-2-yloxy)hexyloxy)hexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolane] To a stirred solution of (5S,8R,9S,10S,13S,14S,17S)-10,13-dimethylhexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolan]-17-ol (2 g, 5.97 mmol) in xylene (50 mL) was added NaNH (50% suspension in toluene, 1.4 mL), and the mixture was heated at 150 °C for 1 h. The reaction mixture was gradually cooled to room temperature, to which 2-(6-chlorohexyloxy)tetrahydro-2H-pyran (2.8 mL) was added, and the resulting mixture was again heated to 150 °C for 16 h. The reaction was monitored by TLC. Upon completion, the mixture was cooled to room temperature, slowly quenched with ice-cold water (250 mL), and extracted with EtOAc (300 mL). The organic layer was washed with water (100 mL × 2), brine (100 mL), dried over NaSO, filtered, and concentrated under reduced pressure to give the crude product, which was purified by CombiFlash® chromatography (Teledyne Isco Rf+) (30% EtOAc / hexane eluted compound) to give (5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-17-(6-(tetrahydro-2H-pyran-2-yloxy)hexyloxy)hexadecahydrospiro[cyclopenta[a]phenanthrene-3,2′-[1,3]dioxolane]. 1 H NMR(400 MHz,CDCl3)δ 4.57(d,J=3.95 Hz,1H),3.91-3.95(m,4H),3.82-3.91(m,2H),3.73(td,J=6.80,9.65 Hz,2H),3.42-3.53(m,3H),3.33-3.42(m,3H),3.26(t,J=8.55 Hz,2H),1.91-2.01(m,2H),1.75-1.90(m,3H),1.46-1.74(m,13H),1.31-1.42(m,6H),1.07 -1.28(m,4H),0.83-0.97(m,4H),0.81(s,4H),0.70-0.76(m,4H),0.07(s,3H),0.00(s,3H).

[0277] Step-3: Preparation of (5S,8R,9S,10S,13S,14S,17S)-17-(6-hydroxyhexyloxy)-10,13-dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one To a stirred solution of (5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-17-(6-(tetrahydro-2H-pyran-2-yloxy)hexyloxy)hexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolane] (1 g, 1.92 mmol) in THF (25 mL) and water (5 mL) was added 6N HCl (15 mL) at room temperature, and the resulting reaction mixture was stirred at room temperature for 16 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was diluted with water (150 mL) and basified using saturated NaHCO3 solution (pH ∼8). The aqueous layer was then extracted with EtOAc (200 mL × 3). The organic layer was washed with saturated NaHCO3 solution (100 mL), water (100 mL), brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give (5S,8R,9S,10S,13S,14S,17S)-17-(6-hydroxyhexyloxy)-10,13-dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one, which was used in the next step without further purification. 1 H NMR(400 MHz,CDCl3)δ 4.90(br.s.,1H),4.12(d,J=7.45 Hz,1H),4.00(br.s.,1H),3.64(t,J=6.58 Hz,3H),3.49-3.58(m,1H),3.37-3.47(m,3H),3.27(t,J=8.55 Hz,1H),2.22-2.43(m,3H),2.10(br.s.,1H),1.93-2.07(m,2H),1.90(d,J=11.84 Hz,2H),1.82(d,J=7.89 Hz,2H),1.70(d,J=10.09 Hz,2H),1.48(d,J=4.38 Hz, 2H), 1.30-1.42 (m, 8H), 1.22-1.29 (m, 2H), 1.01 (s, 3H), 0.77 (s, 3H).

[0278] Step-4: Preparation of 6-((5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxohexadecahydro-1H-cyclopenta[a]phenanthrene-17-yloxy)hexanoic acid To a stirred solution of (5S,8R,9S,10S,13S,14S,17S)-17-(6-hydroxyhexyloxy)-10,13-dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one (0.1 g, 0.256 mmol) in acetone (5 mL) was added Jones reagent (0.5 mL) dropwise over 20 minutes at 0°C. The resulting mixture was stirred at 0°C for 5 minutes. The reaction was monitored by TLC. Upon completion, water (10 mL) was added and the resulting precipitate was filtered through a Buchner funnel. The resulting product was washed with water (5 mL × 2) and n-pentane (5 mL × 2) and dried under vacuum to give 6-((5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxohexadecahydro-1H-cyclopenta[a]phenanthrene-17-yloxy)hexanoic acid, which was carried on to the next step without further purification. 1 H NMR(400 MHz,DMSO-d6)δ 3.19-3.28(m,3H),2.24-2.35(m,2H),2.18(t,J=7.24 Hz,2H),2.08(d,J=13.59 Hz,2H),1.84-1.95(m,3H),1.79(d,J=10.52 Hz,2H),1.61(d,J=13.59 Hz,2H),1.40-1.54(m,8H),1.22-1.38(m,8H),1.19(br.s.,1H),1.09-1.18(m,2H),0.97(s,3H),0.69(s,3H).

[0279] Step-5: Preparation of 4-(3-(4-(6-((5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxohexadecahydro-1H-cyclopenta[a]phenanthrene-17-yloxy)hexanoyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one (Compound 2) To a stirred solution of 6-((5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxohexadecahydro-1H-cyclopenta[a]phenanthrene-17-yloxy)hexanoic acid (0.1 g, 0.247 mmol) in DMA (5 mL) was added 0.1 g of dimethylformamide (DMSO). ℃ HBTU (0.112 g, 0.296 mmol, 1.2 equiv.) was added at rt, and the resulting reaction mixture was stirred for 10 min. Then, DIPEA (0.94 mL, 0.544 mmol, 2.2 equiv.) and 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one (0.108 g, 0.296 mmol, 1.2 equiv.) were added successively to the mixture, and the mixture was stirred at room temperature for 1 h. The reaction was monitored by TLC and LC-MS. After completion, water (10 mL) was added, and the resulting precipitate was filtered through a Buchner funnel. The resulting product was washed with water (5 mL × 2) and n-pentane (5 mL × 2) and dried under vacuum to obtain the crude product, which was purified by reverse-phase HPLC to obtain compound 1.2. LC-MS 753 [M+H] + . 1 H NMR(400 MHz,DMSO-d6)δ 8.37(d,J=7.6 Hz,1H),7.99-7.91(m,1H),7.91-7.79(m,2H),7.48(t,J=6.4 Hz,1H),7.36(d,J=6.1 Hz,1H),7.21-7.11(m,1H),4.38(s,2H),3.82-3.61(m,4H),3.47(ddt,J=22.1,14.2,6.3 Hz,4H),3.37-3.33(m,2H),2.53-2.30(m,4H),2.26-2.16(m,1H),2.08-1.95(m,3H),1.88(t,J=11.6 Hz,1H),1.75-1.50(m,10H),1.50-1.13(m,12H),1.05(s,3H),1.01-0.86(m,2H),0.76(d,J=9.0 Hz,4H).

[0280] Example S-3. Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-(6-((4-((8S,9R)-5-fluoro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3-oxo-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-8-yl)phenyl)amino)-6-oxohexyl)benzamide (Compound 1.3) [ka]

[0281] Step-1a: Preparation of methyl 5-fluoro-2-(2-(1-methyl-1H-1,2,4-triazol-5-yl)acetyl)-3-nitrobenzoate (Z)-6-Fluoro-3-((1-methyl-1H-1,2,4-triazol-5-yl)methylene)-4-nitroisobenzofuran-1(3H)-one (10 g, 34.48 mmol) was added to a reaction vessel containing 2N aqueous HCl in MeOH (50 mL) at room temperature, and the mixture was stirred at room temperature for 16 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was concentrated under reduced pressure to give a sticky solid, which was further lyophilized to give methyl 5-fluoro-2-(2-(1-methyl-1H-1,2,4-triazol-5-yl)acetyl)-3-nitrobenzoate as the hydrochloride salt. LC-MS 323 [M+H] + .

[0282] Step-1b': Preparation of 4-aminobenzaldehyde To a stirred solution of 4-nitrobenzaldehyde (5 g, 33.1 mmol) in ethanol (50 mL) was added SnCl2 (37.35 g, 165.5 mmol, 5 equiv.) at 0 °C, and the mixture was heated for 80 ℃The mixture was heated at rt for 1 h. The reaction was monitored by TLC. Upon completion, the reaction mixture was concentrated under reduced pressure to give a crude residue, which was suspended in water (100 mL) and basified using NaHCO3 solution (pH approx. 8). The aqueous layer was then extracted with EtOAc (500 mL x 3). The combined organic layers were washed with saturated NaHCO3 solution (300 mL), water (200 mL), brine (150 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give 4-aminobenzaldehyde, which was used in the next step without further purification. LC-MS 122 [M+H] + .

[0283] Step-1b: Preparation of methyl 2-(4-aminophenyl)-7-fluoro-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate To a stirred solution of methyl 5-fluoro-2-(2-(1-methyl-1H-1,2,4-triazol-5-yl)acetyl)-3-nitrobenzoate hydrochloride (5.6 g, 15.6 mmol) in THF (60 mL) and MeOH (10 mL) was added 4-aminobenzaldehyde (3.8 g, 31.2 mmol, 2 equiv.). Titanium(III) chloride (20% w / v solution in 2N HCl (50 mL)) was then added dropwise to the mixture at room temperature over 20 minutes, and the mixture was stirred at 50°C for 3 hours. The reaction was monitored by TLC. Upon completion, the solvent was removed under reduced pressure to give the crude residue, which was dissolved in water (300 mL) and basified using saturated NaHCO3 solution (pH 8). The aqueous layer was then extracted with EtOAc (400 mL x 3). The combined organic layers were washed with saturated NaHCO3 solution (300 mL), water (300 mL), brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give the crude product, which was purified by CombiFlash® chromatography (Teledyne Isco Rf+) (40% EtOAc / hexane eluted compound) to give methyl 2-(4-aminophenyl)-7-fluoro-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate. LC-MS 396 [M+H]+ .

[0284] Step-1c: Preparation of 8-(4-aminophenyl)-5-fluoro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one To a stirred suspension of methyl 2-(4-aminophenyl)-7-fluoro-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate (1.5 g, 37.9 mmol) in methanol (20 mL) was added hydrazine hydrate (3 mL) at 0 °C, and the resulting mixture was stirred at room temperature for 4 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was concentrated under reduced pressure, and water (20 mL) was added. The resulting precipitate was filtered through a Buchner funnel. The resulting product was washed with water (10 mL × 2) and n-pentane (10 mL × 2) and dried under reduced pressure to obtain the crude product, which was purified by reverse phase chromatography to obtain 8-(4-aminophenyl)-5-fluoro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one as a racemic mixture. The resulting compound was further separated by chiral chromatography to give 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-(6-(4-((8S,9R)-5-fluoro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3-oxo-3,7,8,9-tetrahydro-2H-pyrido[4,3,2-de]phthalazin-8-yl)phenylamino)-6-oxohexyl)benzal amide (PK-1) (0.300 g) and 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-(6-(4-((8S,9R)-5-fluoro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3-oxo-3,7,8,9-tetrahydro-2H-pyrido[4,3,2-de]phthalazin-8-yl)phenylamino)-6-oxohexyl)benzamide (PK-2) were obtained.

[0285] (PK-1 was used for compound 1.3, and PK-2 was used for ent-compound 1.3) PK-1: LC-MS 378 [M+H] + . 1H NMR(400 MHz,DMSO-d6)δ 12.30(s,1H),7.78(s,1H),7.56(s,1H),7.02(t,J=6.7 Hz,3H),6.90(d,J=11.2 Hz,1H),6.45(d,J=7.9 Hz,2H),5.10(s,2H),4.85(d,J=11.4 Hz,1H),4.72(d,J=11.4 Hz,1H),3.62(s,3H).

[0286] PK-2: LC-MS 378 [M+H] + . 1 H NMR(400 MHz,DMSO-d6)δ 12.29(s,1H),7.78(s,1H),7.56(s,1H),7.02(t,J=6.7 Hz,3H),6.89(d,J=11.2 Hz,1H),6.44(d,J=7.9 Hz,2H),5.10(s,2H),4.85(d,J=11.4 Hz,1H),4.71(d,J=11.4 Hz,1H),3.61(s,3H).

[0287] Step-1: Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-(6-(4-(5-fluoro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3-oxo-3,7,8,9-tetrahydro-2H-pyrido[4,3,2-de]phthalazin-8-yl)phenylamino)-6-oxohexyl)benzamide (Compound 1.3) To a stirred solution of 6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluorobenzamido)hexanoic acid (0.125 g, 0.221 mmol) in DMF (7 mL) at 0° C. was added HATU (0.168 g, 0.442 mmol, 2 equiv.) and the resulting mixture was stirred for 30 min. Then, DIPEA (0.19 mL, 1.11 mmol, 5 equiv.) and 8-(4-aminophenyl)-5-fluoro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one (PK-1) (0.10 g, 0.265 mmol, 1.2 equiv.) were added successively to the reaction mixture, and the resulting mixture was stirred at room temperature for 4 hours. The reaction was monitored by TLC. After completion, the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (100 mL × 2). The combined organic layers were washed with saturated NaHCO3 solution (100 mL), saturated NH4Cl solution (100 mL), water (100 mL), brine (50 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give the crude product, which was purified by reverse-phase HPLC to give compound 1.3. LC-MS 924 [M+H] + . 1 H NMR(400 MHz,CD3OD-d4)δ 8.15(d,J=9.1 Hz,2H),7.97(d,J=8.5 Hz,1H),7.87(d,J=3.0Hz,1H),7.82(t,J=8.8 Hz,1H),7.56-7.48(m,2H),7.34(d,J=8.4 Hz,4H),7.19(dd,J=7.1,4.7 Hz,1H),6.90(d,J=10.4 Hz,1H),3.58(d,J=3.0 Hz,3H),3.46-3.36(m,2H),2.38(d,J=7.6 Hz,2H),1.93(s,2H),1.80-1.64(m,6H),1.59(d,J=2.8 Hz,6H),1.48(ddt,J=14.6,10.8,4.6 Hz,2H).

[0288] Example S-4. Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-(6-((4-((8R,9S)-5-fluoro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3-oxo-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-8-yl)phenyl)amino)-6-oxohexyl)benzamide (compound ent-1.3) [ka]

[0289] Step-1: Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-(6-(4-(5-fluoro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3-oxo-3,7,8,9-tetrahydro-2H-pyrido[4,3,2-de]phthalazin-8-yl)phenylamino)-6-oxohexyl)benzamide To a stirred solution of 6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluorobenzamido)hexanoic acid (0.210 g, 0.371 mmol) in DMF (8 mL) at 0° C. was added HATU (0.282 g, 0.743 mmol, 2 equiv.) and the resulting mixture was stirred for 30 min. Then, DIPEA (0.32 mL, 1.86 mmol, 5 equiv.) and 8-(4-aminophenyl)-5-fluoro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one (PK-2) (0.17 g, 0.446 mmol, 1.2 equiv.) were added successively to the reaction mixture, and the resulting mixture was stirred at room temperature for 4 hours. The reaction was monitored by TLC. After completion, the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (100 mL × 2). The combined organic layers were washed with saturated NaHCO3 solution (100 mL), saturated NH4Cl solution (100 mL), water (100 mL), brine (50 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give the crude product, which was purified by reverse-phase HPLC to give compound ent-1.3. LC-MS 924 [M+H] + . 1 H NMR(400 MHz,CD3OD-d4)δ 8.15(d,J=9.1 Hz,2H),7.98(dd,J=8.1,2.1 Hz,1H),7.90-7.79(m,2H),7.52(d,J=8.9 Hz,2H),7.34(d,J=8.4 Hz,4H),7.21(dd,J=9.0,2.5 Hz,1H),6.90(dd,J=10.8,2.5 Hz,1H),3.59(d,J=3.2 Hz,3H),3.46-3.36(m,2H),2.40(t,J=7.4 Hz,2H),1.93(s,2H),1.72(dp,J=26.6,7.3 Hz, 4H), 1.60 (s, 6H), 1.48 (ddt, J=14.6, 10.8, 4.6 Hz, 2H).

[0290] Example S-5. Preparation of 6-(((5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)oxy)-N-(4-(5-fluoro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3-oxo-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-8-yl)phenyl)hexanamide (Compound 1.4) [ka]

[0291] Step-1: Preparation of (5S,8R,9S,10S,13S,14S,17S)-10,13-dimethylhexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolan]-17-ol To a stirred solution of (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one (3 g, 10.3 mmol) in benzene (100 mL) was added PTSA (0.982 g, 5.1 mmol, 0.5 equiv.), followed by ethylene glycol (2.88 g, 51.61 mmol, 5 equiv.) at room temperature. The resulting mixture was heated at 120 °C for 16 h using a Dean-Stark apparatus. The reaction was monitored by TLC. Upon completion, the reaction mixture was diluted with water (200 mL) and extracted with EtOAc (350 mL). The organic layer was washed with saturated NaHCO3 solution (100 mL), water (200 mL), brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give (5S,8R,9S,10S,13S,14S,17S)-10,13-dimethylhexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolan]-17-ol. LC-MS 335 [M+H] + . 1H NMR(400 MHz,DMSO-d6)δ 4.40(d,J=5.26 Hz,1H),3.81(s,3H),3.37-3.45(m,2H),1.82(br.s.,2H),1.70(d,J=12.72 Hz,2H),1.59(d,J=13.15 Hz,2H),1.52(d,J=10.52 Hz,3H),1.35(br.s.,1H),1.23-1.33(m,3H),1.03-1.21(m,5H),0.87(dt,J=7.89,19.95 Hz,4H),0.76(s,3H),0.61(s,3H).

[0292] Step-2a: Preparation of 2-(6-chlorohexyloxy)tetrahydro-2H-pyran To a stirred solution of 6-chlorohexan-1-ol (10 g, 73.158 mmol) in diethyl ether (100 mL), pTSA (0.05 g, 0.365 mmol, 0.005 equiv.) was added, followed by 3,4-dihydro-2H-pyran (8.4 g, 102.48 mmol, 1.4 equiv.). The resulting reaction mixture was stirred at room temperature for 16 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was diluted with diethyl ether (350 mL). The organic layer was washed with 20% KOH solution (100 mL), water (300 mL), brine (200 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give 2-(6-chlorohexyloxy)tetrahydro-2H-pyran. 1 H NMR(400 MHz,DMSO-d6)δ 4.50(br.s.,1H),4.25(t,J=6.80 Hz,2H),4.20(s,1H),4.00-4.08(m,2H),3.66-3.74(m,2H),3.59(dd,J=6.36,16.01 Hz,2H),2.66(s,2H),1.81-1.90(m,2H),1.67(br.s.,1H),1.38-1.45(m,2H),1.20-1.27(m,2H),1.17(t,J=7.02 Hz,2H).

[0293] Step-2: Preparation of (5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-17-(6-(tetrahydro-2H-pyran-2-yloxy)hexyloxy)hexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolane] To a stirred solution of (5S,8R,9S,10S,13S,14S,17S)-10,13-dimethylhexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolan]-17-ol (2 g, 5.97 mmol) in xylene (50 mL) was added NaNH (50% suspension in toluene, 1.4 mL), and the mixture was heated at 150 °C for 1 h. The reaction mixture was gradually cooled to room temperature, to which 2-(6-chlorohexyloxy)tetrahydro-2H-pyran (2.8 mL) was added, and the resulting mixture was again heated to 150 °C for 16 h. The reaction was monitored by TLC. Upon completion, the mixture was cooled to room temperature, slowly quenched with ice-cold water (250 mL), and extracted with EtOAc (300 mL). The organic layer was washed with water (100 mL × 2), brine (100 mL), dried over NaSO, filtered, and concentrated under reduced pressure to give the crude product, which was purified by CombiFlash® chromatography (Teledyne Isco Rf+) (30% EtOAc / hexane eluted compound) to give (5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-17-(6-(tetrahydro-2H-pyran-2-yloxy)hexyloxy)hexadecahydrospiro[cyclopenta[a]phenanthrene-3,2′-[1,3]dioxolane]. 1H NMR(400 MHz,CDCl3)δ 4.57(d,J=3.95 Hz,1H),3.91-3.95(m,4H),3.82-3.91(m,2H),3.73(td,J=6.80,9.65 Hz,2H),3.42-3.53(m,3H),3.33-3.42(m,3H),3.26(t,J=8.55 Hz,2H),1.91-2.01(m,2H),1.75-1.90(m,3H),1.46-1.74(m,13H),1.31-1.42(m,6H),1.07 -1.28(m,4H),0.83-0.97(m,4H),0.81(s,4H),0.70-0.76(m,4H),0.07(s,3H),0.00(s,3H).

[0294] Step-3: Preparation of (5S,8R,9S,10S,13S,14S,17S)-17-(6-hydroxyhexyloxy)-10,13-dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one To a stirred solution of (5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-17-(6-(tetrahydro-2H-pyran-2-yloxy)hexyloxy)hexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolane] (1 g, 1.92 mmol) in THF (25 mL) and water (5 mL) was added 6N HCl (15 mL) at room temperature, and the resulting reaction mixture was stirred at room temperature for 16 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was diluted with water (150 mL) and basified using saturated NaHCO3 solution (pH ∼8). The aqueous layer was then extracted with EtOAc (200 mL × 3). The organic layer was washed with saturated NaHCO3 solution (100 mL), water (100 mL), brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give (5S,8R,9S,10S,13S,14S,17S)-17-(6-hydroxyhexyloxy)-10,13-dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one, which was used in the next step without further purification. 1H NMR(400 MHz,CDCl3)δ 4.90(br.s.,1H),4.12(d,J=7.45 Hz,1H),4.00(br.s.,1H),3.64(t,J=6.58 Hz,3H),3.49-3.58(m,1H),3.37-3.47(m,3H),3.27(t,J=8.55 Hz,1H),2.22-2.43(m,3H),2.10(br.s.,1H),1.93-2.07(m,2H),1.90(d,J=11.84 Hz,2H),1.82(d,J=7.89 Hz,2H),1.70(d,J=10.09 Hz,2H),1.48(d,J=4.38 Hz, 2H), 1.30-1.42 (m, 8H), 1.22-1.29 (m, 2H), 1.01 (s, 3H), 0.77 (s, 3H).

[0295] Step-4: Preparation of 6-((5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxohexadecahydro-1H-cyclopenta[a]phenanthrene-17-yloxy)hexanoic acid To a stirred solution of (5S,8R,9S,10S,13S,14S,17S)-17-(6-hydroxyhexyloxy)-10,13-dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one (0.1 g, 0.256 mmol) in acetone (5 mL) was added Jones reagent (0.5 mL) dropwise over 20 minutes at 0°C. The resulting mixture was stirred at 0°C for 5 minutes. The reaction was monitored by TLC. Upon completion, water (10 mL) was added and the resulting precipitate was filtered through a Buchner funnel. The resulting product was washed with water (5 mL × 2) and n-pentane (5 mL × 2) and dried under vacuum to give 6-((5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxohexadecahydro-1H-cyclopenta[a]phenanthrene-17-yloxy)hexanoic acid, which was carried on to the next step without further purification. 1H NMR(400 MHz,DMSO-d6)δ 3.19-3.28(m,3H),2.24-2.35(m,2H),2.18(t,J=7.24 Hz,2H),2.08(d,J=13.59 Hz,2H),1.84-1.95(m,3H),1.79(d,J=10.52 Hz,2H),1.61(d,J=13.59 Hz,2H),1.40-1.54(m,8H),1.22-1.38(m,8H),1.19(br.s.,1H),1.09-1.18(m,2H),0.97(s,3H),0.69(s,3H).

[0296] Step-5: Preparation of 6-((5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxohexadecahydro-1H-cyclopenta[a]phenanthrene-17-yloxy)-N-(4-(5-fluoro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3-oxo-3,7,8,9-tetrahydro-2H-pyrido[4,3,2-de]phthalazin-8-yl)phenyl)hexanamide To a stirred solution of 6-((5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxohexadecahydro-1H-cyclopenta[a]phenanthrene-17-yloxy)hexanoic acid (0.080 g, 0.197 mmol) in THF (5 mL) at 0 °C was added T3P solution (50% in EtOAc, 0.25 mL, 0.435 mmol, 2.2 equiv.) and the resulting mixture was stirred for 30 min. Then, DIPEA (0.24 mL, 1.38 mmol, 7 equiv.) and 8-(4-aminophenyl)-5-fluoro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one (PK-1) (0.074 g, 0.197 mmol, 1 equiv.) were added successively to the reaction mixture, and the resulting mixture was stirred at room temperature for 16 hours. The reaction was monitored by TLC. After completion, the reaction mixture was diluted with water (50 mL) and extracted using EtOAc (100 mL × 3). The combined organic layers were washed with saturated NaHCO3 solution (80 mL), saturated NH4Cl solution (60 mL), water (80 mL), brine (60 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give the crude product, which was purified by reverse-phase HPLC to give compound 1.4. LC-MS 764[M+H] + . 1 H NMR(400 MHz,MeOD-d4)δ 7.88(s,1H),7.56-7.49(m,2H),7.35(d,J=8.5 Hz,2H),7.21(dd,J=9.0,2.4 Hz,1H),6.92(dd,J=2.41,10.74 Hz,1H),3.60(s,3H),3.42-3.50(m,3H),2.31-2.40(m,2H),1.91-2.12(m,5H),1.88(br.s.,2H),1.64-1.78(m,4H),1.57(dd,J=6.36,13.81 Hz,4H),1.46(dd,J=7.45,15.79 Hz, 4H), 1.13-1.40 (m, 10H), 0.82-0.97 (m, 4H), 0.71-0.82 (m, 3H).

[0297] Example S-6. Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-(6-((4-(8-fluoro-1-oxo-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-5-yl)benzyl)amino)hexyl)benzamide (Compound 1.5) [ka]

[0298] Step-1: Preparation of 4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)benzaldehyde To a stirred solution of 2-bromo-8-fluoro-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one (2 g, 7.06 mmol, 1 equiv.) in DMA (37.5 mL) was added a solution of NaCO (1.48 g, 14.1 mmol, 2 equiv.) and 4-formylphenylboronic acid (1.27 g, 8.4 mmol, 1.2 equiv.) in HO (18.5 mL) at room temperature. The resulting mixture was degassed under nitrogen at room temperature for 30 minutes, followed by the addition of Pd(dppf)Cl.DCM (0.142 g, 0.18 mmol, 0.025 equiv.). The mixture was further degassed using nitrogen for 15 minutes. The reaction mixture was then heated at 95 °C for 4 hours. The reaction was monitored by TLC. Upon completion, the mixture was cooled to room temperature, water (30 mL) was added, and the resulting precipitate was filtered through a Buchner funnel. The resulting crude material was washed with water (20 mL x 2) and n-pentane (10 mL x 2) and dried under reduced pressure to give 4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)benzaldehyde. LC-MS 309 [M+H] + . 1H NMR(400 MHz,DMSO-d6)δ 11.90(s,1H),10.06(s,1H),8.31(br.s.,1H),8.02-8.08(m,J=7.89 Hz,2H),7.81-7.89(m,J=7.89 Hz,2H),7.46(d,J=10.96 Hz,1H),7.37(d,J=9.21 Hz,1H),3.41(br.s.,2H),3.11(br.s.,2H).

[0299] Step-2a: Preparation of tert-butyl 6-aminohexylcarbamate To a stirred solution of hexane-1,6-diamine (10 g, 86.05 mmol) in DCM (400 mL) was added di-tert-butyl dicarbonate (4.69 g, 21.5 mmol, 0.25 equiv.) dissolved in DCM (100 mL) dropwise over 1 h, and the resulting mixture was stirred at room temperature for 16 h. The reaction was then filtered through a Buchner funnel to remove unreacted hexane-1,6-diamine. The resulting crude residue was dissolved in water (200 mL) and then extracted with DCM (200 mL × 3). The combined organic layers were washed with saturated NaHCO3 solution (300 mL), water (200 mL), brine (150 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give tert-butyl 6-aminohexylcarbamate, which was used in the next step without further purification. 1 H NMR (400 MHz, CDCl3) δ 4.70 (br, 1H), 3.02 (m, 2H), 2.62 (m, 2H), 1.37 (s, 15H), 1.26 (m, 4H).

[0300] Step-2: Preparation of tert-butyl 6-(4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)benzyl-amino)hexylcarbamate To a stirred solution of 4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)benzaldehyde (0.6 g, 1.94 mmol) in MeOH (36 mL) and THF (18 mL) was added tert-butyl 6-aminohexylcarbamate (1.26 g, 5.8 mmol, 3 equiv.), and the reaction mixture was stirred at room temperature for 2 h. NaBH4 (0.22 g, 5.8 mmol, 3 equiv.) was then slowly added to the mixture at 0 °C, and the resulting mixture was stirred at room temperature for 2 h. The reaction was monitored by TLC. Upon completion, the reaction mixture was diluted with water (100 mL) and extracted with EtOAc (150 mL × 2). The combined organic layers were washed with water (75 mL) and brine (75 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give the crude material, which was triturated with DCM / hexane (1:4) to give tert-butyl 6-(4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)benzyl-amino)hexylcarbamate. LC-MS 509 [M+H] + . 1 H NMR(400MHz,MeOD-d4)7.60(d,J=7.89 Hz,2H),7.46-7.56(m,3H),7.30(br.s.,1H),3.83(s,2H),3.54(br.s.,2H),3.14(m,3H),3.02(s,1H),2.62(t,J=7.24 Hz,2H),1.57(br.s.,4H),1.46(m,4H),1.42(s,5H),1.36(br.s.,4H).

[0301] Step-3: Preparation of 2-(4-((6-aminohexylamino)methyl)phenyl)-8-fluoro-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one To a stirred solution of tert-butyl 6-(4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)benzyl-amino)hexylcarbamate (0.3 g, 0.58 mmol, 1 equiv.) in MeOH (1 mL) at 0° C. was added 4N HCl in 1,4 dioxane (10 mL). The mixture was stirred at room temperature for 1 hour. The reaction was monitored by TLC. Upon completion, the solvent was removed under reduced pressure to give a residue which was triturated with diethyl ether to give 2-(4-((6-aminohexylamino)methyl)phenyl)-8-fluoro-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one as the hydrochloride salt. LC-MS 445 [M+H] + .

[0302] Step-4: Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-(6-(4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)benzylamino)hexyl)benzamide To a stirred solution of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluorobenzoic acid (0.15 g, 0.32 mmol) in DMA (6 mL) was added HBTU (0.15 g, 0.39 mmol, 1.2 equiv.) at 0 °C, and the resulting mixture was stirred at the same temperature for 30 min. Then, DIPEA (0.128 g, 0.99 mmol, 3 equiv.) and 2-(4-((6-aminohexylamino)methyl)phenyl)-8-fluoro-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one (0.221 g, 0.43 mmol, 1.5 equiv.) were added successively to the reaction mixture, and the resulting mixture was stirred at room temperature for 2 h. The reaction was monitored by TLC. Upon completion, the mixture was cooled to room temperature, water (30 mL) was added, and the resulting precipitate was filtered through a Buchner funnel. The resulting crude material was purified by reverse-phase HPLC to give compound 1.5. LC-MS 842 [M+H] + . 1 H NMR(400 MHz,DMSO-d6)δ 11.67(s,1H),8.50(br.s.,1H),8.40(d,J=8.33 Hz,1H),8.29(s,1H),8.24(br.s.,1H),8.09(s,1H),7.74(s,1H),7.54-7.61(m,J=7.89 Hz,2H),7.44-7.51(m,J=7.89 Hz,2H),7.40(s,1H),7.43(s,1H),7.27-7.36(m,2H),3.5-3.3(m,4H),3.26(d,J=5.70 Hz,2H),3.04(br.s.,2H),1.89(s,2H),1.48-1.58(m,6H),1.47(br.s.,2H),1.33(br.s.,4H).

[0303] Example S-7. Preparation of 4-[[4-fluoro-3-(piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one [ka]

[0304] Step-1: Preparation of (Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile To a stirred solution of dimethyl 3-oxo-1,3-dihydroisobenzofuran-1-ylphosphonate (10 g, 41.28 mmol) and 2-fluoro-5-formylbenzonitrile (6.15 g, 41.28 mmol, 1 equiv.) in THF (50 mL) at 0 °C, triethylamine (5.76 mL, 41.28 mmol, 1 equiv.) was slowly added. The resulting mixture was stirred at room temperature for 16 h. The reaction was monitored by TLC. Upon completion, water (200 mL) was added, and the resulting precipitate was filtered through a Buchner funnel. The resulting product was washed with water (50 mL), hexane (50 mL), diethyl ether (30 mL), and dried under vacuum to give the title compound as a mixture of E- and Z-isomers, which was used in the next step without further purification. LC-MS 266 [M+H] + . 1 H NMR(400 MHz, CDCl3)δ 8.13(1H,m),8.05(1H,m),7.98(1H,m),7.79(2H,m),7.61(1H,m),7.30(1H,m),6.35(1H,s).

[0305] Step-2: Preparation of 2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid To a stirred suspension of (Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile (3.7 g, 13.94 mmol) in water (20 mL) was added 13N NaOH solution (5 mL), and the mixture was heated at 90°C under nitrogen for 16 h. The reaction mixture was cooled to 70°C, and hydrazine hydrate (10 mL) was added and stirred at 70°C for 16 h. The reaction was monitored by TLC. Upon completion, the reaction was cooled to room temperature and acidified using 2N HCl (pH 1-2) at 0-5°C to give a precipitate. The precipitated solid was filtered through a Buchner funnel, washed with water (50 mL), n-hexane (50 mL), diethyl ether (30 mL), and dried under vacuum to give the title compound. LC-MS 299 [M+H] + .1 H NMR(400 MHz,DMSO-d6)δ 13.22(1H,br s),12.61(1H,s),8.27(1H,m),7.99-7.81(4H,m),7.59(1H,m),7.25(1H,m),4.36(2H,s).

[0306] Step-3: Preparation of tert-butyl 4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazine-1-carboxylate To a stirred suspension of 2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid (0.100 g, 0.335 mmol) in DMA (4 mL) was added HBTU (0.15 g, 0.402 mmol, 1.2 equiv.) at 0 °C, and the mixture was stirred for 10 min. DIPEA (0.17 mL, 1.00 mmol, 3 equiv.) and tert-butyl piperazine-1-carboxylate (0.075 g, 0.402 mmol, 1.2 equiv.) were then added sequentially to the reaction mixture at 0 °C, and the resulting reaction mixture was stirred at room temperature for 75 min. The reaction was monitored by TLC. Upon completion, water (10 mL) was added, and the resulting precipitate was filtered through a Buchner funnel. The resulting product was washed with water (10 mL x 2) and n-pentane (10 mL x 2) and dried under reduced pressure to give the title compound, which was carried on to the next step without further purification. LC-MS 467 [M+H] + .

[0307] Step-4: Preparation of 4-[[4-fluoro-3-(piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one To tert-butyl 4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazine-1-carboxylate (10.0 g, 76.23 mmol) was added 2N HCl in MeOH (30 mL) at room temperature, and the mixture was stirred at room temperature for 16 hours. 1H NMR was used to monitor. Upon completion, the reaction mixture was concentrated under reduced pressure to give the compound, which was triturated with diethyl ether and pentane to give the title compound as the hydrochloride salt. LC-MS 403 [M+H] + . 1 H NMR(400 MHz,MeOD-d4)δ 3.66(s,3H),2.92(t,J=7.67 Hz,2H),2.37(t,J=7.45 Hz,2H),1.62-1.71(m,6H),1.37-1.45(m,2H).

[0308] Example S-8. Preparation of (R)-methyl 6-(4-(3-(4-cyano-3-(trifluoromethyl)phenylamino)-2-hydroxy-2-methyl-3-oxopropylsulfonyl)phenylamino)hexanoate [ka]

[0309] Step 1: Preparation of (R)-3-bromo-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide To a solution of (R)-3-bromo-2-hydroxy-2-methylpropanoic acid (13 g, 71.04 mmol) in THF (250 mL) cooled to 0 °C, SOCl (14.1 g, 118.53 mmol) and a catalytic amount of DMF were added dropwise. The solution was stirred at this temperature for 1.5 hours. Then, a solution of 4-amino-2-(trifluoromethyl)-benzonitrile (7.4 g, 39.78 mmol) and TEA (15.8 g, 156.29 mmol) in THF (50 mL) was added dropwise at this temperature. The mixture was allowed to warm to room temperature overnight. TLC showed that the reaction was complete. The mixture was quenched with NaHCO and extracted with EtOAc. The organic layer was dried over NaSO and concentrated under reduced pressure. The crude product was purified using a silica gel column to give the title compound.

[0310] Step 2: Preparation of (R)-3-(-4-aminophenylthio)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide To a solution of NaH (251 mg, 6.26 mmol) in THF (30 ml) was added 4-aminobenzenethiol (712 mg, 5.68 mmol) in THF (20 mL) dropwise at 0 °C under N. The mixture was warmed to room temperature and stirred for 1 h. Then, a solution of (R)-3-bromo-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide (2 g, 5.68 mmol) in THF (20 mL) was added dropwise to the mixture at 0 °C. The mixture was stirred overnight at room temperature. TLC showed that the reaction was complete. Water was carefully added, and the mixture was extracted with EtOAc, dried over NaSO, and concentrated under reduced pressure. The compound was purified by silica gel column to give the title compound.

[0311] Step 3: Preparation of (R)-methyl 6-(4-(3-(4-cyano-3-(trifluoromethyl)phenylamino)-2-hydroxy-2-methyl-3-oxopropylthio)phenylamino)hexanoate To a solution of (R)-3-(4-aminophenylthio)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide (2 g, 5 mmol) in DMF (100 mL) was added K2CO3 (2.1 g, 15 mmol), KI (100 mg, 0.5 mmol), and methyl 6-bromohexanoate (10 g, 50 mmol). The mixture was stirred overnight at 60 °C. TLC showed the reaction was complete. The mixture was washed with water, extracted with EtOAc, and dried over Na2SO4. The organic layer was concentrated under reduced pressure and purified by flash chromatography to give the title compound.

[0312] Step 4: Preparation of (R)-methyl 6-(4-(3-(4-cyano-3-(trifluoromethyl)phenylamino)-2-hydroxy-2-methyl-3-oxopropylsulfonyl)phenylamino)hexanoate To a solution of (R)-methyl 6-(4-(3-(4-cyano-3-(trifluoromethyl)phenylamino)-2-hydroxy-2-methyl-3-oxopropylthio)phenylamino)hexanoate (2 g, 2.8 mmol) in DCM (60 mL) was added m-CPBA (1.83 g, 8.4 mmol), and the mixture was stirred at room temperature for 2 h. The mixture was quenched with aqueous NaHCO, washed with water, and extracted with DCM. The organic layer was dried over NaSO and purified by flash chromatography to give the title compound. 1 H NMR(400 MHz,DMSO-d6)δ 10.27(s,1H),8.41(s,1H),8.16(d,J=8.6 Hz,1H),8.04(d,J=8.6 Hz,1H),7.45(d,J=8.9 Hz,2H),6.63-6.37(m,3H),6.30(s,1H),3.79(d,J=14.5 Hz,1H),3.58(s,3H),3.47(d,J=14.5 Hz,1H),2.89(dq,J=11.8,7.0,6.3 Hz,2H),2.31(t,J=7.4 Hz,2H),1.55(p,J=7.5 Hz,2H),1.47(q,J=7.2 Hz, 2H), 1.38 (s, 3H), 1.36-1.26 (m, 2H).

[0313] Example S-9. Preparation of (S)-methyl 6-(4-(3-(4-cyano-3-(trifluoromethyl)phenylamino)-2-hydroxy-2-methyl-3-oxopropoxy)phenylamino)hexanoate [ka]

[0314] Step 1: Preparation of (S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methyl-3-(4-nitrophenoxy)propanamide To a stirred suspension of 4-nitrophenol (1.2 g, 8.55 mmol) and K2CO3 (3.9 g, 28.50 mmol) in isopropyl alcohol (40 mL) was added (R)-3-bromo-N-(4-cyano)-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide (2 g, 5.70 mol). The reaction was refluxed for 2 hours. TLC showed the reaction was complete. The reaction mixture was concentrated in vacuo, diluted with water, and extracted with EtOAc. The combined organic layers were washed with saturated NaHCO3 and brine, dried over anhydrous Na2SO4, and concentrated in vacuo to give the residue as an oil. The residue was purified by column chromatography on silica gel to give the title compound.

[0315] Step 2: Preparation of (S)-3-(-4-aminophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide To a stirred suspension of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methyl-3-(4-nitrophenoxy)propanamide 3 (2.0 g, 4.64 mmol) in EtOH (20 mL) and HO (20 mL) was added NH4Cl (2.5 g, 46.42 mmol) and iron powder (2.1 g, 3.71 mmol). The reaction was degassed with N2 and stirred at 90 °C for 1 h. TLC showed the reaction was complete. The mixture was diluted with EtOAc, filtered through a pad of Celite, washed with brine, dried over anhydrous Na2SO4, and concentrated in vacuo to give the title compound.

[0316] Step 3: Preparation of (S)-methyl 6-(4-(3-(4-cyano-3-(trifluoromethyl)phenylamino)-2-hydroxy-2-methyl-3-oxopropoxy)phenylamino)hexanoate To a solution of (S)-3-(4-aminophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide (1.7 g, 4.48 mmol) and methyl 6-bromohexanoate (0.7 g, 3.45 mmol) in DMF (30 mL) was added K2CO3 (1.0 g, 7.56 mmol) and KI (0.6 g, 3.80 mmol). The reaction was stirred at 100 °C for 4 h. TLC showed that approximately 30% of (S)-3-(4-aminophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide still remained. The mixture was diluted with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, and concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel to give the title compound. LCMS 508.6[M+1] + . 1 H NMR(400 MHz,DMSO-d6)δ 10.54(s,1H),8.57(d,J=2 Hz,1H),8.32(dd,J=2 Hz,8.4 Hz 1H),8.11(d,J=8.8 Hz,1H),6.70-6.68(m,1 H),6.48-6.46(m,1H),6.17(s,1H),5.18(s,1H),4.10(d,J=9.6 Hz,1H),3.87(d,J=9.6 Hz,1H),3.58(s,1H),2.32(t,J=7.2 Hz),1.57-1.49(m,4H),1.41(s,3H),1.36-1.33(m,2H).

[0317] Example S-10. Preparation of (R)-3-(4-(6-bromohexyloxy)phenylsulfonyl)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide [ka]

[0318] Step 1: Preparation of (R)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-3-(4-hydroxyphenylthio)-2-methylpropanamide A solution of (R)-3-bromo-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methyl-propanamide (1.5 g, 4.27 mmol), 4-mercaptophenol (0.539 g, 4.27 mmol) and K2CO3 (0.649 g, 4.69 mmol) in acetone (15 mL). The reaction mixture was stirred at room temperature for 3 hours. TLC showed the reaction mixture was complete. The solution was concentrated in vacuo. The crude product was purified by column chromatography to give the title compound.

[0319] Step 2: Preparation of (R)-3-(4-(6-bromohexyloxy)phenylthio)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide A mixture of (R)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-3-(4-hydroxyphenylthio)-2-methylpropanamide (1.34 g, 3.38 mmol), 1,6-dibromohexane (8.25 g, 33.81 mmol), and K2CO3 (2.34 g, 16.9 mmol) in ACN (20 mL). The reaction mixture was stirred at room temperature for 3 hours. TLC showed the mixture was complete. The solution was concentrated in vacuo and purified by column chromatography to give the title compound.

[0320] Step 3: Preparation of (R)-3-(4-(6-bromohexyloxy)phenylsulfonyl)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide A mixture of (R)-3-(4-(6-bromohexyloxy)phenylthio)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide (1.5 g, 2.68 mmol) in DCM (15 mL) was cooled to 0° C., and m-CPBA (1.39 g, 8.04 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. TLC showed the mixture was complete. The solution was poured into 1N NaOH and extracted with DCM (50 mL×3). The organic layer was washed with brine, dried over NaSO, concentrated, and purified by column chromatography to give the title compound. 1 H NMR(400 MHz,CDCl3)δ 8.94(s,1H),7.88(d,J=2.8 Hz 1H),7.74-7.68(m,2H),7.34-7.30(m,2H),6.66-6.62(m,2H),3.81-3.71(m,4H),3.43(t,J=6.8 Hz 2H),2.99(d,J=14.4 Hz 1H), 1.93-1.86(m, 2H), 1.78-1.71(m, 2H), 1.57-1.43(m, 7H).

[0321] Example S-11. Preparation of 4-(1-(4-(2-bromoethoxy)phenyl)-2-phenylbut-1-enyl)phenyl pivalate [ka]

[0322] Step 1: Preparation of 4-(4-hydroxybenzoyl)phenyl Part 1: To a solution of bis(4-hydroxyphenyl)methanone 1 (2 g, 9.34 mmol) in 100 mL of THF was added EtN (3.8 g, 37.36 mmol). PivCl (2.82 g, 23.35 mmol) was then added dropwise to the mixture at 0 °C. The mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with 1 N HCl and brine, dried over NaSO, and concentrated under reduced pressure to give the crude product.

[0323] Part 2: To a solution of the crude product (3.5 g) in THF (45 mL) and MeOH (3 mL) was added LiOH (290 mg, 12.14 mmol), and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure and purified by silica gel chromatography to give the title compound.

[0324] Step 2: Preparation of (E)-4-(1-(4-hydroxyphenyl)-2-phenylbut-1-enyl)phenyl pivalate To a suspension of Zn (1.7 g, 26.8 mmol) in anhydrous THF (150 mL) under N was added TiCl (2.5 g, 13.4 mmol) at 0 °C. The mixture was refluxed for 2 h and cooled to 40 °C. A mixture of 4-(4-hydroxybenzoyl)phenyl pivalate (1 g, 3.35 mmol) and propiophenone (1.5 g, 10.72 mmol) in anhydrous THF (50 mL) was added in one portion, and the mixture was refluxed for 1 h. The reaction mixture was quenched with 10% KCO, extracted with EtOAc, washed with brine, dried over NaSO, and purified by silica gel chromatography to give the crude product, which was then added with MeOH (10 mL) and stirred for 20 min to give the title compound.

[0325] Step 3: Preparation of 4-(1-(4-(2-bromoethoxy)phenyl)-2-phenylbut-1-enyl)phenyl pivalate To a solution of (E)-4-(1-(4-hydroxyphenyl)-2-phenylbut-1-enyl)phenyl pivalate 4 (0.4 g, 1 mmol) in acetone (6 mL) was added K2CO3 (0.56 g, 4 mmol) and 1,2-dibromoethane 5 (1.9 g, 10 mmol). The mixture was stirred at 110 °C overnight. TLC showed that the reaction was complete. The mixture was washed with water, extracted with EtOAc, and dried over Na2SO4. The organic layer was concentrated under reduced pressure and purified by silica gel column to give the title compound. 1H NMR(400 MHz,CDCl3,E / Z=1:1)δ 7.23(d,J=8.7 Hz,2H),7.20-7.14(m,6H),7.14-7.07(m,6H),7.05(d,J=8.6 Hz,2H),6.87(dd,J=15.3,8.8 Hz,4H),6.77(d,J=8.9 Hz,2H),6.70(d,J=8.8 Hz,2H),6.55(d,J=8.9 Hz,2H),4.31(t,J=6.3 Hz,2H),4.15(t,J=6.3 Hz,2H),3.66(t,J=6.3 Hz,2H),3.55(t,J=6.3 Hz, 2H), 2.57-2.39 (m, 4H), 1.37 (s, 9H), 1.28 (s, 9H), 0.97-0.89 (m, 6H).

[0326] Example S-12. Preparation of (R)-3-(4-(2-bromoethylamino)phenylsulfonyl)-N-(4-cyano-3-(trifluoromethyl)-phenyl)-2-hydroxy-2-methylpropanamide [ka]

[0327] Step 1: Preparation of (R)-3-(-4-aminophenylsulfonyl)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide To a solution of (R)-3-(4-aminophenylthio)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide 1 (3.0 g, 7.59 mmol) in DCM (20 mL) kept at 0 °C was added 85% mCPBA (4.6 g, 22.76 mmol). The reaction was stirred at room temperature for 4 h. TLC showed the reaction was complete. The mixture was washed with saturated NaHCO. The organic phase was washed with brine, dried over anhydrous NaSO, concentrated under reduced pressure, and purified by column chromatography to give the title compound.

[0328] Step 2: Synthesis of 2-bromoacetaldehyde A mixture of 2-bromo-1,1-diethoxyethane (20 g, 0.101 mol) in HBr (47%, 32 mL) was stirred at 100° C. for 2 hours. The mixture was extracted with Et O. The combined organic layers were washed with brine, dried over anhydrous Na SO , and concentrated under reduced pressure to give the title compound, which was used directly in the next step.

[0329] Step 3: Synthesis of (R)-3-(4-(2-bromoethylamino)phenylsulfonyl)-N-(4-cyano-3-(trifluoromethyl)-phenyl)-2-hydroxy-2-methylpropanamide To a solution of (R)-3-(4-aminophenylsulfonyl)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide (2 g, 4.68 mmol) and 2-bromo-1,1-diethoxyethane (5.2 g, 42.11 mmol) in MeOH (40 mL) was added AcOH (0.18 g, 3.04 mmol), followed by BH3NMe3 (4.8 g, 65.51 mmol). The reaction was monitored by TLC, and additional portions of 2-bromo-1,1-diethoxyethane were added until the conversion was complete. The mixture was diluted with EtOAc, washed with saturated NaHCO3 and brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude material was purified by column chromatography to give the title compound. LCMS 536.1 [M+1] + . 1 H NMR(600 MHz,DMSO-d6)δ 10.33(s,1H),8.44(d,J=3 Hz,1H),8.20(dd,J=3 Hz,12.6 Hz,1H),8.08(d,J=12.6 Hz,1H),7.51(d,J=13.8 Hz,2H),6.60(d,J=13.8 Hz,2H),6.33(s,1H),2.98(s,3H),3.82(d,J=21.6 Hz,1H),3.53(m,6 H),1.39(s,3H).

[0330] Example S-13. Preparation of (R)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-(6-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin)-1-yl)methyl)benzoyl)piperazin-1-yl)-6-oxohexylamino)phenylsulfonyl)-2-hydroxy-2-methylpropanamide (Compound 1.68) [ka]

[0331] Step-A: Preparation of (S)-6-(4-(3-(4-cyano-3-(trifluoromethyl)phenylamino)-2-hydroxy-2-methyl-3-oxopropylsulfonyl)phenylamino)hexanoic acid To (S)-methyl 6-(4-(3-(4-cyano-3-(trifluoromethyl)phenylamino)-2-hydroxy-2-methyl-3-oxopropylsulfonyl)phenylamino)hexanoate (0.20 g, 0.360 mmol) in THF:MeOH:HO (6 mL:3 mL:1 mL) was added lithium hydroxide monohydrate (0.151 mg, 3.6 mmol, 10 equiv.) and the mixture was heated at 50° C. for 2 h. Upon completion, the mixture was concentrated under reduced pressure. The resulting residue was acidified with 1N HCl (pH ∼2) to give a precipitate which was filtered through a Buchner funnel to give the title compound. LC-MS 542 [M+H] + .

[0332] Preparation of (R)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-(6-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)-6-oxohexylamino)phenylsulfonyl)-2-hydroxy-2-methylpropanamide (Compound 1.68) To a stirred solution of (S)-6-(4-(3-(4-cyano-3-(trifluoromethyl)phenylamino)-2-hydroxy-2-methyl-3-oxopropylsulfonyl)phenylamino)hexanoic acid (0.20 g, 0.369 mmol) in DMF (5 mL) was added HATU (0.21 g, 0.554 mmol, 1.5 equiv.) at 0 °C, and the mixture was stirred at 0 °C for 30 min. Then, DIPEA (0.34 mL, 1.84 mmol, 5 equiv.) and 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one hydrochloride hydrochloride (0.297 g, 0.739 mmol, 2.0 equiv.) were added successively to the mixture, and the resulting mixture was stirred at room temperature for 16 h. The reaction was monitored by TLC and LC-MS. After completion, the reaction was diluted with EtOAc (250 mL). The organic layer was washed with water (100 mL), brine (50 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give the crude residue, which was purified by reverse phase HPLC to give compound 1.68. LC-MS 890 [M+H] + . 1 H NMR(400 MHz,CD3OD-d4)δ 8.36(d,J=7.8 Hz,1H),8.21(s,1H),7.98-7.77(m,5H),7.56-7.43(m,3H),7.38(d,J=6.4 Hz,1H),7.15(t,J=9.0 Hz,1H),6.42(dd,J=9.0,5.2 Hz,2H),4.38(s,2H),4.00(d,J=14.5 Hz,1H),3.80-3.60(m,4H),3.55-3.38(m,3H),3.28(s,1H),2.89(tt,J=12.3,6.0 Hz,2H),2.43(dt,J=28.6,7.4 Hz,2H),1.60(ddt,J=36.4,15.2,7.6 Hz,4H),1.44(d,J=14.4 Hz,5H).

[0333] Example S-14. Preparation of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-(6-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)-6-oxohexylamino)phenoxy)-2-hydroxy-2-methylpropanamide (Compound 1.83) [ka]

[0334] Step-A: Preparation of (R)-6-(4-(3-(4-cyano-3-(trifluoromethyl)phenylamino)-2-hydroxy-2-methyl-3-oxopropoxy)phenylamino)hexanoic acid To (R)-methyl 6-(4-(3-(4-cyano-3-(trifluoromethyl)phenylamino)-2-hydroxy-2-methyl-3-oxopropoxy)phenylamino)hexanoate (0.20 g, 0.360 mmol) in THF:MeOH:HO (6 mL:3 mL:1 mL) was added lithium hydroxide monohydrate (0.151 mg, 3.6 mmol, 10 equiv.) and the mixture was heated at 50° C. for 2 h. Upon completion, the mixture was concentrated under reduced pressure. The resulting residue was acidified with 1N HCl (pH ∼2) to give a precipitate which was filtered through a Buchner funnel to give the title compound. LC-MS 494 [M+H] + .

[0335] Preparation of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-(6-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)-6-oxohexylamino)phenoxy)-2-hydroxy-2-methylpropanamide (Compound 1.83) To a stirred solution of (R)-6-(4-(3-(4-cyano-3-(trifluoromethyl)phenylamino)-2-hydroxy-2-methyl-3-oxopropoxy)phenylamino)hexanoic acid (0.20 g, 0.405 mmol) in DMF (5 mL) was added HATU (0.23 g, 0.608 mmol, 1.5 equiv.) at 0 °C, and the mixture was stirred at 0 °C for 30 min. Then, DIPEA (0.37 mL, 2.02 mmol, 5 equiv.) and 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one hydrochloride (0.24 g, 0.608 mmol, 1.5 equiv.) were added successively to the reaction mixture, and the mixture was stirred at room temperature for 16 h. The reaction was monitored by TLC and LC-MS. After completion, the mixture was diluted with EtOAc (250 mL). The organic layer was washed with water (100 mL), brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a crude residue which was purified by reverse phase HPLC to give compound 1.83. LC-MS 842.8 [M+H] + . 1 H NMR(400 MHz,DMSO-d6)δ 8.55(d,J=2.9 Hz,1H),8.28(d,J=10.5 Hz,2H),8.08(d,J=8.6Hz,1H),7.96(d,J=8.1 Hz,1H),7.89(t,J=7.4 Hz,1H),7.83(t,J=7.5 Hz,1H),7.44(t,J=6.6 Hz,1H),7.36(s,1H),7.23(t,J=9.0 Hz,1H),7.06(d,J=8.5 Hz,1H),6.89(s,1H),6.67(d,J=7.8 Hz,2H),6.45(d,J=8.1 Hz,2H),5.06(t,J=5.5 Hz,1H),4.33(s,2H),4.06(d,J=9.5 Hz,1H),3.86(t,J=9.9 Hz,1H),3.62(s,2H),3.51(t,J=4.9 Hz,2H),3.15(d,J=14.4 Hz,2H),2.91(d,J=17.5 Hz,2H),2.28(d,J=7.9 Hz,1H),1.69(s,2H),1.51(q,J=6.5,5.7 Hz,4H),1.38(d,J=12.8 Hz,6H).

[0336] Example S-15. Preparation of (R)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-(6-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)hexyloxy)phenylsulfonyl)-2-hydroxy-2-methylpropanamide (Compound 1.96) [ka]

[0337] To a stirred solution of 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one hydrochloride (0.15 g, 0.254 mmol) in EtOH (4 mL) was added DIPEA (0.234 mL, 1.27 mmol, 5 equiv.), followed by (S)-3-(4-(6-bromohexyloxy)phenylsulfonyl)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide (0.153 g, 0.381 mmol, 2.0 equiv.), and the mixture was stirred at 80° C. for 16 h. The reaction was monitored by TLC and LC-MS. Upon completion, the reaction was concentrated under reduced pressure to give the crude residue, which was purified by reverse-phase HPLC to give compound 1.96. LC-MS 877 [M+H] + . 1H NMR(400 MHz,DMSO-d6)δ 12.53(d,J=39.4 Hz,1H),10.47(s,1H),8.39(d,J=2.1 Hz,1H),8.26(d,J=7.8 Hz,1H),8.18-8.10(m,1H),8.05(d,J=8.6 Hz,1H),7.96(d,J=8.0 Hz,1H),7.88(t,J=7.5 Hz,1H),7.82(t,J=7.4 Hz,1H),7.73(d,J=8.4 Hz,2H),7.42(ddd,J=8.2,5.1,2.4 Hz,1H),7.30(dd,J=6.4,2.4 Hz,1H),7.21(t,J=9.0 Hz,1H),6.94(d,J=8.5 Hz,2H),4.32(s,2H),3.85(dt,J=15.8,11.9 Hz,3H),3.65-3.56(m,3H),3.13(t,J=5.0 Hz,2H),2.37(t,J=5.0 Hz,2H),2.27(t,J=7.3 Hz,2H),2.24-2.17(m,2H),1.78(s,2H),1.66(p,J=7.2 Hz,2H),1.50-1.27(m,7H).

[0338] Example S-16. Preparation of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-(2-(4-((4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)ethylamino)phenylsulfonyl)-2-hydroxy-2-methylpropanamide (Compound 1.97) [ka]

[0339] Step-1: Preparation of (S)-3-(4-(2-azidoethylamino)phenylsulfonyl)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide To a stirred solution of (S)-3-(4-(2-bromoethylamino)phenylsulfonyl)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide (0.30 g, 0.56 mmol) in DMF (5 mL) was added sodium azide (0.073, 0.112 mmol, 2 equiv.) at room temperature and the mixture was heated at 80° C. for 2 h. The reaction was monitored by TLC. Upon completion, the mixture was diluted with EtOAc (250 mL). The organic layer was washed with water (100 mL×2), brine (100 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give the crude product, which was purified by CombiFlash® chromatography to give the title compound. LC-MS 497 [M+H] + .

[0340] Step-2a: Preparation of 4-(4-fluoro-3-(4-(prop-2-ynyl)piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one To a stirred solution of 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one hydrochloride (0.40 g, 0.99 mmol) in EtOH (5 mL) was added DIPEA (0.91 mL, 4.97 mmol, 5 equiv.), followed by bromoethine (0.176 g, 1.49 mmol, 2.0 equiv.), and the mixture was heated at 80° C. for 16 h. The reaction was monitored by TLC and LC-MS. After completion, the mixture was concentrated under reduced pressure to give the crude product, which was purified by CombiFlash® chromatography to give the title compound. LC-MS 405 [M+H] + .

[0341] Step-2: Preparation of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-(2-(4-((4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)ethylamino)phenylsulfonyl)-2-hydroxy-2-methylpropanamide (compound 1.97) To a stirred solution of (S)-3-(4-(2-azidoethylamino)phenylsulfonyl)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide (0.150 g, 0.301 mmol) and 4-(4-fluoro-3-(4-(prop-2-ynyl)piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one (0.182 g, 0.452 mmol, 15 equiv) in MeCN:HO (2:1) (6 mL) was added copper sulfate pentahydrate (0.024 g, 0.15 mmol, 0.5 equiv) and hydrazine hydrate (0.011 mg, 1.00 mmol, 1 equiv) successively, and the resulting mixture was heated at 60 °C for 2 h. The reaction was monitored by TLC and LC-MS. After completion, the mixture was diluted with water (50 mL) and extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with 10% NHOH solution, dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give the crude product, which was purified by CombiFlash® chromatography to give compound 1.97. LC-MS 901 [M+H] + . 1 H NMR(400 MHz,DMSO-d6)δ 12.59(s,1H),10.35(s,1H),8.43(d,J=2.1 Hz,1H),8.29-8.15(m,2H),8.06(d,J=8.6 Hz,1H),8.00(s,1H),7.96(d,J=8.0 Hz,1H),7.88(t,J=7.5 Hz,1H),7.82(t,J=7.5 Hz,1H),7.48(d,J=8.5 Hz,2H),7.42(s,1H),7.32(d,J=6.1 Hz,1H),7.22(t,J=8.9 Hz,1H),6.72(t,J=6.0 Hz,1H),6.56(d,J=8.5 Hz,2H),6.32(s,1H),4.47(s,2H),4.32(s,2H),3.78(d,J=14.5 Hz,1H),3.52(dt,J=19.4,11.7 Hz, 6H), 3.14 (s, 2H), 2.40 (s, 2H), 2.28 (s, 1H), 1.38 (s, 3H), 1.23 (s, 1H).

[0342] Example S-17. Preparation of (R)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-(2-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)-2-oxoethylamino)phenylsulfonyl)-2-hydroxy-2-methylpropanamide (Compound 1.98) [ka]

[0343] Step-1: Preparation of 4-(3-(4-(2-bromoacetyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one To 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one hydrochloride (1.0 g, 2.48 mmol) in DCM (5 mL) was added EtN (3.58 mL, 24.8 mmol) at room temperature, and the mixture was slowly added to a pre-stirred solution of 2-bromoacetyl chloride (3.85 g, 24.8 mmol) in DCM (20 mL) at 0 °C. The resulting mixture was stirred at room temperature for 10 minutes and monitored by TLC and LC-MS. After completion, the reaction was quenched with saturated NaHCO solution (30 mL) and extracted with DCM (200 mL × 2). The combined organic layers were washed with HO (100 mL), brine (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the crude residue, which was purified by CombiFlash® chromatography to give the title compound. LC-MS 487[M+H] +

[0344] Step-2: Preparation of (R)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-(2-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)-2-oxoethylamino)phenylsulfonyl)-2-hydroxy-2-methylpropanamide To a stirred solution of (R)-3-(4-aminophenylsulfonyl)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide (0.105 g, 0.246 mmol, 1 equiv.) in DMF (5 ml), 4-(3-(4-(2-bromoacetyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one (0.12 g, 0.246 mmol, 1 equiv.) was added and the reaction mixture was stirred at 80° C. for 16 h. The reaction was monitored by TLC and LC-MS. Upon completion, the mixture was diluted with EtOAc (100 mL). The organic layer was washed with ice-cold HO (50 mL×2), brine (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the crude residue, which was purified by reverse-phase HPLC to give the title compound. LC-MS 487 [M+H] + . 1 HNMR(400 MHz,DMSO-d6)δ 12.60(s,1H),10.33(s,1H),8.43(d,J=2.1 Hz,1H),8.31-8.23(m,1H),8.21-8.15(m,1H),8.06(d,J=8.5 Hz,1H),7.97(t,J=5.2 Hz,1H),7.90(d,J=6.6 Hz,1H),7.85(d,J=7.9 Hz,1H),7.48(t,J=9.7 Hz,1H),7.42-7.33(m,3H),7.25(q,J=7.6 Hz,2H),6.64(dd,J=11.7,8.2 Hz,2H),6.32(s,1H),4.34(s,2H),3.90(d,J=19.0 Hz,2H),3.79(d,J=14.5 Hz,1H),3.70(s,1H),3.63(s,1H),3.57(s,2H),3.52(s,1H),3.42(s,2H),3.26(s,2H),3.20(s,1H),1.39(s,3H).

[0345] Example S-18. Preparation of (R)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-(2-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)ethylamino)phenylsulfonyl)-2-hydroxy-2-methylpropanamide (Compound 1.99) [ka]

[0346] Step-1: Preparation of (R)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-(2-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)ethylamino)phenylsulfonyl)-2-hydroxy-2-methylpropanamide To a stirred solution of 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one hydrochloride (0.075 g, 0.187 mmol, 1.0 equiv.) in EtOH (10 mL) was added DIPEA (0.201 mL, 1.12 mmol, 6 equiv.), followed by (R)-3-(4-(2-bromoethylamino)phenylsulfonyl)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide (0.10 g, 0.187 mmol), and the mixture was stirred at 80° C. for 16 h. The reaction was monitored by TLC and LC-MS. Upon completion, the reaction was concentrated under reduced pressure to give the crude residue, which was purified by reverse-phase HPLC to give the title compound. LC-MS=820 [M+H] + . 1HNMR(400 MHz,DMSO-d6)δ 12.61(br.s.,1 H),8.41(br.s.,1 H),8.26(d,J=7.5 Hz,1 H),8.14(d,J=7.0 Hz,1 H),8.03(d,J=7.9 Hz,1 H),7.96(d,J=7.5 Hz,1 H),7.91-7.80(m,2 H),7.50-7.38(m,3 H),7.32(d,J=4.4 Hz,1 H),7.22(t,J=9.0 Hz,1 H),6.58-6.48(m,2 H),6.40(br.s.,1 H),3.76(d,J=14.0 Hz,1 H),3.62(br.s.,2 H),3.50(d,J=14.5 Hz,1 H),3.16(br.s.,2 H),3.07(d,J=5.3 Hz,2 H),2.49-2.4(m,4H),2.31(br.s.,2 H),1.68(s,2 H),1.37(s,3 H).

[0347] Example S-19. Preparation of 4-(3-(4-(2-(2-((5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yloxy)ethoxy)acetyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one (Compound 1.104) [ka]

[0348] Step-1: Preparation of (5S,8R,9S,10S,13S,14S,17S)-10,13-dimethylhexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolan]-17-ol To a stirred solution of (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one (15 g, 51.65 mmol) in benzene (500 mL) was added PTSA (4.85 g, 25.8 mmol, 0.5 equiv.), followed by ethylene glycol (14.5 mL, 258 mmol, 5 equiv.) at room temperature. The resulting mixture was refluxed for 16 h using a Dean-Stark apparatus. The reaction was monitored by TLC. Upon completion, the reaction mixture was diluted with water (500 mL) and extracted with EtOAc (500 mL × 2). The combined organic layers were washed with saturated NaHCO.sub.3 solution (250 mL), water (400 mL), brine (200 mL), dried over Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure to give the title compound. 1 HNMR(400 MHz,DMSO-d6)δ 4.40(d,J=5.26 Hz,1H),3.81(s,3H),3.45-3.37(m,2H),1.82(br.s.,2H),1.70(d,J=12.72 Hz,2H),1.59(d,J=13.15 Hz,2H),1.52(d,J=10.52 Hz,3H),1.35(br.s.,1H),1.33-1.23(m,3H),1.21-1.03(m,5H),0.87(dt,J=7.89,19.95 Hz,4H),0.76(s,3H),0.61(s,3H)

[0349] Step-2a: Preparation of 2-(2-(2-chloroethoxy)ethoxy)tetrahydro-2H-pyran To a stirred solution of 2-(2-chloroethoxy)ethanol (10 g, 80.6 mmol) in diethyl ether (150 mL) was added PTSA (1.54 g, 0.806 mmol, 0.1 equiv.), followed by 3,4-dihydro-2H-pyran (8.12 g, 96.7 mmol, 1.2 equiv.). The resulting reaction mixture was stirred at room temperature for 16 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was diluted with diethyl ether (700 mL). The organic layer was washed with 20% KOH solution (300 mL), water (600 mL), brine (300 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give the title compound, which was carried on to the next step without further purification. 1 HNMR(400 MHz,DMSO-d6)δ 4.62-4.56(m,1H),3.75-3.66(m,6H),3.63-3.56(m,2H),3.53-3.46(m,1H), 3.46-3.39(m,1H),1.75-1.67(m,1H),1.65-1.57(m,1H),1.52-1.39(m,4H).

[0350] Step-2: Preparation of (5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-17-(2-(2-(tetrahydro-2H-pyran-2-yloxy)ethoxy)ethoxy)hexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolane] To a stirred solution of (5S,8R,9S,10S,13S,14S,17S)-10,13-dimethylhexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolan]-17-ol (1.2 g, 3.59 mmol) in xylene (12 mL), NaNH (50% suspension in toluene, 3.5 mL) was added, and the mixture was heated at 150 °C for 1 h. The reaction mixture was gradually cooled to 25 °C, to which 2-(6-chlorohexyloxy)tetrahydro-2H-pyran (7.47 g, 35.9 mmol) was added, and the resulting mixture was further heated at 150 °C for 16 h. The reaction was monitored by TLC. Upon completion, the mixture was cooled to room temperature, slowly quenched with ice-cold water (500 mL), and extracted with EtOAc (300 mL × 2). The combined organic layers were washed with water (250 mL x 2), brine (200 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product, which was purified by CombiFlash® chromatography to give the title compound. 1 HNMR(400 MHz,CDCl3)δ 4.64(t,J=3.5 Hz,1H),3.93(s,4H),3.90-3.81(m,4H),3.74(dd,J=5.5,3.7 Hz,1H),3.70-3.64(m,4H),3.64-3.54(m,4H),3.54-3.44(m,2H),3.32(t,J=8.3 Hz,2H),2.02-1.93(m,2H),1.90-1.80(m,2H),1.66-1.60(m,6H),1.44-1.33(m, 4H), 1.28-1.16(m,6H), 0.98-0.84(m,4H), 0.84-0.77(m,2H), 0.76-0.69(m,2H).

[0351] Step-3: Pr...

Claims

1. Formula IIIB, IVA, VB, or VIA: 【Chemical Formula 72】 or a stereoisomer, a mixture of stereoisomers, or a pharma- ceutically acceptable salt thereof, During the ceremony, Each R 2 is -L-(B) m and m is 1, Each L is independently a covalent bond or a linking moiety, said linking moiety having the formula: -Y 1 -(CH 2 ) n’ -Y 2 -(CH 2 ) m’ -Y 3 - The Y 1 , Y 2 , and Y 3 each independently represents a bond, -NR 11 -, -O-, -S(O) 0-2 --, --NR 11 C(O)-, -C(O)NR 11 --, --NR 11 S (O) 2 -, -S(O) 2 N.R. 11 -, -CR 12 =N-NR 11 --, --NR 11 -N=CR 12 -, -C(O)-, arylene, heteroarylene, cycloalkylene, or heterocycloalkylene, each arylene, heteroarylene, cycloalkylene, or heterocycloalkylene independently being oxo, halo, C 1-4 Alkyl, C 1-4 Alkoxy, and C 1-4 optionally substituted with 1 to 5 substituents independently selected from haloalkyl; Each R 11 are independently hydrogen, C 1-4 Alkyl, C 1-4 haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; Each R 12 is independently 1-4 Alkyl, C 1-4 haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; n' and m' are each independently 0, 1, 2, 3, 4, 5, 6, 7, or 8; Each B is independently 【Chemistry 1-1】 【Chemistry 1-2】 or a stereoisomer, mixture of stereoisomers, or pharma- ceutically acceptable salt thereof, which is a nuclear receptor targeting epitope selected from the group consisting of:

2. Each L is independently a covalent bond or a linking moiety, said linking moiety having the formula: -Y 1 -(CH 2 ) n’ -Y 2 -(CH 2 ) m’ -Y 3 - The Y 1 , Y 2 , and Y 3 each independently represents a bond, -NR 11 -, -O-, -S(O) 0-2 --, --NR 11 C(O)-, -C(O)NR 11 --, --NR 11 S (O) 2 -, -S(O) 2 N.R. 11 -, -CR 12 =N-NR 11 --, --NR 11 -N=CR 12 -, -C(O)-, arylene, heteroarylene, cycloalkylene, or heterocycloalkylene, each arylene, heteroarylene, cycloalkylene, or heterocycloalkylene independently being oxo, halo, C 1-4 Alkyl, C 1-4 Alkoxy, and C 1-4 optionally substituted with 1 to 5 substituents independently selected from haloalkyl; Each R 11 is independently 1-4 Alkyl, C 1-4 haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; Each R 12 is independently 1-4 Alkyl, C 1-4 haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; 2. The compound of claim 1, wherein n' and m' are each independently 0, 1, 2, 3, 4, 5, 6, 7, or 8, or a stereoisomer, mixture of stereoisomers, or a pharma- ceutically acceptable salt thereof.

3. 3. The compound of claim 1 or 2, wherein the compound is a compound of formula IIIB, or a stereoisomer, mixture of stereoisomers, or a pharma- ceutically acceptable salt thereof.

4. 3. The compound of claim 1 or 2, wherein the compound is a compound of formula IVA, or a stereoisomer, mixture of stereoisomers, or a pharma- ceutically acceptable salt thereof.

5. 3. The compound of claim 1 or 2, wherein the compound is a compound of formula VB, or a stereoisomer, mixture of stereoisomers, or a pharma- ceutically acceptable salt thereof.

6. 3. The compound of claim 1 or 2, wherein the compound is a compound of formula VIA, or a stereoisomer, mixture of stereoisomers, or a pharma- ceutically acceptable salt thereof.

7. The compound is 【Table 1-1】 【Table 1-2】 【Table 1-3】 【Table 1-4】 【Table 1-5】 【Table 1-6】 【Table 1-7】 【Table 1-8】 【Table 1-9】 【Table 1-10】 【Table 1-11】 【Table 1-12】 【Table 1-13】 【Table 1-14】 【Table 1-15】 【Table 1-16】 【Table 1-17】 【Table 1-18】 【Table 1-19】 【Table 1-20】 【Table 1-21】 【Table 1-22】 【Table 1-23】 【Table 1-24】 【Table 1-25】 【Table 1-26】 【Table 1-27】 【Table 1-28】 【Table 1-29】 【Table 1-30】 【Table 1-31】 【Table 1-32】 【Table 1-33】 【Table 1-34】 【Table 1-35】 【Table 1-36】 【Table 1-37】 【Table 1-38】 【Table 1-39】 【Table 1-40】 【Table 1-41】 【Table 1-42】 【Table 1-43】 【Table 1-44】 【Table 1-45】 【Table 1-46】 【Table 1-47】 【Table 1-48】 【Table 1-49】 【Table 1-50】 【Table 1-51】 【Table 1-52】 【Table 1-53】 【Table 1-54】 【Table 1-55】 【Table 1-56】 【Table 1-57】 【Table 1-58】 【Table 1-59】 【Table 1-60】 【Table 1-61】 2. The compound of claim 1, selected from the group consisting of:

8. 8. The compound of claim 7, or a pharma- ceutically acceptable salt thereof, wherein the compound is selected from the group consisting of compounds 1.1, 1.11, 1.68, 1.83, 1.98, 1.99, 1.104, 1.107, 1.111, 1.117, and 1.

119.

9. 10. A pharmaceutical composition comprising a compound according to any one of claims 1, 2, 7 and 8, or a stereoisomer, a mixture of stereoisomers, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

10. A composition comprising a compound according to any one of claims 1, 2, 7 and 8, or a stereoisomer, mixture of stereoisomers, or pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 9, for use in treating a condition that can be ameliorated by inhibiting PARP in an individual in need thereof.

11. A composition comprising a compound according to any one of claims 1, 2, 7 and 8, or a stereoisomer, mixture of stereoisomers, or pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 9, for use in treating cancer in an individual in need thereof.

Citation Information

Patent Citations

  • Substituted 1,3,4,5-tetrahydro-6H-pyrrolo[4,3,2-EF] [2] benazepine-6-ketone derivatives

    CN107286166A

  • Cancer specific radiolabeled conjugates regulated by the cell cycle for the treatment and diagnosis of cancer

    US20050069495A1

  • Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor

    US20170217903A1

  • Cyclooctenes for bioorthogonol reactions

    US20170233365A1

  • Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer

    WO2011079245A1